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Abstract 
 
Aims: 
The aim of this study was to determine association between inflammation, 
glucose control and type 2 diabetes (T2D) related complications.  
 
Methods: 
We determined cytokines, adipokines & Toll-like receptors (TLR) mRNA 
expression in monocytes (M) and neutrophils (N) using QPCR in a cohort 
of 146 subjects: non-diabetic controls [NGT; n=34, BMI 26 (24-30) kg/m2, 
HbA1c 5.6 (5.4-5.7)%] and compared them with T2D with four different 
profiles:  good glycaemic control without complications [GC; n=27, BMI 32 
(29-38) kg/m2, HbA1c 6.4 (6.0-6.9)%], good glycaemic control with 
complications [GCC; n=32, BMI 31 (28-35) kg/m2, HbA1c 6.9 (6.4-7.4)%], 
poor glycemic control without complications [PC; n=21, BMI 35 (31-37) 
kg/m2, HbA1c 10.2 (9.2-11)%] and poor glycaemic control with 
complications [PCC; n=32, BMI 34 (29-37) kg/m2, HbA1c 9.6 (8.9-10.8)%]. 
Data are expressed as median (Inter quartile range). 
 
Results: 
The highest expressions of IL-6, TNFα, Rantes & IFNβ mRNA in 
neutrophils, and IL-6 and IFNβ mRNA in monocytes were seen in GC, 
compared to NGT. In contrast, IL-1β mRNA expression was significantly 
decreased in monocytes from GCC, PC and PCC. 
 
Retinol binding protein 4 (RBP4), Lipocalin 2 and adiponectin mRNA in 
neutrophils, and RBP4 mRNA in monocytes were significantly 
overexpressed in GC, compared to NGT. In contrast, Lipocalin 2 and 
adiponectin mRNA were significantly suppressed in monocytes from PC 
and PCC. 
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Similarly, TLRs mRNA 1-10, except TLR 2 in neutrophils, and TLR1, 3, 5, 
7, 9 & 10 in monocytes were overexpressed from GC group compared to 
NGT.  
 
Conclusions: 
The overexpressed cytokine, adipokine & TLR mRNA levels in monocytes 
and neutrophils from GC group indicate an inflammatory milieu in T2D with 
good glycaemic control with no complications. In contrast, suppressed 
levels of inflammatory markers in PC, GCC & PCC indicate compromised 
innate immune state i.e. “burnt out” disease in poor glycaemic control, and 
in patients with complications.  
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1.1 Type 2 Diabetes: an inflammatory disease 
Type 2 Diabetes (T2D) is one of the world's most important diseases with 
a global epidemic ensuing, fuelled by population growth, aging, 
urbanisation and increasing obesity and inactivity. It is estimated that, in 
many countries, including those, such as India, China and the USA, that 
have the highest numbers of diabetic patients currently (>90% of these 
with T2D), the prevalence will double in the next 20 years or so. The 
disease is, in short, common, costly and associated with devastating 
complications. T2D is caused by a combination of insulin resistance (IR) at 
skeletal muscle, liver and adipose tissues (AT) and impaired insulin 
secretion from the pancreatic islets.  It is thought that environmental 
trigger factors, such as overeating and underactivity cause a decrease in 
insulin release and action in individuals with a susceptibility to the disease 
(Leahy et al., 2005). Passing first through a stage of impaired glucose 
tolerance and/or impaired fasting glucose concentration, frank T2D 
eventually develops, in association with a varying number of other clinical 
and biochemical features, which are themselves cardiovascular risk 
factors and are together called the metabolic syndrome (Festa et al., 
2000a). Overall, T2D occurs when beta-cell function fails to compensate 
for insulin resistance, partly because of beta-cell demise through 
apoptosis.  
 
In the last decade, increasing evidence suggests that patients with T2D 
display features of inflammation years before the disease onset 
(Alexandraki et al., 2006). Moreover, low-grade inflammation has been 
proposed to be involved in the pathogenetic processes causing T2D 
(Festa et al., 2000a; Navarro & Mora, 2006a). In fact, numerous studies 
have demonstrated a strong link between inflammatory markers and 
carbohydrate and lipid metabolism abnormalities and obesity (Festa et al., 
2000b; Duncan et al., 2003). Given that T2D is a polygenic disease, 
defects in many molecular pathways have been demonstrated or 
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implicated. Recent evidence suggests common molecular mechanisms 
between inflammatory and insulin signalling pathways both of which cause 
insulin resistance (Rotter et al., 2003). Also, there is evidence that 
inflammatory mediators may not only represent markers of metabolic 
aberrations in T2D (Navarro & Mora, 2005; Navarro & Mora, 2006a) but 
may also contribute to β-cell death due to impaired function and 
progressive decline in β-cell function and mass (Alexandraki et al., 2006). 
In fact, apoptotic cells alone can activate the innate immune system and 
hyperglycaemia can induce β-cell expression of several molecules 
involved in immunological processes including Interleukin (IL)-1β itself 
(Maedler et al., 2002). Regarding the investigation of the origin of the 
inflammatory process in T2D, recent studies have demonstrated that an 
accumulation of macrophages in the AT of obese subjects as well as their 
participation in the inflammatory pathways activated in adipocytes 
(Weisberg et al., 2003). Macrophages reside in human AT and their 
number has been found positively related with body mass index (BMI), 
suggesting their contribution to the dysregulation of AT as well as to the 
impairment of adipocytes function. Moreover, these macrophages are a 
source of proinflammatory cytokines such as tumor necrosis factor-alpha 
(TNFα) and interleukin 6 (IL-6). Also, another source of the circulating 
proinflammatory cytokines may be the mononuclear cells as these cells 
are the precursors to tissue macrophages. The peripheral blood 
mononuclear cells (PBMC) of obese subjects have been shown to be in an 
inflammatory state, expressing increased amounts of proinflammatory 
cytokines and related factors with an increase in the transcription of 
proinflammatory genes regulated by the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) (Ghanim et al., 2004), the central 
proinflammatory transcription factor as well as an increase in the 
intranuclear expression of p65 (Rel A), the major protein component of 
NF-kB. These cells also express diminished amounts of the inhibitor of 
kappa B (IκB) β, which is the inhibitor of NF-kB activation (Dandona et al., 
2004). Interestingly, it has been shown that macrophages and adipocytes 
are quite similar and functional capability of these two cells overlap. 
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Macrophages can take up and store lipid to become atherosclerotic foam 
cells (Wellene et al., 2005). Preadipocytes, the progenitors of mature 
adipocytes can exhibit phagocytic and antimicrobial properties and 
differentiate into macrophages under some conditions (Cousin et al., 1999; 
Charrière et al., 2003). Gene expression is also highly similar; 
macrophages express many adipocyte gene products such as the 
adipocyte/macrophage fatty-acid-binding protein (FABP) aP2 (also known 
as FABP4) and PPARγ, while adipocytes can express many macrophage 
proteins such as TNF-α, IL-6, and matrix metalloproteinases (MMP) 
(Hotamisligil et al., 1993; Makowski et al., 2001; Tontonoz et al., 1998; 
Bouloumie et al., 2001). Furthermore, it has been observed that monocyte 
chemoattractant protein-1 (MCP-1), a proinflammatory chemokine mainly 
produced by macrophages and endothelial cells, can be secreted from 
isolated adipocytes (Alexandraki et al., 2006). 
 
A few years ago, a hypothesis was proposed which suggested that 
elements of the innate immune system contribute to the development of 
T2D (Navarro & Mora, 2006a). In this model, the idea was forwarded that 
the innate immune system modulates the effects of many factors including 
genes, ethnicity, foetal programming, nutrition and age upon the later 
development of metabolic sequelae associated with insulin resistance. 
The innate immune system, which is phylogenetically older than the so-
called acquired or adaptive immunity, is a rapid first line defence 
mechanism based on non-lymphoid tissue components, including 
macrophages and polymorphonuclear cells (PMNs). A major component 
of innate immunity is a series of sentinel cells (classically macrophages, 
antigen-presenting B-cells, and dendritic cells (DC), but probably also 
intestinal epithelial cells, endothelium, Kupffer cells in the liver, adipocytes, 
and others) that act as "trouble detectors." A number of germ line-encoded 
(i.e., nonclonal) pattern recognition receptors (PRRs) on and in these cells 
recognize conserved molecular structures, pathogen-associated molecular 
patterns (PAMP), that are characteristic of a class of harmful agents 
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(Miggin and O’Neill, 2006). The most studied PRRs are probably the 
family of at least 10 Toll-like receptors (TLRs) (named after the toll 
receptor, first identified in the fruit fly, drosophila) that are present at the 
cell surface as transmembrane receptors. TLR-4, for example, recognizes 
lipopolysaccharide (LPS) from Gram-negative bacteria, in conjunction with 
associated accessory molecules (Cluster of differentiation (CD) 14, MD-2). 
Other cell surfaces PRRs include the macrophage scavenger receptors, 
the mannose receptor, and the receptor for advanced glycation end 
products (RAGE). There are also intracellular PRRs, e.g., for double-
stranded RNA (present in viruses). Binding to PRR activates NF-κB 
signaling pathways that induce immune response genes, especially those 
for inflammatory cytokines (including  (IL)-1α, TNFα, IL-6), which are the 
main mediators of inflammation and the acute-phase response (Miggin 
and O’Neill, 2006). Secreted and circulating PRRs such as C-reactive 
protein (CRP) and mannan-binding lectin function as opsonins, binding to 
microbial cell components and flagging them for recognition by the 
complement system and phagocytes. An important second function of 
innate immunity, which has only recently been appreciated, is to control 
the adaptive immune response. T-cells require two signals to be activated: 
the complex of presented antigen and the major histocompatibility 
complex class II molecule on the surface of an antigen-presenting cell and 
costimulatory molecules (CD80 and CD86), which are invoked by the 
innate immune system and the binding of pathogen-associated molecular 
patterns to PRRs. Thus, the innate immune system ensures that the 
adaptive immune system responds only to harmful antigens and that the 
biological context of a threat is recognized.  
 
The acute phase response is part of the innate immune system and 
results in pronounced changes in the concentration of plasma proteins in 
response to a variety of stresses including infection, tissue injury or 
inflammation. Some of these proteins increase (positive acute phase 
proteins) such as CRP, fibrinogen and SAA, whilst others decrease 
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(negative acute phase proteins) such as albumin and transferrin. The 
acute phase proteins are synthesized in the liver, stimulated by certain 
proinflammatory cytokines including IL-1β, IL-6 and TNFα, which are 
released from macrophages, monocyte and endothelium (Figure 1).  
Interestingly, it has also been shown that AT can release cytokines and, 
thus, subclinical low-grade chronic inflammation may in part be due to 
obesity. Several studies have shown that elevated levels of inflammatory 
and endothelial cell markers predict diabetes. Acute phase reactants and 
certain cytokines are involved in a plethora of metabolic pathways, such 
as insulin regulation, reactive oxygen species, lipoprotein lipase action and 
adipocyte function, all that could be relevant to IR. 
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Figure 1.1 The components of the innate immune system 
Sentinel cells such as macrophages, intestinal epithelial cells, endothelium, Kupffer 
cells in the liver and adipocytes detect potential environmental threats from 
infection, chemicals, and foods by specific pattern recognition receptors (PRRs) 
called Toll like receptors (TLRs) that activate signalling pathways and release 
proinflammatory cytokines (IL-6 and TNFα). For example, TLR4 senses bacterial 
LPS and the receptor for advanced glycation end products (RAGE) detects 
advanced glycation end products (AGEs). Cytokines stimulate acute-phase protein 
production from the liver and also act on the brain to release adrenocorticotrophic 
hormone (and thereby cortisol from the adrenal gland) and activate the sympathetic 
nervous system with the release of catecholamines. Psychological stress can cause 
an acute-phase response via innervation of cytokine-producing cells and via 
activation of the sympathetic nervous system and adrenergic receptors on 
macrophages. The central cytokines induced "sickness behaviour" includes 
lethargy, sleep changes and depression. The innate immune system also controls 
the adaptive (acquired) immune system via costimulatory molecule expression that 
is necessary for antigen presentation. SAA, serum amyloid A.   
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TLRs are members of the IL-1 receptor family, an evolutionary conserved 
signalling system against invading pathogens (Miggin and O’Neill, 2006). 
Due to their ability to recognize microbial components, mammalian TLRs 
are among the most important components of the innate immunity 
pathway. The first described and best-known member of this family is 
TLR4, identified as the signalling receptor for LPS. TLR4 also interacts 
with endogenous ligands such as heat shock proteins, fibronectin, 
fibrinogen, minimally modified and oxidized low-density lipoprotein (LDL) 
and free fatty acids (FFA), which are elevated in diabetes (Kolz et al., 
2008; Siednienko & Miggin, 2009a). TLR4 ligation activates several 
intracellular signalling pathways, with TLR4/NF-κB pathway being the 
most important one, leading to the synthesis and release of inflammatory 
cytokines including IL-1β, IL-6 and TNFα and other co-stimulatory 
molecules that provide a link to adaptive immunity (Figure 1.2). Given that 
TLRs are expressed in macrophages and mononuclear cells (Siednienko 
& Miggin, 2009a) and that TLR engagement elicits the production of pro-
inflammatory cytokines such as TNFα and IL-6 (Miggin and O’Neill, 2006), 
it is plausible to speculate that TLRs may play a role in the pathogenesis 
of T2D. 
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Figure 1.2 TLR3 and TLR4 mediated signalling pathways. Whereas TLR4 
activates the MyD88-dependent and the Trif-dependent pathways, TLR3 
activates the Trif-dependent pathway only. MyD88 recruits IRAK4 and TRAF6 
upon ligand stimulation. TRAF6 activates TAK1/TAB1/TAB2/TAB3 complex via 
K63-linked ubiquitination (UB). Activated TAK1 complex then activates the IKK 
complex, which catalyzes IκB phosphorylation and degradation by the 
proteasome pathway, thus allowing NF-κB to translocate into nuclei. NF-κB and 
AP-1 control inflammatory responses by inducing proinflammatory cytokines such 
as TNF, IL-1β and IL-6. TLR4 also recruits TRAM and Trif, which interacts with 
TBK1. TBK1 together with IKKi mediates phosphorylation of IRF3. 
Phosphorylated IRF3 is dimerized and translocated into nucleus to bind DNA. Trif 
also interacts with TRAF6 and RIP1, which mediate NF-κB activation. Activation 
of IRF3, NF-κB and AP-1 is required for induction of type I interferon, particularly 
interferon (IFN) β. TLR3, which resides in endosomal vesicles, utilizes Trif but not 
MyD88, mediating the induction of type 1 interferons. 
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Our hypothesis is that long-term innate immune system activation, 
resulting in chronic inflammation, elicits disease instead of repair in 
individuals who develop T2D. Interestingly, chronic infections, including 
periodontal disease, Helicobacter pylori or Chlamydia pneumoniae can 
also evoke an inflammatory response (Nishimura et al., 2000; Cassell, 
1998).  In the case of T2D, this may be a two-way relationship. It is, of 
course, plausible to speculate that the very factors that the innate immune 
system modulates may also cause its long-term activation. 
 
The chronic inflammatory hypothesis has been strongly supported by 
various research groups throughout the world. One study by the ARIC 
Investigators showed that increased inflammatory markers, including white 
blood count, plasma fibrinogen and SA, were associated with the risk of 
developing T2D (Schmidt et al., 1999; Duncan et al., 2003). The 
Cardiovascular Health Study reported serum CRP concentrations were 
associated with the development of diabetes in the elderly (Barzilay et al., 
2001). Additionally, increased serum gamma globulin concentrations, 
another expression of the acute phase response, predict risk of developing 
T2D in the Pima Indian population, as did raised leukocyte count (Lindsay 
et al., 2001 & 2002). In a Nurses's Health Study, elevated inflammatory 
markers, namely serum CRP, TNF-alpha receptor 2 and IL-6, were 
associated with the development of T2D in healthy middle-aged women 
(Hu et al., 2004). A supportive observation was made in the West of 
Scotland Coronary Prevention Study where CRP was shown to be an 
independent predictor of risk for the development of T2D in middle-aged 
men (Freeman et al., 2002). These were similar findings to the MONICA 
Augsburg Cohort Study that reported low-grade inflammation being 
associated with increased T2D risk in middle-aged men. Further 
confirmation of the 'chronic inflammatory' hypothesis has also come from 
the 'Insulin Resistance Atherosclerosis Study' where those individuals that 
converted to T2D had higher base-line levels of inflammatory proteins, 
including plasma fibrinogen, CRP and plasminogen activator inhibitor-1 
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(PAI-1) than non-convertors. After adjustment for body fat (BMI or waist 
circumference), this association was attenuated, albeit less for PAI-1 than 
the other acute phase proteins Festa et al., 2000a & 2002). The authors 
also concluded that chronic inflammation is a risk factor for the 
development of T2D. Also pertinent is that elevated serum SA is higher in 
women developing gestational T2D. 
 
In the present study, the expression of various inflammatory marker, 
cytokines, chemokines, adipokines and TLRs, that are purported to play a 
role in T2D, were examined relative to glucose control levels in the 
absence and presence of complications.  The role of the inflammatory 
markers in the context of diabetes and micro/macro vascular 
complications, obesity and IR are summarized in Table 1.  
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Table 1: Inflammatory markers that were evaluated in healthy and T2D subjects 
No Acute phase 
reactant 
Cytokine Chemokine Cytokine Chemokine Adipokine TLRs 
 Serum levels mRNA expressions 
1. CRP TNF- α RANTES* TNF- α RANTES RBP4 TLR 1 
2.  1L -10 IL-8** IL-1 β  LCN2 TLR 2 
3.  IL-1 β  IL-6  Adiponectin TLR 3 
4.  IL-6  IFN- β   TLR 4 
5.  IFN- β     TLR 5 
6.  IFN-γ     TLR 6 
7.  IL-12p70     TLR 7 
8.       TLR 8 
9.       TLR 9 
10.       TLR 10 
 
*RANTES, Regulated upon Activation, Normal T-cell Expressed, and Secreted 
**IL-8, a cytokine sub classified as chemokine 
CRP, C-reactive protein, TNF- α, Tumour necrosis factor-alpha, IL, 
Interleukin, IFN, Interferon, RBP4, Retinol binding protein 4, LCN2, 
Lipocalin-2, TLR, Toll like receptors !!!!!!
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1.2 Acute phase reactant 
 
1.2a CRP 
CRP, a member of the pentraxin family of oligomeric proteins is an acute 
phase reactant produced mainly by the liver in response to IL-6 and TNFα.  
It is involved in PRRs activation and is a common marker for inflammation 
(Pearson et al., 2003).  
 
It is associated with β - cell dysfunction and IR and plays a critical role in 
T2D (Pfutzner et al., 2006). It has been shown that it inhibit cell 
proliferation and increases the rates of apoptotic cell death (Nabata et al., 
2008) 
 
Numerous prospective studies have shown an independent positive 
association of CRP with the risk of developing T2D (Pradhan et al., 2001; 
Spranger et al., 2003; Hu et al., 2004; Doi et al., 2005), while others show 
no association after adjustment for adiposity and IR (Thorand et al., 2003; 
Duncan et al., 2003; Krakoff et al., 2003). A meta-analysis of a 10 
prospective studies showed a positive association between serum CRP 
and T2D independent of obesity (Dehgan et al., 2007). Another meta-
analysis of 16 published studies with 3,920 T2D cases and 24,914 
controls demonstrated a relative risk (RR) of T2D of 1.72 (95% CI: 1.54–
1.92) for subjects with high CRP levels (Lee et al., 2009).  
 
It has been shown that CRP levels are higher in obese subjects who are 
also IR and levels decrease with weight loss and improvement of insulin 
sensitivity (Klover et al., 2005; McLaughlin et al., 2002). Circulating levels 
of CRP may decrease following bariatric surgery (Vazquez et al., 2005; 
Schernthaner et al., 2006; Kopp et al., 2005). Several single nucleotide 
polymorphisms (SNPs) were identified in the CRP gene and have been 
linked to elevated levels of serum CRP, low insulin sensitivity, and 
incidence of T2D (Hage & Szalai, 2007; Obisesan et al., 2006). 
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1.3 Cytokines  
Cytokines are a group of small and pharmacologically active polypeptides 
produced by cells that exert autocrine and paracrine functions. In the 
context of inflammation individual cytokines may trigger several biological 
activities, and different cytokines may function through the same 
transcription factors and signal transduction pathways. Pro-inflammatory 
and anti-inflammatory cytokines are important to host defense and innate 
immunity because they respond to multiple stresses very early, trigger the 
local inflammation cascade and allow the immune cells to get access to 
injured tissues (Alexandraki et al., 2006). 
 
1.3a TNFα 
It is a pleiotropic cytokine secreted both by immune cells and adipocytes. 
It is found in extracellular matrix, endothelium, and vessel walls of 
fibrovascular tissue. TNFα is known to stimulate the production of other 
cytokines such as IL-8 and IL-6 (Bruun et al., 2001; Barnes & Karin, 1997) 
and has been shown to play a role in obesity and particularly in the 
development of IR (Hotamisligil et al., 1993). While some studies have 
reported increases in serum TNFα in human subjects with IR (Dandona et 
al., 1998; Katsuki et al., 1998), others have reported the reverse (Muller et 
al., 2002; Bruun et al 2003b). It has been suggested that TNFα 
downregulates the tyrosine kinase activity of the insulin receptor 
(Hotamisligil et al., 1994 & 1996). The infusion of anti-TNFα antibodies in 
T2D patients, however, showed no effect on insulin sensitivity (Ofei et al., 
1996). 
 
The patients with T2D have 3-4 times greater serum levels of TNF-α 
compared to non diabetic subjects, and these levels are higher in diabetic 
patients with microalbuminuria compared with those that have 
normoalbuminuria (Moriwaki et al., 2003; Navarro et al., 2003). The 
urinary TNFα excretion correlates well with the clinical markers of diabetic 
nephropathy (DN) and progression of disease (Navarro et al., 2006b). The 
widespread distribution of TNFα  noticed in the retina of diabetic subjects 
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from both animals (Zhang et al., 2006) and humans (Limb et al., 1996) 
suggested that it also plays an important role in the pathogenesis of 
proliferative diabetic retinopathy. This cytokine is reported to be a key 
player in the development of T1D, contributing to beta cell dysfunction and 
death. The effects of TNFα in vivo, however, are age-dependent and there 
is evidence that TNFα can also have anti-diabetogenic effects (Meagher et 
al., 2001; Rabinovitch et al., 2001).  
 
1.3b IL-10 
IL-10 (initially characterized as cytokine synthesis inhibitory factor (CSIF)) 
is a pleiotropic type 2 helper T cells (Th2) -type cytokine that is produced 
by a wide range of immunological cell types, including B-cells, T-cells, 
monocytes and macrophages. It is a centrally operating anti-inflammatory 
cytokine that plays a crucial role in the regulation of the innate immune 
system (Akdis et al., 2001). Immunosuppressive effects of IL-10 involve 
both inhibition of cytokine synthesis (e.g., TNF-α, IL-6, IFN-γ) and their 
biological activities on target cells (Pestka et al., 2004)).  
 
It has been shown that polymorphisms and haplotypes of the IL-10 
promoter are associated with obesity and IR (Scarpelli et al., 2006) and 
co-treatment with IL-10 attenuates IR following acute lipid infusion (Kim et 
al., 2004). Lumeng et al. (2007) demonstrated that IL-10 was over 
expressed in adipose tissue macrophages from lean animals and these 
adipocytes showed polarization toward an alternatively activated state. 
This study further showed that IL-10 increases glucose uptake and 
protects against TNFα -mediated IR in isolated adipocytes. Another study 
showed that IL-10 improved insulin sensitivity and protected skeletal 
muscle from obesity-associated macrophage infiltration in transgenic IL-
10–overexpressed mice following high fat diet (Hong et al., 2009). 
 
The Leiden 85-Plus Study showed that low IL-10 production capacity (i.e., 
a pro-inflammatory cytokine response) was associated with high plasma 
glucose, high glycosylated haemoglobin (HbA1c), T2D, and dyslipidemia 
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(Exel et al., 2012). In another study, Yaghini et al. (2011) showed that IL-
10 serum levels were low in T2D patients compared to healthy controls 
and suggested that low levels of IL-10 is a risk factor in T2D. It appears 
that IL-10 levels prevent the development of the metabolic syndrome and 
T2D by counter regulating the effects of pro-inflammatory cytokines such 
as TNF-α and IL-6 and causes an upregulation of tyrosine kinase activity 
of the insulin receptor and decreases lipolysis (Hotamisligil et al., 1994 & 
1996; Feingold et al., 1992). 
 
IL-10 is crucial in the pathogenesis of T1D as well (Yang et al., 2002). IL-
10 was shown to increase pancreatic β -cell functions in response to 
glucose in vitro, and IL-10 plasmid therapy significantly reduced insulitis 
and prevented T1D in nonobese diabetic mice (Pennline et al., 1994).  
 
1.3c IL-1β 
IL-1β is the prototypical inflammatory cytokine and a critical early mediator 
of inflammation (Koh et al., 2005).  The primary sources of IL-1β are blood 
monocytes, tissue macrophages, and DCs. B-lymphocytes and natural 
killer (NK) cells also produce IL-1β (Dinarello et al., 2009).  
 
It has been shown that IL-1β impair insulin release, induces Fas 
expression and enables Fas-triggered apoptosis in rodent and human 
islets (Giannoukakis et al., 2000; Maedler et al., 2001; Stasis et al., 1997), 
and share similarities with glucose-induced apoptosis.  
 
A low concentration of IL-1β stimulates insulin release and proliferation in 
rat and human islets (Maedler et al., 2006; Spinas et al., 1986). The 
beneficial IL-1β effects appear to be partly mediated by the increased 
secretion of the naturally occurring anti-inflammatory cytokine and 
antagonist of IL-1α and IL-1β, the IL-1receptor antagonist (IL-1RA) 
(Dinarello, 2000). 
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In a prospective study, it was shown that elevated concentrations of both 
IL-6 and IL-1β were associated with a three fold increased risk of 
developing diabetes compared to the control group, but when only IL-6 
levels were increased and IL-1β levels undetectable, no increased risk 
was documented (Yuan et al., 2001; Kim et al., 2001) 
 
1.3d IL-6 
IL6, a 26kD glycoprotein, is an interleukin that acts as both a pro-
inflammatory and an anti-inflammatory cytokine. It is secreted by T cells 
and induces B cells to form antibody-forming plasma cells, and is also 
known as B cell stimulating factor-2 (BSF-2). Additionally, endothelial 
cells, skeletal and smooth muscle cells, islet β-cells, hepatocytes, 
microglial cells, astrocytes etc. also express and secrete IL-6  (Kamimura 
et al., 2003). 
 
Few studies demonstrated that elevated levels of IL-6 predict future risk of 
T2D development (Spranger et al., 2003; Hu et al., 2004; Pradhan et al., 
2001). However, CRP was found to be a stronger predictor than IL-6 of 
future T2D in two of the studies investigating both parameters (Hu et al., 
2004; Pradhan et al., 2001). These studies showed an association but not 
the causation.  
 
Adipose tissue is a major source of circulating IL-6 and that in obese 
subjects with or without T2D, adipose tissue IL-6 content correlates with 
impaired whole-body insulin–mediated glucose uptake and glucose 
tolerance (Bastard et al., 2002; Kern et al., 2001). The weight loss and 
bariatric surgery leads to decrease of IL-6 concentrations and 
improvement of IR (Kopp et al., 2003). IL-6 production in visceral adipose 
tissue is 3-fold higher compared with subcutaneous adipose tissue, 
indicating that IL-6 might be one of the factors that make visceral adipose 
tissue a high risk factor for the development of IR (Fried et al., 1998). 
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The role of IL-6 in IR is debatable. In humans, circulating IL-6 levels may 
(Ridker et al., 2000; Koukkunen et al., 2001; Bastard 2002) or may not 
(Carey et al., 2004; Petersen et al., 2007) be associated with IR. 
Interventional studies, using acute or chronic application of IL6, confirmed 
its potential to induce IR (Stith & Luo, 1994; Klover et al., 2003) and 
antibody neutralization experiments of IL6 also showed reversal of IL-6 
induced IR (Klover et al., 2005).  
 
However, IL-6 application to healthy volunteers not only failed to initiate IR 
(Krogh-Madsen et al., 2006), but also improved muscular glucose disposal 
and decreased endogenous glucose production (Weigert et al., 2006). 
These studies were however limited by a confined observation period of a 
maximum 3 hours, which was probably not sufficient to detect deleterious 
effects of IL-6 on insulin sensitivity. In humans, infusion of a physiological 
IL-6 concentration in healthy subjects, as well as T2D patients, increases 
lipolysis and enhances glucose infusion rates during euglycemic–
hyperinsulinemic clamp (Carey et al., 2006; Van Hall et al., 2003; Petersen 
et al., 2005).  
 
Mechanistically, the role of IL-6 in inducing IR is thought to be due to its 
ability to impair insulin signalling primarily in the liver by induction of 
suppressor of cytokine signalling 3 (SOCS3) and inhibitory IRS-1 
phosphorylation (Weigert et al., 2006). On the other hand, the role of IL-6 
in improving insulin sensitivity was attributed to IL-6 dependent activation 
of AMP-activated protein kinase (AMPK) (Weigert et al., 2006). 
 
Skeletal muscle contraction during exercise improves skeletal muscle 
insulin sensitivity (Holloszy et al., 2005; O’Gorman & Krook, 2011) and 
also increases IL-6 mRNA expression and subsequently the circulating IL-
6 concentration (Steensberg et al., 2000; Febbraio et al., 2004).  Acute IL-
6 exposure increases insulin action in cultured human skeletal muscle (Al-
Khalili et al., 2006; Weigert et al., 2005; Carey et al., 2006). Recent 
evidence suggests IL-6 is a crucial exercise-dependent signal and 
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increases circulating glucagon-like peptide 1 (GLP-1) and enhances β-cell 
function (Ellingsgaard et al., 2011).  
 
1.3e IFN-γ 
It is a Th1 cytokine and plays a role in defense against viruses and 
intracellular pathogens and in the induction of immune-mediated 
inflammatory responses. It is produced predominantly by natural killer and 
natural killer T (NKT) cells as part of the innate immune response, and by 
T helper type 1 lymphocytes (Th1) CD4 and CD8 cytotoxic T lymphocyte 
(CTL) effector T cells once antigen‐specific immunity develops 
(Schoenborn & Wilson, 2007). There is evidence that B cells and antigen-
producing cells (APC) also produce IFN-γ (Frucht et al., 2001). Its 
production is controlled by cytokines secreted by APCs, most notably 
interleukin IL-12 and IL-18. In macrophages, NK and T cells, the 
combination of IL-12 and IL-18 stimulation further increases IFN-γ 
production. Negative regulators of IFN-γ production include IL-4, IL-10, 
transforming growth factor (TGF)-β, and glucocorticoids (Munder et al., 
1998; Schindler et al., 2001). 
 
IFN-γ plays an important role in type 1 diabetes and lower levels of IFN-γ 
and IL-4 were noticed in newly diagnosed diabetic patients (Halminen et 
al., 2001; Avanzini et al., 2005). It has been proposed that absence of IFN- 
γ production makes beta cells highly susceptible to viral infection and 
subsequent attack by natural killer cells lead to hyperglycaemia and 
diabetes mellitus. Low IFN- γ and IL-12 levels has also been observed in 
T2D patients (Tsiavou et al., 2004 & 2005). The frequency of the low IFN- 
γ production allele (IFN-γ 874*A) was significantly higher in T2D, and 
CD4+ and CD8+ cells obtained from T2D released significantly lower 
amounts of IFN- γ in the intracellular space. Based on a combination of 
molecular and immunological observations it appears that IFN-γ also 
contributes in development of T2D.  
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IL-1β along with TNFα and IFN γ has been shown to induce β-cell 
apoptosis in both types of diabetes. In vitro, IL-1β appeared the most β-
cell cytotoxic cytokine sufficient to cause inhibition of β-cell function and 
often sufficient to promote an apoptotic response. However, massive 
induction of apoptosis in β-cells usually requires a combination of IL-1β 
plus IFN-γ and/or TNFα. (Maedler et al., 2001 & 2002; Giannoukakis et al., 
1999; Stassi et al., 1997; Cnop et al., 2005). 
 
1.3f IFN-β 
IFN-β is generally produced in response to a viral infection, and the IFN-β 
dependent upregulation of genes increase presentation of viral peptides 
by major histocompatibility complex (MHC) class I molecules to facilitate 
CD8 T cell recognition and destruction of infected cells. IFN-β activates 
and induces proliferation in NK cells (Janeway et al., 1999). 
 
IFN-β has been shown to immunomodulate the Th1/Th2 cytokine profile 
by attenuating the secretion of IFN-γ and IL-12 and augmenting IL-4 and 
IL-10 secretion (Sellner et al., 2008). Literature search did not reveal any 
study on IFN-β in relation to T2D. However, in an animal study, transgenic 
mice, expressing IFN-β in β-cells, presented with impaired β-cell function, 
hypoinsulinemia, and altered glucose tolerance test, all features of a 
prediabetic state, and it was demonstrated that there might be an 
association between IFN-β and T1DM (Pelegrin et al., 1998). 
 
1.3g IL-12p70 
It is a pro-inflammatory cytokine, produced by antigen presenting cells like 
DCs, macrophages and NK cells.  It plays a critical role in cell-mediated 
immunity (CMI)-IL12p70 induces NK cells and T cells to produce pro-
inflammatory cytokines, such as IFN-γ, IL-2, IL-3 and TNFα. It contributes 
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to NK cell maturation (Trinchieri et al., 1997) and, along with other pro-
inflammatory factors; it stimulates CD4+CD25_ T cell activation in the 
presence of regulatory T cells (King et al., 2005). 
 
IL-12p70 also regulates naïve T cell differentiation into type 1 T helper 
cells (Th1), and inhibits differentiation into Th2 (Kang et al., 2005; Stern et 
al., 1996). IL-12 and Th1 cell infiltration has emerged as an important 
pathway for autoimmune diabetes as well as chronic inflammation 
associated with atherosclerosis (Alleva et al., 2000; Ferrnandes et al., 
2004). 
 
It is involved in the pathogenesis of T1D (Kang et al., 2005; Skarsvik et al., 
2005), but its role in T2D is uncertain. It has been shown that IL-12 plasma 
levels are elevated in T2D (Winkler et al., 1998; Wegner et al., 2008), and 
it contributes in atherosclerotic plaque formation and probably augments 
macrovascular complications in T2D (Uyemura et al., 1996; Hauer et al., 
2005). Wegner et al. (2008) also demonstrated that the IL-12 serum 
concentration in T2D primarily is dependent upon fasting serum proinsulin 
concentration. 
 
1.4 Chemokines 
Chemokines /chemotactic cytokines are low molecular weight signaling 
proteins that regulate the migration of different types of cells by interacting 
with corresponding G protein coupled transmembrane receptors present 
on the surfaces of their target cells and play a fundamental role in host 
and innate immunity. The KORA Survey S4 study population showed not 
only upregulated chemokines IL-10 and RANTES in T2D but also raised 
RANTES in impaired glucose tolerance (IGT) and supported the fact that 
these immune abnormalities precede T2D by several years (Herder et al., 
 45 
2005). Chemokines have been hypothesized to be involved in 
macrophage infiltration into adipose tissue in obesity and might therefore 
play an important role in the development of obesity-related disorders like 
T2D. Recently, CCX140-B, an inhibitor of the chemokine receptor known 
as CCR2, has been shown to have beneficial effect on glycaemic control 
in Phase 2 clinical trial in T2D (Hanefield et al., 2012).  
 
1.4a RANTES 
RANTES is a protein encoded by CCL5 gene. It belongs to the β-subgroup 
of the chemokine family with pro-inflammatory actions. It is expressed by a 
large variety of cells, such as T-cells, endothelial cells, gestational tissues 
(Wender-Ozegowska et al., 2008) as well as adipocytes and has been 
hypothesized to mediate leukocyte infiltration of adipose tissue in obesity 
(Wu et al., 2007; Poulain-Godefroy et al., 2007).  
 
Circulating RANTES concentrations are elevated in obesity, IGT and T2D 
(Normura et al., 2000; Herder et al., 2005). In the Finnish Diabetes 
Prevention Study, high RANTES levels were associated with resistance to 
lifestyle intervention and higher incidence of T2D in the intervention group 
(Herder et al., 2006).  It has been shown in a large cohort of subjects that 
the CCL5 gene variant and RANTES serum concentration were not 
causally related to T2D and it was argued that the elevated level of 
RANTES in both T2D and IGT group might be a consequent of 
hyperglycaemia (Herder et al., 2008) instead of the cause of 
hyperglycaemia. 
 
1.4b IL- 8 
IL-8 is a potent chemoattractant (chemokine) and its main sources are 
macrophages, endothelial and epidermal cells. It induces recruitment of 
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neutrophils and T-cells into the subendothelial space, as well as adhesion 
of monocytes to endothelium (Gerzten et al., 1999). It seems that the PMN 
activation in diabetic patients is an important pathogenic link in long-term 
complications of the disease (Huseynova et al., 2009).  
 
 IL-8 is stimulated by high glucose concentrations in endothelial cells in 
vitro and has a chemotactic activity for PMN, lymphocyte T and smooth 
muscle cells (Urakaze et al., 1996.) Plasma levels of IL-8 have been found 
to be significantly increased in patients with both T1D and T2D compared 
with healthy subjects (Zozulinska et al., 1999; Esposito et al., 2003). A 
study showed increased levels of serum IL-8, TNF-α and TGF-β1 levels in 
T2D patients with a significant increase in the stage of decompensation, 
suggesting that these cytokines may participate in the development and 
progression of diabetic complications (Huseynova et al., 2009). Another 
study revealed an increase in IL-8 concentrations in the vitreous of 
patients with diabetic retinopathy and suggested that IL-8 participates in 
the pathogenesis of diabetic retinopathy (Elner et al., 1995). It has been 
reported that urinary levels of IL-8 were significantly increased in patients 
with T2D nephropathy (Tashiro et al., 2002). 
 
It has been reported that circulating IL-8 correlates with measures of 
adiposity and insulin sensitivity, suggesting its involvement obesity-related 
health complications (Bruun et al., 2003b).  The plasma levels of IL-8 in 
abdominally obese subjects is noticed higher than in lean subjects 
(Straczkowski et al., 2002). Brunn et al. (2004) further demonstrated that 
there was increased release of IL-8 from visceral adipose tissue compared 
with subcutaneous AT and primarily the release was from nonfat cells from 
AT. IL-8 has also been reported to play a role in plaque destabilization and 
to predict cardiovascular death in patients with coronary artery disease 
(CAD) (Blankenberg at al., 2002).  
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1.5 Adipokines 
Adipokines are biologically active substances that are secreted by the 
adipocytes of white adipose tissue (WAT). Notably, these factors may be 
synthesised at other sites within the body and participate in functions 
unrelated to those within WAT (Lago et al., 2007). They play a key role in 
modulating not only inflammation, but also immune and autoimmune 
reactivity. Adipokines include a variety of pro-inflammatory peptides 
including TNF and anti-inflammatory factors such as IL-1RA, which binds 
competitively to the IL-1 receptor without triggering activity within the cell, 
and IL-10. We measured the following adipokines in the current study- 
 
1.5a Retinol binding protein                                                                                   
RBP4 is an adipokine associated with obesity and comorbidities, 
especially IR, T2D, and certain components of the metabolic syndrome 
(Graham et al., 2006). Liver has the highest expression level of RBP4; 
however, AT has the second highest rate of expression, i.e. 20–40% of 
that found in the liver (Tsutsumi et al., 1992). The RBP4 gene is located 
on chromosome 10 (10q23–q24) near the region that has been linked to 
increased fasting glucose levels in European Caucasians and to T2D in 
Mexican–Americans (Duggirala et al., 1999). 
 
RBP4 is preferentially expressed in visceral fat when compared with 
subcutaneous fat  (Kloting et al., 2007). Omental adipose tissue is an 
important source of RBP4 in severely obese patients (Kelly et al., 2010). In 
a recent study, higher waist circumference and waist-to-hip ratio were 
associated with higher RBP4 levels and markers of systemic inflammation 
(Hermsdorff et al., 2010). Few studies have shown that significant 
decrease in weight, achieved by diet, exercise, or bariatric surgery, leads 
to a decrease in circulating and/or adipose tissue RBP4 levels.  The 
changes in RBP4 levels in non-diabetic subjects during weight loss were 
significantly correlated with the amount of visceral fat loss but were not 
associated with the amount of total body fat loss or abdominal 
subcutaneous fat loss (Lee et al., 2008). A decrease in serum RBP4 levels 
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achieved by exercise training predicts the improvement in insulin 
sensitivity with greater specificity than leptin, adiponectin, IL-6, or CRP 
(Graham et al., 2006).  
Serum RBP4 levels are increased in subjects with impaired glucose 
tolerance, T2D, and correlate inversely with insulin sensitivity in non-
diabetic subjects with a family history of T2D (Yang et al., 2005; Graham 
et al., 2006). Circulating RBP4 levels correlate with the degree of IR in 
these subjects and relationship is independent of obesity. Weight loss and 
exercise decrease RBP4 levels in subjects with IR and T2D (Graham et 
al., 2006). Therapy with insulin sensitizing agent rosiglitazone also 
decreases circulating RBP4 levels (Jia et al., 2007).  The RBP4 
haplotypes were related to an increased risk of T2D (Craig et al., 2007) 
 
However, in several clinical studies, associations and/or causality of 
observed RBP4 expression changes with these states could not be shown 
(Yao-Borengasser et al., 2007; Broch et al., 2007; Ulgen et al., 2010; 
Promintzer et al., 2007). 
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Figure 1.3 Role of adipocytokines in the modulation of glucose 
metabolism. Increased adipose tissue mass is associated with decreased 
adiponectin levels and increased RBP4, IL-6, and TNFα production, which 
in turn stimulates LCN2 synthesis. LCN2 upregulates adiponectin & 
downregulates TNFα. The circulating levels of FFAs are increased in 
obesity. Decreased adiponectin and increased RBP4 levels leads to 
decreased fatty acid oxidation, increased gluconeogenesis in the liver and 
accounts for IR. Adiponectin suppresses expression of ICAM-1, E-selectin, 
and VCAM-1, macrophage-associated SR-A and decreases foam cell 
formation and exerts antiatherosclerotic effects. FFA, free fatty acid; 
ICAM-1, intercellular adhesion molecule-1; IR, insulin receptor; IRS, insulin 
receptor substrate; PPARγ, peroxisome proliferator-activated receptor 
gamma; SR-A, scavenger receptor-A; VCAM-1, vascular cell adhesion 
molecule-1. (Reproduced from ref. Esteve et al., 2009). 
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1.5b Lipocalin-2 (LCN2) 
LCN2, also known as oncogene 24p3 or neutrophil gelatinase-associated 
lipocalin (NGAL), is an adipokine that belongs to the superfamily of 
lipocalins (such as RBP4) and in humans is encoded by the LCN2 gene. It 
is expressed in neutrophils and in low levels in the kidney, adipocytes, 
prostate, and epithelia of the respiratory and alimentary tracts (Cowland et 
al., 1997) and also used as a biomarker of kidney function (Devarajan et 
al., 2010). LCN2 is implicated in innate immunity and recently the LCN2 
gene was identified as a novel IL-17–induced gene (Shen et al., 2006).  
LPS and TNFα are two of the strongest inducers of LCN2 production. The 
TLRs, expressed on immune cells, stimulate the synthesis and secretion 
of LCN2 upon exposure to bacteria and LCN2 can bind to the bacterial 
siderophores and so limit bacterial growth (Yang et al., 1997; Flo et al., 
2004). LCN2 deficiency resulted in an increased susceptibility to bacterial 
infection in a mice experiment (Berger et al., 2006). 
 
LCN2 is highly expressed in adipose tissue levels and circulating levels 
are increased in obese animals and human subjects with T2D (Wang et 
al., 2007; Yan et al., 2007). The agents that promote IR including TNFα, 
glucocorticoids, and hyperglycaemia increased the expression of LCN2, 
and thiazolidinediones, an insulin-sensitizing agent reduced it (Wang et 
al., 2007; Yan et al., 2007).  Yan et al. (2007) further demonstrated that 
LCN2 2 promotes IR in cultured adipocytes. These data suggest that 
LCN2 acts as an adipocyte-derived mediator of insulin resistance in 
obesity and inflammation (Jun et al., 2011). However, studies revealed 
discordant results on the role of LCN2 in the modulation of insulin 
sensitivity. One group showed that Lcn2−/− mice were leaner and more 
insulin sensitive and the other showed that Lcn2−/− mice were more 
obese and insulin resistant (Guo et al., 2010; Law et al., 2010). Contrary to 
this, Jun et al. (2011) found that only male Lcn2−/− mice on a high-fat diet 
(HFD) had a small improvement in glucose tolerance, but that ablation of 
LCN2 had no effect on insulin sensitivity in the chow-fed mice of either sex 
or in female HFD-fed mice. 
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LCN2 has been shown to antagonise the detrimental effects of 
inflammatory molecules on inflammation and metabolism in adipocytes 
and macrophages. Moreover, LCN2 upregulated peroxisome proliferator– 
activated receptor (PPAR)-γ and its target genes, adiponectin, leptin, fatty 
acid synthase, and lipoprotein lipase in adipocytes and suppression of 
LCN2 expression resulted in decreased expression of PPAR-γ (Zhang et 
al., 2008).  LCN2 antagonized the effect of TNFα on adipocytes and 
macrophages, protected adipocytes from TNF-α–induced production of IL-
6 and MCP-1, attenuated TNFα effect on glucose uptake, and completely 
reversed TNFα mediated inhibition of leptin and adiponectin secretion from 
adipocytes (Zhang et al., 2008).   The stimulatory effect of LPS on 
cytokine gene expression in macrophages was also significantly 
attenuated by LCN2 (Zhang et al., 2008). This suggests that the anti-
inflammatory effect of LCN2 is associated with modulation of PPARγ 
activity via direct or indirect mechanisms, may be through the inhibition 
NF-κB activity (Zhang et al., 2008).  These findings suggests that anti-
inflammation is the primary role of LCN2 and the increased LCN2 levels in 
obesity and IR is reflection of protective mechanism against inflammation 
(Esteve et al., 2009)). 
 
1.5c Adiponectin 
Adiponectin is the most abundant protein secreted by adipocytes and acts 
as a hormone with anti-inflammatory and insulin sensitizing properties 
(Esteve et al., 2009).  The animal models and humans studies suggest 
that adiponectin decreases the risk of T2D by lowering hepatic 
gluconeogenesis, enhancing fatty acid oxidation in the liver, stimulating 
fatty acid oxidation and glucose uptake in skeletal muscle, and improving 
insulin secretion (Kadowaki et al., 2006; Rabe et al., 2008). 
 
Adiponectin exerts its effect through two distinct receptors termed 
adiponectin receptor 1 (AdipoR1) and adiponectin receptor2 (AdipoR2) 
and leads to phosphorylation and activation of AMPK and increased 
expression of PPAR-α.  TNFα and IL-6 regulate adiponectin production by 
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reducing gene expression whereas insulin sensitizers and PPAR-γ 
agonists increase adiponectin levels in mice and humans (Kadowaki et al., 
2005). Adiponectin secretion, in contrast to secretion of other adipokines, 
is paradoxically decreased in obesity (Bruun et al., 2003a).  This may be 
attributable to inhibition of adiponectin gene transcription by inflammatory 
and angiogenic factors secreted by hypertrophic adipocytes (Hajer et al., 
2008) 
 
In intervention studies, circulating adiponectin levels increased after 
weight loss in humans. Diet, gastric bypass surgery, orlistat, or selective 
cannabinoid receptor type 1 (CB1) -receptor blockade with rimonabant 
significantly increased adiponectin levels in parallel to reduced body 
weight (Despres et al., 2005). Thiazolidinediones increased adiponectin 
expression and circulating levels in rodents, nondiabetic subjects, and 
patients with T2D. Exercise without significant weight loss did not affect 
circulating adiponectin, but improved insulin resistance, suggesting 
different pathways for the insulin-sensitive mechanism of exercise other 
than adipokine modulation (Kadowaki et al., 2006). 
 
A meta - analysis of thirteen prospective studies with a total of 14 598 
participants and 2623 incident cases of T2D showed that higher 
adiponectin levels are associated with a lower risk of T2D across diverse 
populations, consistent with a dose-response relationship (Li et al., 2009) 
 
Despite the well-documented negative association between adiponectin 
and several inflammatory factors, adiponectin was found increased in 
chronic inflammation associated with autoimmune diseases, such as T1D, 
systemic lupus erythematosus (SLE), RA, and inflammatory bowel disease 
(IBD), suggesting that adiponectin levels increase in chronic inflammatory 
conditions that are not associated with obesity. It is possible that 
adiponectin could have a protective role in inflammation related to adipose 
tissue loss during starvation and fasting, but not in inflammation 
unassociated with obesity (Esteve et al., 2009). 
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1.6 Toll-like receptors  
TLRs are a conserved family of pattern recognition receptors that play a 
fundamental role in the innate immune system by triggering 
proinflammatory-signalling pathways in response to microbial pathogens.  
Thirteen mammalian TLRs, TLR1-13, have been identified to date, which 
includes 11 human (Miggin and O’Neill et al., 2006). Different microbial 
structures are recognized by different TLRs (Fig. 1). LPS from Gram-
negative bacteria is recognized by TLR4. Gram-positive bacteria activate 
TLR2, while bacterial components, such as lipopeptides and lipoteichoic 
acid (LTA) are recognized by TLR2 in cooperation with TLR1 or TLR6. 
Viral and/or bacterial nucleic acids are recognized by TLR3, TLR7, TLR8 
and TLR9 (Quereshi et al., 2003; Schwandner et al., 1999; Okusawa et 
al., 2004). TLR3 recognizes viral dsRNA and synthetic 
polyinosinepolycytidylic acid (polyIC), while viral single-stranded RNA 
(ssRNA) and the antiviral compounds imiquimod and resiquimod (R848) 
are ligands for TLR7 and TLR8 (Alexopoulou et al., 2001; Diebold et al., 
2004).  
 
Bacterial DNA and the synthetic unmethylated oligonucleotides containing 
CpG dinucleotides (CpG) are recognized by TLR9 (Hemmi et al., 2000). 
TLR5 is activated by flagellin from bacterial flagella (Hayashi et al., 2001). 
TLR11 recognises uropathogenic bacteria and a protozoan-derived 
profilin-like protein (Yarovinsky et al., 2005). The ligands for TLR10, 
TLR12 and TLR13 are currently unknown. 
 
 
1.6a   TLR signalling 
TLRs 1, 2, 4, 5, 6 are trans-membrane proteins, while TLRs 3, 7, 8 and 9 
are predominantly localized intracellularly. Their common structure 
consists of an extracellular leucine-rich repeat (LRR) domain and a 
cytoplasmic domain, sharing homology with the mammalian IL-1 receptor 
(Takeda et al., 2003). The LRR domain binds ligands, while the 
cytoplasmic Toll-IL-1 receptor (TIR) domain initiates intracellular signalling 
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pathways through homotypic protein-protein interaction with TIR-adapter 
molecules (O'Neill et al., 2007). Four TIR-adapter molecules have been 
shown to mediate TLR signalling; myeloid differentiation factor 88 
(MyD88), myeloid adapter-like protein (Mal) also known as Toll/interleukin-
1-receptor (TIR)-domain-containing adaptor protein (TIRAP), TIR-domain 
containing adaptor inducing protein inducing IFN-β (TRIF) and TRIF-
related adapter molecule (TRAM) (Figure 1). In TLR4 signalling MyD88 
dependent signaling is facilitated by the adaptors, MyD88 and Mal, 
resulting in the activation of NF-κB and production of inflammatory 
cytokines (Fitzgerald et al., 2001). MyD88-independent signalling, 
facilitated by the adaptors TRIF and TRAM, leads to activation of 
interferon regulatory factor 3 (IRF-3) and induction of Type I IFNs 
(Yamamoto et al., 2003a). TLR2 signaling utilizes both Mal and MyD88 in 
a manner similar to TLR4, while TLR7/8 and TLR9 require only MyD88 for 
signalling (Akira et al., 2006). TLR3 signalling requires TRIF alone, and is 
the only TLR known to signal in a MyD88-independent manner 
(Yamamoto et al., 2003b). A fifth TIR-adapter SARM (sterile alpha and 
HEAT-Armadillo motifs containing protein) may interact with TRIF and 
inhibit its function (Carty et al., 2006). However, cells from animals 
deficient in SARM do not display altered TLR signaling (Carty et al., 2006). 
Interestingly, SARM has been shown to contribute to neuronal death in 
viral infections (Peterson et al., 2012). 
 
 
 
 55 
 
Figure 1.4 Overview of selected members of the TLR family, ligands and the 
TIR-adapters. TLRs 1, 2, 4, 5, and 6 are located primarily in the plasma membrane 
and interact with components of microbial pathogens while TLRs 3, 7, 8, and 9 are 
situated in the membranes of endosomes and lysosomes. TLR4 activates two 
distinct signalling pathways: one pathway is activated by the adaptors MAL and 
MyD88 leading to activation of NF-κB and finally production of inflammatory 
cytokines, and the second pathway is activated by the adaptors TRIF and TRAM 
leading to the induction of IRF-3 and type I IFNs. TLR2 signalling utilises both Mal 
and MyD88, while TLR7/8 and TLR9 require only MyD88 for signalling. TLR3 
signalling requires TRIF alone. TLR, Toll like receptors, MAL, myeloid adapter-like 
protein, MyD88, myeloid differentiation factor 88, TRIF, TIR-domain containing 
adaptor inducing protein inducing IFN-β, TRAM, TRIF-related adapter molecule, 
NF-κB, Nuclear factor kappa- -light-chain-enhancer of activated B cells, IRF-3, 
interferon regulatory factor 3 and IFN, Interferon. 
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1.6b TLR responses 
Activation of the MyD88-dependent pathway results in the induction of 
many genes including IkB protein IκBζ, which functions as an inducible 
coactivator for the NF-κB p50 subunit to facilitate IL-6 and IL-12p40 
induction (Yamamoto et al., 2004). Also, C/EBPδ, which acts together with 
NF-κB serves to maximize IL-6 production (Litvak et al., 2009). IκB-NS 
(also known as IkB-d, or Nfkbid: nuclear factor of k light polypeptide gene 
enhancer in B-cells inhibitor, delta), a TLR-inducible nuclear IkB protein, 
suppresses the induction of both IL-6 and TNF by modulating the DNA-
binding activity of the NF-κB p65 subunit (Kuwata et al., 2006). Also, 
activating transcription factor 3 (ATF3) restricts NF-κB activity by recruiting 
histone deacetylase (Gilchrist et al., 2006) In addition to NF-κB activation; 
the TRIF dependent pathway also activates IRF3 and interferon-β 
transcription (Kawai et al., 2010). 
 
The immune response is determined by the actual TLRs that are activated 
(Agrawal et al., 2003; Seya et al., 2006).  Distinct TLR ligands instruct 
human DCs to induce distinct T helper (Th) cell responses by differentially 
modulating mitogen-activated protein kinase signalling (Agrawal et al., 
2003). TLR3, TLR8 and surface-expressed TLRs are expressed in 
antigen-presenting myeloid dendritic cells (mDCs) while TLR7 and 9 are 
expressed in human plasmacytoid DCs (pDCs) (Liu et al., 2006). Thus, 
TLR3, TLR8 and surface-expressed TLRs such as TLR2, 4 and 5 are 
mainly involved in the modulation of antigen-presentation in mDC.  DCs 
activated by TLR9 and TLR7/8 ligands yield IL-12, IFNα and induce strong 
Th1 and CTL responses in a MyD88-dependent manner (Blasius et al., 
2010). DCs triggered via TLR3 yield mostly IFNα and also induce Th 1 and 
CTL responses (Blasius & Beutler, 2010). TLR4 ligands predominantly 
induce IL-12, IFNα and drive a Th1 response.  LPS and poly (I:C) 
additionally induce upregulation of costimulatory molecules such as CD40, 
CD80 and CD86 in an IFN-β dependent manner, via type I interferon 
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receptor (IFNRI), on macrophages and DC (Hoebe et al., 2003).  
 
The activation of DCs by TLR ligands is necessary for their maturation and 
consequent ability to initiate adaptive immune responses. mDCs are 
central to T/B cell activation and facilitate production of antibodies through 
the induction of differentiation of B lymphocytes. T lymphocytes are 
differentiated by matured mDCs into Th1, Th2 and CTL. mDCs process 
antigens, alter their function and migrate to draining lymph nodes (Fig. 1).  
 
The disruption in negative regulators of TLRs results in persistent 
inflammation. These include splice variants for adaptors or their related 
proteins, ubiquitin ligases, deubiquitinases, transcriptional regulators and 
microRNAs. The negative regulators are helpful in suppressing 
inflammation and might plat an important role in immunity (Kawai et al., 
2010). 
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Figure 1.5 Role of human TLRs in mDC maturation followed by 
activation of various lymphocytes. Immature dendritic cells (mDC) 
residing in local tissue phagocytose exogenous antigen (Ag) and pattern 
molecule (namely adjuvant) and initiate the maturation process. During 
maturation mDC induce IFNs, cytokines and chemokines, allow the 
upregulation of co-stimulators, NK-activating ligands (ULBP, MIC, etc.) 
and MHC, and activate a variety of lymphocytes. These maturation events 
are largely dependent on adjuvant properties. Also, adjuvant may 
participate in switching on of some unknown mechanisms, which are 
essential in induction of CD8+ CTL by mDCs. Adapted from ref. Seya et 
al., 2006.  
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1.6c TLRs and diabetes 
Both human and rodent pancreatic islets (Wen et al., 2004) express TLRs 
and TLRs been shown to play a multifaceted role in the development of 
diabetes, which include β-cell immune response and metabolic disorder 
associated inflammation. 
 
Emerging evidence indicates that the pro-inflammatory pathways may 
become activated due to metabolic syndrome, which includes insulin 
resistance, hyperinsulinemia, dyslipidemia, obesity and hypertension, and 
lead to consequential interference with insulin signalling and cause insulin 
insensitivity in the target organs, such as endothelium, adipose tissue, 
liver, skeletal muscle and most recently podocytes (Shrivastava et al., 
2013).  The LPS-derived saturated FFA which is present in abundance in 
metabolic abnormalities plays a key role in modulating the IR and it is 
postulated that the TLRs signaling cascade may become activated by the 
FFA and thereby affect the pathogenesis of obesity and metabolic 
syndrome (Schaeffler et al., 2009). Increased expression of TLR2 and 
TLR4 along with IL-1b, IL-6, IL-8 and NF-κB nuclear binding has been 
demonstrated in metabolic syndrome patients without diabetes or CAD 
(Jilal et al., 2012). 
 
The mechanism by which TLR2 and TLR4 modulate insulin resistance 
was studied in different tissues (Mohammad et al., 2006).  In adipose 
tissue, TLRs/NF-κB pathway may be directly activated by nutrients, 
especially the saturated fatty acid, and so may mediate inflammation 
through interaction between adipocytes and infiltrated macrophages 
(Nguyen et al., 2007; Shi et al., 2006; Suganami et al., 2007; Vitseva et 
al., 2008; Yeop Han et al., 2010). The functional expression of TLR2 and 
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TLR4 has also been confirmed in human AT (Song et al., 2006; Zhang et 
al., 2009).  Elevated TLR4 expression, but not TLR2, was detected in 
muscle biopsies from obese and T2D patients, and correlated with 
homeostatic model assessment, HOMA-IR and fasting plasma FFA 
concentrations (Reyna et al., 2008).  
 
The role of PBMC TLRs in diabetes has been extensively studied using a 
series of clinical and animal study. In T1DM patients, the increased TLR2 
and TLR4 expression in monocytes was associated with increased HbA1c 
levels (Devaraj et al., 2008), while in newly-diagnosed T2D subjects, the 
upregulation of TLR2 and TLR4 was correlated with HOMA-IR (Dasu, et 
al., 2010).   Another study showed that TLR4 expression and signalling 
was elevated in IR patients (Reyna et al., 2008), which may be caused by 
elevated plasma FFA levels and contributed to the pathogenesis of IR in 
humans. In another study, TLR4 deficient 10ScN mice were exposed to 
high saturated fat and it showed that TLR4 deficiency, protected mice 
against the obesigenic effects of SFA and altered obesity-related 
inflammatory responses in adipose tissue (Davis et al., 2008). 
Interestingly, insulin infusion significantly suppressed TLR1, 2, 4, 7 and 9 
mRNA expressions in mononuclear cells within 2 h (Ghanim et al., 2008), 
whereas high glucose induces the expression of TLR mRNA (Dasu et al., 
2008).  In vitro, hyperglycaemia induced TLR2 and TLR4 expression via 
protein kinase C (PKC) and NADPH oxidase activation, and knocking 
down of TLR2 and TLR4 significantly downregulated the high glucose-
induced NF-κB activation. Additionally, high glucose also induces TLR2 
receptor dimerisation with TLR6 and activate downstream MyD88-
dependent signaling pathway (Dasu, et al., 2008).  In vivo, PPARγ agonist 
could exert its anti-inflammatory effect via modulating the TLR2 and TLR4 
signaling in db/db mice. Therefore, the role of TLR2 and TLR4 in 
monocytes and macrophages provides further evidence of systemic 
proinflammatory state in diabetes. 
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Recent results from TULIP and METSIM studies showed that TLR4 
genetic variation (D299G/T399I) correlated with increased total body fat, 
visceral fat and impaired insulin sensitivity, and they may contribute to the 
risk factor for diabetes and metabolic syndrome in more than 6000 non-
diabetic Caucasians (Weyrich et al., 2010). This result was consistent with 
the data of other studies, which showed that TLR4 polymorphism was 
associated with dyslipidemia, vascular inflammation, and diabetic 
neuropathy in T2D patients (Buraczynska et al., 2009; Kolek et al., 2004; 
Rudofsky et al., 2004). However, a number of other studies found no 
correlation between TLR2 or TLR4 polymorphism and diabetes or 
metabolic syndrome (Illig et al., 2003; Santin et al., 2006). On the other 
hand, TLR2 (Ht4 and rs3804100 T) variation was reported to be strongly 
associated with T1DM (Bjornvold et al., 2009; Park et al., 2004), and (593 
C/T, 2642 C/Am and 2690 A/G) polymorphism in TLR3 was associated 
with T1D in South African Blacks with T1DM (Pirie et al., 2005).  However, 
a recent study evaluated the association of TLR4 +3725G/C and 
+11367G/C polymorphisms with T2D in the Chinese population and it was 
demonstrated that people carrying 11367CC genotype may have 46 % 
less risk of developing T2D compared to those with GG genotype (Jiang et 
al., 2013a). 
 
Collectively, we noticed that there is paucity of data examining adipokine 
and TLR expression in T2D. In particular, the role of glycaemic control in 
modulating adipokine and TLR expression is uncertain. With this concern, 
we carried out a pilot study to investigate mRNA expressions of TLR2, 
TLR6 and TLR4 in non-diabetic subjects (n=10, HbA1c 5.3±0.2%) and 
compared to T2D subjects with good (n=9, HbA1c 6.7± 0.7%*) and poor 
glucose control (n=8, HbA1c 10.9±2.2%*) by qPCR (*p<0.05 vs. control).  
Interestingly, our data showed that TLR2, TLR4 and TLR6 mRNA 
expressions were suppressed in T2D subjects (presented as Late 
breaking abstract in ADA in 2009, Siednienko et al., 2009b). This was in 
contrast to previous studies, which had shown overexpressed TLR2 and 
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TLR4 in T2D (Reyna et al., 2008; Dasu et al., 2010). The T2D subjects in 
our pilot study were not classified according to the presence or absence of 
diabetes-related complications and it was conceivable that complications 
and treatment could have affected the TLRs result in this study. To explore 
the role of glycaemic control and diabetes-related micro/macrovascular 
complications in TLRs expresion, we decided to divide the T2D cohort in 4 
groups i.e. GC, T2D with good glycaemic control (HbA1c <7.5%) and no 
macrovascular complications (heart disease, Transient ischaemic stroke 
(TIA)/stroke or peripheral arterial disease (PAD)) and microvascular 
complications  (retinopathy, neuropathy or nephropathy); GCC, T2D with 
good glycaemic control and complications; PC, T2D with poor glycaemic 
control (HbA1c >7.5%) without complications, and PCC, T2D with poor 
glycaemic control and complications, and compare them with the healthy 
controls (NGT, normal glucose tolerant). It has been shown that 
monocytes and neutrophils differ in the surface expression of TLR mRNAs 
(Muzio et al., 2000) and with this in mind, we aimed to evaluate mRNA 
expressions in both monocytes and neutrophils. Knowing that adipokines 
data are lacking in T2D, we aimed to investigate the adipokines mRNA 
expression in these 4 different T2D study groups.  
 
Previous studies have shown altered cytokines level in T2D subjects. In 
our pilot study we also measured serum levels of pro-inflammatory 
cytokines IL-6, IL-1β and TNF-α by ELISA and showed elevated IL-6 in 
T2D subjects compared to healthy controls (presented as Late breaking 
abstract in ADA in 2009, Siednienko et al., 2009b).  There has been no 
prior study in relation to IFNβ and T2D. IFN-β has been shown to 
immunomodulate the Th1/Th2 cytokine profile by attenuating the secretion 
of IFN- γ and IL-12 and augmenting IL-4 and IL-10 secretion (Sellner et 
al., 2008). With the aim of exploring the inflammatory and anti-
inflammatory milieu in T2D, we sought to investigate pro-inflammatory 
cytokines; IL-6, TNF-α and IL-1β and IFNβ, anti-inflammatory cytokines; 
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IL-10, IL-8 and Rantes, and Th1 cytokines: IL-12 and IFN-γ in 4 different 
T2D study groups and comparing with NGT subjects.  
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Aims of Study 
 
The overall aim of this study was to determine whether T2D is a chronic 
inflammatory condition and is associated with raised inflammatory 
markers. Our aim was to investigate if the degree of inflammation varies 
with glycaemic control and with diabetes associated long-term 
microvascular and macrovascular complications. To investigate this, we 
determined the serum concentration of various inflammatory markers 
including CRP, pro-inflammatory and anti-inflammatory cytokines and 
chemokine in different T2D profile subjects, those with good and poor 
glycaemic control with or without complications and compare them with 
the healthy controls. We sought to evaluate cytokines, adipokines and 
TLR’s gene expression in the monocytes and neutrophils of T2D subjects 
and compare them with the healthy controls. In particular our objectives 
were as follows: 
 
1.  To compare the circulating pro-inflammatory cytokine levels in the 
blood of T2D subjects and healthy controls by employing biochemical 
techniques 
2.  To perform comparative analysis of cytokines expression in subjects 
with T2D (with either good or poor glucose control, +/-complications) 
relative to normal individuals. 
3.  To perform comparative analysis of adipokine expression in subjects 
with T2D (with either good or poor glucose control, +/-complications) 
relative to normal individuals. 
4.  To perform comparative analysis of TLR expression in subjects with 
T2D (with either good or poor glucose control, +/-complications) relative to 
normal individuals. 
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Materials and Methods 
 
 
 
 
 
 
 
 66 
2.1 Patients and Methods 
The local research ethics committee, Department of Public Health, Health 
Service Executive, Midland area and Ethical Review Board, National 
University of Ireland Maynooth, Co. Kildare, Ireland, approved the 
research project of this study. 
 
Research participants were identified following inspection of the lists of 
patients due to attend the Diabetes Day Centre (DDC) and outpatient 
endocrinology clinic at the Midland Regional Hospital (MRH), Mullingar.  
Potential research participants were approached during their clinic visit.   
 
 
If the potential research participant gave informed consent, a subject 
contact sheet and an anonymous case report form was created and 
completed for each research participant and used to ensure optimal data 
collection.  All participant data were kept anonymous.   
 
 
Given that immune function is affected by both metabolic control and 
intercurrent illness, participants who had evidence of infection were 
excluded. The inclusion and exclusion criteria were as follows- 
 
2.1a Inclusion criteria 
- An age of 18 years or more  
- Type 2 diabetic subjects diagnosed according to American Diabetes 
Association criteria  
 
2.1b Exclusion criteria 
- Signs of current infection,  
- Current treatment with antibiotics,  
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- Neutropenia (a leucocyte count of less than 2000 per cubic millimeter) 
- Pregnancy or breast-feeding (contraception for at least 3 months before -
inclusion was required for fertile women) 
- Liver or renal disease (a level of asparate aminotransferase or alanine 
aminotransferase of more than three times the upper limit of the normal 
range) 
- Ongoing or previous cancer: the use of oral glucocorticoid medication 
and immunosuppressive treatment or immunodeficiency. 
 
2.1c Healthy control subjects 
Healthy adults were recruited as control subjects from laboratory, 
secretarial, medical, porter staff and ambulance crew from the Midland 
regional Hospital, Mullingar catchment area. Each healthy control 
participant was screened for diabetes and pre-diabetes using the standard 
oral glucose tolerance test (American Diabetes Association (ADA) 
reference). Participants with abnormal results were excluded from the 
study.  
 
2.2 Oral Glucose Tolerance Test (OGTT) 
The OGTT was performed according to World Health Organisation (WHO) 
criteria. Participants were asked not to eat or drink, except water for 10 h 
prior to the test. The first fasting venous blood sample was collected by 
venepuncture at 08.00 h and then the participants were given 410 ml of 
Lucozade from a standard Lucozade bottle (70 kcal/100mmls) or 
equivalent drink containing 75 grams of anhydrous glucose. Participants 
were asked to consume the glucose load within 5 min and second blood 
sample was collected at 120 min (10.00 h). Participants remain seated 
throughout the test in the department and were not allowed to smoke 
during the test.  
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2.3 ADA criteria for diagnosis of diabetes 
The ADA recommends following criteria for the diagnosis of diabetes and 
pre-diabetes -  
1. A1C ≥6.5%. The test should be performed in a laboratory using a 
method that is NGSP certified and standardized to the Diabetes Control 
and Complications Trial (DCCT) assay. 
 
      OR 
 
2. Fasting plasma glucose (FPG) ≥7mM.  Fasting is defined as 8 hours or 
more without caloric intake. 
 
                                                      OR 
 
 3. Two-hour plasma glucose (2hPG) ≥11.1mM during performance of an 
oral OGTT.  
                                                      OR 
 
4. In a patient with classic Symptoms of hyperglycaemia or 
hyperglycaemic crisis a random plasma glucose ≥11.1mM. In absence of 
symptoms, result should be confirmed by repeat testing. 
 
 
 Table 2.1. Criteria for diagnosis of diabetes  
Normal IFG or IGT Diabetes 
FPG < 5.6mM FPG 5.6-6.9mM FPG > 7mM 
2hPG < 7.8mM 2hPG 7.8-11.0mM 2hPG > 11.1mM 
 A1C 5.7-6.4% A1C  > 6.5% 
IFG – Impaired fasting glucose, IGT – Impaired glucose tolerance 
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2.4 The study design 
Based on these criteria, 146 participants were recruited from a hospital 
based diabetes clinic and diabetes day centre. Among these 34 healthy 
volunteers without diabetes acted as control, normal glucose tolerant 
(NGT) and 112 as T2D subjects. The T2D subjects (mean duration 95 
months) were classified in four different profiles based on glycaemic 
control and complications: T2D with good glycaemic control (HbA1c 
<7.5%) and no macrovascular complications (heart disease, Transient 
ischaemic stroke (TIA)/stroke or peripheral arterial disease (PAD)) and 
microvascular complications  (retinopathy, neuropathy or nephropathy): 
(GC, n=27), T2D with good glycaemic control and complications (GCC, 
n=32), T2D with poor glycaemic control (HbA1c >7.5%) without 
complications (PC, n=21), and T2D with poor glycaemic control and 
complications (PCC, n=32).  
 
Table 2.2. The study design showing T2D groups 
T2D subjects 
(n = 112) 
Good glycaemic control 
(HbA1c < 7.5%) 
Poor glycaemic control 
(HbA1c > 7.5%) 
No Complications GC = 27 PC = 21 
Complications GCC = 32 PCC = 32 
HbA1c – Glycosylated haemoglobin, T2D – Type 2 diabetes mellitus 
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Clinical data that were collected include: 
1. Signs detected by the recruiting personnel 
2. Medications taken prior to hospital admission 
3. Known medical illnesses 
4. Family history of diabetes 
5. Smoking habits and alcohol consumption 
6. General physical examination 
7. Results of blood tests and other diagnostic procedures.   
 
The research participants were invited to attend the diabetes centre in a 
fasting state for blood tests. The fasting state involved fasting overnight for 
at least 12 hours. The personal and medical data were obtained by patient 
interview, by using hospital medical notes, and from using hospital blood 
test results. The demographic information was obtained from research 
participants and their weight, height, blood pressure & waist and hip 
circumferences were determined. BMI was calculated as body weight (in 
kilograms) divided by body height (in meters) squared. Waist-to-hip ratio 
(WHR) was calculated as per WHO criteria. 
 
 
2.4a Waist hip ratio 
Waist and hip circumference was measured as per the WHO STEPwise 
Approach to Surveillance (STEPS)  (WHO, 2008b). Waist circumference 
was measured at the midpoint between the lower margin of the least 
palpable rib and the top of the iliac crest, using a stretch resistant tape that 
provides a constant 100 g tension. Hip circumference was measured 
around the widest portion of the buttocks, with the tape parallel to the 
floor.   For both measurements, the subject stand with feet close together, 
arms at the side and body weight evenly distributed, and wore little 
clothing. The subject was relaxed, and the measurements were taken at 
the end of a normal expiration. Each measurement was repeated twice; if 
the measurements were within 1 cm of one another, the average was 
calculated. If the difference between the two measurements exceeds 1 
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cm, the two measurements were repeated.  The WHO recommendations 
for waist circumference and WHR are as follows: 
 
Table 2.3 World Health Organization cut-off points and risk of 
metabolic complications 
Indicator Cut-off points 
Risk of metabolic 
complications 
Waist circumference >94 cm (M); >80 cm (W) Increased 
Waist circumference >102 cm (M); >88 cm (W) Substantially increased 
WHR ≥0.90 cm (M); ≥0.85 cm (W) Substantially increased 
M, men; W, women 
 
2.4b Retinopathy assessment 
This MRH, Mullingar has an excellent ophthalmology department and 
diabetic patients are followed up and treated closely based on severity of 
retinopathy. The digital retinal examination and fundus photographs are 
used as a screening tool in this centre. The fundus examination and 
retinopathy staging including history of laser treatment was noted from 
ophthalmology assessment part of medical notes.  
 
2.4c Neuropathy assessment 
Subjects with diabetes were examined for presence of distal symmetric 
polyneuropathy by using following tests: 
1. Vibration perception (using a 128-Hz tuning fork) 
2. 10-g mono-filament pressure sensation at the distal plantar aspect 
of both great toes and metatarsal joints, and  
3. Assessment of ankle reflexes 
In T2D subjects with neuropathy, particularly when severe, causes other 
than diabetes, such as neurotoxic mediations, alcohol abuse, vitamin B12 
deficiency (especially in those taking metformin for prolonged periods), 
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renal disease, chronic inflammatory demyelinating neuropathy, inherited 
neuropathies, and vasculitis were ruled by taking proper history, 
examination and vitamin B12 blood level check up. History of autonomic 
neuropathy was noted from medical notes. 
 
2.4d Nephropathy assessment 
An early morning urine sample for measurement of albumin-creatinine 
ratio (ACR) and urine microalbumin was collected.  The urine albumin 
concentrations and urine creatinine were determined using an automated 
immunoturbidity method and alkaline picrate method respectively. ACR 
was then categorized as normoalbuminuria, microalbuminuria and 
macroalbuminuria (Table 3). As per ADA recommendations, ACR was 
considered abnormal, if two of three specimens collected within a 3- to 6-
month period were abnormal (> 2.5 mg/mmol for men, > 3.5 mg/mmol for 
women). 
 
Table 2.4 Definitions of abnormalities in ACR 
Category Spot collection urine  (ACR in mg/mmol) 
Normal 0.00 – 2.50 
Micro albuminuria 2.5 – 25 
Macro (clinical)-albuminuria >25 
ACR - Albumin-Creatinine Ratio  
 
 
 
 
 
 73 
The National Kidney Foundation classification based on level of GFR was 
used for staging chronic kidney disease (CKD) (Levey et al., 2003).  
 
Table 2.5 Stages of CKD  
Stage Description 
GFR (ml/min per 1.73 
m2 body surface area) 
1. Kidney damage* with normal or 
increased GFR 
≥90 
2. 
Kidney damage* with mildly decreased 
GFR 
60–89 
3. Moderately decreased GFR 30–59 
4. Severely decreased GFR 15–29 
5. Kidney failure <15 or dialysis 
* Kidney damage defined as abnormalities on pathological, urine, blood, or 
imaging tests. (Adapted from Levey et al., 2003) 
 
2.4e Foot examination 
All participants were examined for active foot ulcers, amputations, 
structural abnormality and Charcot foot. History of previous ulcer was 
noted from medical notes. 
 
The foot was examined for dorsalis pedis and posterior tibial artery 
pulsations to look for PAD. Few patients already had PAD and were 
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attending vascular consultant.  The foot was assessed for neuropathy 
(mentioned above). 
 
2.5 Lab techniques 
2.5a Blood sampling procedures 
Fasting blood sample was used to measure various biochemical 
parameters and cytokines. About 40 ml peripheral blood was collected 
from each participant including healthy volunteers.  
 
A haemoglobin analyser HA-8160 (Menarini Pharmaceuticals, Ireland) 
was used for HbA1C (HPLC Chromatography Method) and Advia 
analysers were used to measure the whole blood count measurement. 
Lipid profile (Enzymatic Colourmetric Methods), urea (Kinetic UV Method), 
creatinine (Jaffe rate-blanked compensated kinetic colourimetric Method), 
sodium, potassium, asparate aminotransferase, alanine aminotransferase, 
bilirubin, alkaline phosphatase, gamma glutamyl transferase, CRP 
(Particle-enhanced immunoturbidimetric), ferritin, coagulation screen, 
thyroid profile (competitive immunoassay using direct chemiluminescent 
technology) & plasma glucose (Hexokinase) were measured using Roche 
Modular 1800 analyser. Erythrocyte Sedimentation Rate (ESR) was 
measured manually using an automated Westergren equivalent 
(Sedimentation Method). An early morning urine sample for measurement 
of ACR (Immunoturbidimetric assay for urine microalbumin & Jaffe rate 
blanked compensated kinetic colourmetric for urine creatinine) was also 
collected at the same time. The blood and urine samples were assayed at 
the MRH, Mullingar. 
 
Analysis of cytokines, chemokines, adipokines and TLR expression 
Analysis of cytokines, chemokines, adipokines and TLR mRNA expression 
was performed at the Immune Signal Laboratory (ISL), National University 
of Ireland Maynooth, Co. Kildare, supervised by Dr Sinead Miggin. Fresh 
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blood sample was transported in ice cold packs from MRH, Mullingar to 
ISL, Maynooth and processed the same day for mRNA assay.  
 
 
2.5b Preparation of Optiprep reagent 
A working solution of Optiprep was prepared by dissolving 4 vol of 
OptiPrep (density 1.320±0.001 g/ml) with 2 vol of Dulbecco's Modified 
Eagle Medium (DMEM).  Next, 9 vol of DMEM was added to the working 
solution of Optiprep to achieve the required density of 1.080 g/ml.  
 
2.5c Preparation of buffy coat 
Peripheral blood samples (30 ml) was collected in five 
Ethylenediaminetetraacetic acid (EDTA) vacutainer tubes and was 
transferred to 50 ml Falcon tubes and centrifuged at 500g for 20 min at 
20oC at RAD 180 & RCF 350 using a Hettich Mikro 120 centrifuge. The 
plasma supernatant was aspirated and erythrocytes were allowed to settle 
at the bottom. The buffy coat i.e. Leucocyte-rich plasma (LRP) (10 ml) was 
collected and transferred into a fresh 50 ml polypropylene conical tube. 
The buffy coat was under layered with 1.080 g/ml solution of OptiPrep. 
Care was taken to avoid mixing the layers. The buffy coat/OptiPrep 
mixture was centrifuged at 800 g for 30 min at 18-22°C using a Hettich 
Mikro 120 centrifuge. No brake was applied during deceleration.  
 
2.5d Isolation of Peripheral Blood Mononuclear Cell (PBMC) 
The PBMCs were harvested from the upper interface into a 15 ml tube 
followed by centrifugation at 350 g for 10 min at 20oC using a Hettich 
Mikro 120 centrifuge. The supernatant was discarded and the cell pellet 
was used for monocyte isolation (described in section 2.6.4). 
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The polymorphonuclear (PMN) cell pellet was isolated from the lower 
interface and transferred to a new 50 ml Falcon tubes to avoid 
contamination with remaining mononuclear cells left in the tube. Next, an 
ammonium chloride solution (NH4Cl) 0.8% (RBC lysis buffer, Catalog ♯ 
07850, Stem cell) was added to the PMN cell pellet at a ratio of 9:1 to lyse 
the red blood cell (RBC) pellet. About 45 ml of NH4Cl was added to 5 ml of 
pellet and kept on ice for 10 min.  
 
The tube was then centrifuged at 500 g for 10 min at 4oC using a Hettich 
Mikro 120 centrifuge and the brake speed was set to low. The supernatant 
was then removed. Next, to remove the platelets, the pellet was washed 
with 15 ml of phosphate Buffered Saline (PBS) containing 2% FBS and 1 
mM EDTA and centrifuged at 120 g for 10 min at 4oC using a Hettich Mikro 
120 centrifuge with the brake off. This step was repeated once. 
 
Next, the supernatant was discarded and cells were resuspeded in 5 ml of 
PBS containing 2% FBS and 1 mM EDTA and transferred to a 5 ml 
polystyrene round-bottom tube. The tube was then centrifuged at 500 g for 
10 min at 20oC using an Eppendorf centrifuge 5810R refrigerated 
ultracentrifuge. The supernatant was discarded and the cell pellet was 
used for isolation of neutrophils. 
 
2.5e Monocyte extraction 
Human CD14 positive monocytes were isolated from PBMCs using the 
EasySep® Human CD14 Positive Selection Cocktail. The CD14 positive 
monocytes were specifically labeled with dextran-coated magnetic 
nanoparticles using bispecific Tetrameric Antibody Complexes (TAC). 
These complexes recognise both dextran and the target cell surface 
antigen (Figure 2.1). The small size of the magnetic dextran iron particle 
permitted efficient binding to the TAC-labeled cells, and did not interfere 
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with subsequent FACS analysis. Magnetically labeled cells were then 
separated from unlabeled cells using the EasySep® procedure. 
 
2.5e.1 Component description and principle 
The EasySep® Human CD14 Positive Selection Cocktail contained a 
combination of monoclonal antibodies purified from hybridoma culture 
supernatant by affinity chromatography using Protein A or Protein G 
Sepharose. These antibodies were then bound in bispecific TAC, which 
are directed against CD14 and dextran. The mouse monoclonal antibody 
subclass is IgG1. The cocktail was supplied in phosphate buffered saline. 
The EasySep® Magnetic Nanoparticles were supplied as a suspension of 
magnetic dextran iron particles in water. Where indicated, PBS containing 
2% FBS and 1 mM EDTA was utilised and was calcium and magnesium 
free.  
 
2.5e.2 Experimental protocol 
The PBMCs were resuspended in 5 ml PBS containing 2% FBS and 1 mM 
EDTA and transferred to a 5 ml polystyrene round-bottom tubes. The tube 
was centrifuged at 350 g for 10 min at 20oC. The supernatant was 
discarded and the cells were resuspended in 100 µL of PBS containing 
2% FBS and 1 mM EDTA.  Next, 10 µL of EasySep® Positive Selection 
Cocktail was then added to the cell suspension. The solution was mixed 
well and incubated at RT for 15 min. Next, 10 µL of EasySep® Magnetic 
nanoparticles was added to the suspension followed by vigorously 
pipetting up and down 5 times, as vortexing was not recommended.  The 
solution was incubated at RT for 10 min. Next, PBS containing 2% FBS 
and 1 mM EDTA was added to the cell suspension to bring the volume 
total to 2.5 ml. The cells in the tube were then mixed gently by pipetting up 
and down 2-3 times. The tube (without cap) was then placed into the 
magnet for 5 min. The magnet was then picked up and in one continuous 
motion; the magnet and tube were inverted then permitting the 
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supernatant to be removed. Thus, the cells that were not bound to the 
magnetic particles were removed by inversion of the magnet. The magnet 
containing the tube was maintained in the inverted position for 2-3 s and 
then returned to upright position. Drops of liquid that remained on the edge 
of the tube were not removed. Next, the tube was removed from the 
magnet and 2.5 ml of PBS containing 2% FBS and 1 mM EDTA was 
added. The cell suspension was then mixed by gently pipetting up and 
down 2-3 times. The tube was then returned to the magnet and incubated 
at RT for 5 min. The washing and incubation step was repeated once 
more. The tube then removed from the magnet and the cells were 
resuspended in an appropriate amount of desired medium. 
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Figure 2.1: Schematic drawing of EasySep® Human CD14 Positive 
Selection Cocktail. The CD14 positive monocytes were specifically 
labeled with dextran-coated magnetic nanoparticles using bispecific 
Tetrameric Antibody Complexes (TAC). These complexes recognise both 
dextran and the target cell surface antigen and are composed of a specific 
anti-cell-antibody and an anti-dextran antibody (a pair of mouse 
monoclonal antibody IgG1). Adapted from Human CD14 selection kit 
catalog ♯18058 (www.stemcell.com). 
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2.5f Neutrophil extraction 
To isolation neutrophils, the EasySep® Human Neutrophil Enrichment Kit 
(catalog ♯ 19257; Stem Cell) was used whereby neutrophil enrichment 
was facilitated by depletion of non-neutrophil. Unwanted cells were 
specifically labeled with dextran-coated magnetic nanoparticles using 
bispecific TAC. These complexes recognised both dextran and the cell 
surface antigen expressed on the unwanted cells (Figure 1). The small 
size of the magnetic dextran iron particles permitted efficient binding to the 
TAC-labeled cells. Next, the magnetically labelled cells were separated 
from the unlabelled target cells using the EasySep® procedure. 
 
2.5f.1 Component description and principle 
The EasySep® Negative Selection Human Neutrophil Enrichment Cocktail 
contained a combination of murine monoclonal antibodies (IgG1) purified 
from hybridoma culture supernatant by affinity chromatography using 
Protein A or Protein G Sepharose. These antibodies were bound in 
bispecific TAC which were directed against cell surface antigens on 
human blood cells, namely CD2, CD3, CD9, CD19, CD36, CD56, 
glycophorin A and dextran. The EasySep® Magnetic Nanoparticle was 
supplied as a suspension of magnetic dextran iron particles in water 
 
2.5f.2 Experimental protocol 
The PBMC pellet was dissolved in 5 ml of PBS containing 2% FBS and 1 
mM EDTA in a 5 ml polystyrene tube and centrifuged at 350 g for 10 min. 
The supernatant was discarded. The nucleated cell suspension was 
prepared by dissolving the pellet in 500 µl of PBS containing 2% FBS and 
1 mM EDTA. To the cell suspension was added 25 µl of EasySep® Human 
Neutrophil Enrichment Cocktail followed by mixing and incubation for 10 
min at RT. Next, 50 µl of the EasySep® magnetic nanoparticles were 
added followed by mixing and vigorously pipetting more than 5 times as 
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vortexing was not recommended. The solution was incubated for 10 min at 
RT. Next, the volume of the solution was increased to a total volume of 2.5 
ml using PBS containing 2% FBS and 1 mM EDTA. The cells were then 
mixed by pipetting up and down to disrupt the red blood cell aggregates. 
The tube (without cap) was then placed into the magnet and set aside for 
5 min. Next, the EasySep® Magnet was picked up, and in one continuous 
motion the magnet and tube were inverted, pouring off the desired fraction 
into a new 5 ml polystyrene tube. The magnetically labeled unwanted cells 
remained bound inside the original tube, held by the magnetic field of the 
magnet. The magnet and the tube were retained in the inverted position 
for 2-3 s, and then returned to upright position. The tube was removed 
from the EasySep® magnet and the new tube containing the supernatant 
fraction was placed into the magnet for 5 min and the inversion and 
collection step was repeated. The negatively selected enriched cells in the 
new tube were used for RNA extraction. 
 
2.5g RNA extraction 
To isolate RNA from the monocytes and neutrophils, the RNeasy isolation 
kit was used (catalog no. ♯74104; Qiagen). 
 
2.5g.1 Component description and principle 
The RNeasy Micro technology combined the selective binding properties 
of a silica-based membrane with the speed of microspin technology. The 
guanidine-thiocyanate–containing lysis buffer and ethanol were added to 
the sample to create conditions that promoted the selective binding of 
RNA to the RNeasy MinElute membrane. The sample was then applied to 
the RNeasy MinElute spin column whereby the RNA bound to the silica 
membrane. Next, traces of DNA that copurified were removed by DNase 
treatment on the RNeasy MinElute spin column. DNase and any 
contaminants were washed away and high-quality total RNA was eluted in 
RNase-free water. RNA molecules longer than 200 nucleotides were 
purified. The procedure enriched for mRNA, since most RNAs <200 
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nucleotides (such as 5.8S rRNA, 5S rRNA, and tRNAs, which together 
make up 15–20% of total RNA) were selectively excluded. The size 
distribution of the purified RNA was comparable to that obtained by 
centrifugation through a CsCl cushion, where small RNAs do not sediment 
efficiently. The kit utilised RLT buffer, which contained guanidine 
thiocyanate, buffer RW1 containing ethanol and RPE buffer.  
 
2.5g.2 Experimental protocol 
The cells were disrupted by adding 350 µl of buffer RLT followed by 
thorough mixing using a vortex. The lysate was directly pipette into a 
QIAshredder 2 ml collection tube. Next, 350 µl of 70% ethanol was added 
to the lysate followed by pipetting up and down to mix. The 700 µl of 
sample including any precipitate that may have formed was transferred to 
an RNeasy MinElute spin column, which had been placed in a 2 ml 
collection tube. The lid was closed gently and the sample centrifuged for 
30 s at 14,000 rpm. The flow through was discarded. Next, 700 µl of buffer 
RW1 was added to the RNeasy MinElute spin column. The lid was closed 
gently and the sample was centrifuged for 15 s at 14,000 rpm to wash the 
spin column membrane. The flow-through was then discarded. Next, 500 
µl of buffer RPE was added to the spin column. The lid of the tube was 
closed gently and the sample was centrifuged for 15 s at 14,000 rpm. 
Thereafter, 500 µl of buffer RPE was added to the spin column followed by 
centrifugation for 2 min at 14,000 rpm to wash the sample. The RNeasy 
MinElute spin column was then placed in a new 1.5 ml collection tube and 
30 µl RNase-free water was added directly to the center of the spin 
column membrane followed by centrifugation for 1 min at 14000 rpm to 
elute the RNA. The concentration of RNA was measured using a 
Nanodrop spectrophotometer, which was pre-blanked using 1 µl of RNAse 
free water. A260/280 nm was determined to assess purity where a ratio of 
A260/A280 > 1.8 indicates minimal protein contamination in the RNA 
sample. RNA was stored at -80oC until further use. 
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2.5h Reverse transcription and first strand cDNA synthesis 
To 1 µg of RNA in a total volume of 11 µl, was added 1 µl of random 
hexamers (100 pM/µl). This solution was mixed well and placed at 70oC 
for 5 min, followed by 5 min incubation on ice. To this solution, the other 
components/reagents were added in the following order, 4 µl of 5 × RT 
buffer (Promega), 2 µl of dNTP (10 mM), 1 µl of RNasin (Promega) and 1 
µl of MMLV Reverse transcriptase (Promega) and mixed well. The 
samples were placed at 37oC for 40 min, followed by 42oC for 40 min and 
finally at 80oC for 5 min.  The first strand cDNA was stored at -20oC until 
further use.  
 
2.5i Quantitative real time PCR 
Total first strand cDNA was used as a template for quantitative polymerase 
chain reaction (qPCR or real-time (RT)-PCR) quantification using a 
DyNAmoHS SYBR Green kit (Finnzymes) and a RT-PCR system (DNA 
Engine OPTICON® system; MJ Research). For the amplification of TLRs, 
cytokines, MMPs the respective primers were used as described in Table 
2.6. For each TLR mRNA quantification, the housekeeping gene 
hypoxanthine phosphoribosyl transferase (HPRT) was used as a reference 
point using the respective primers.
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Table 2.6 Human real time PCR Oligonucleotides used for the amplification of human genes (TLR, cytokine and chemokine) and 
HPRT-housekeeping gene. 
Human 
Gene 
Gene 
accession 
number 
Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’) Fragment size (bp) 
Annealing 
Temp  
(Tm, oC) 
HPRT NM_000194.2 AGCTTGCTGGTGAAAAGGAC TTATAGTCAAGGGCATATCC 104 60 
TLR1 NM_003263.3 TATTCCTCCTGTTGATATTGCTGCT TAAATGGTGAACTGCGACCCGAAG 135 60 
TLR2 NM_003264.3 ACCTGTCCAACAACAGGATCACCT TGTTCAAGACTGCCCAGGGAAGAA 139 60 
TLR3 NM_003265.2 AAGAACTCACAGGCCAGGAATGGA AAGAGGCTGGAATGGTGAAGGAGA 182 60 
TLR4 NM_138554.3 GCCGAAAGGTGATTGTTGTGGTGT TACCAGCACGACTGCTCAGAAACT 108 60 
TLR5 NM_003268 GTTGCAACTTGCCTGGGAAACTGA AGCCTGTTGGAGTTGAGGCTTAGT 162 60 
TLR6 NM_006068.2 TGAGGTTAGCCTGCCAGTTAGAGA TTTGGGAAAGCAGAGTGGAGAGGA 126 60 
TLR7 NM_016562 TATTCCCACGAACACCACGAACCT GCAGCCTCTTGATGCACATGTTGT 164 60 
TLR8 NM_138636 TGTCTCAGAGGCTGCAATGTAGGT AGGCTCGCATGGCTTACATGAGTA 136 60 
TLR9 NM_017442 CCACAACAACATCCACAGCCAAGT TGGGACAAGTCCAGCCAGATCAAA 162 60 
TLR10 NM_030956 CTGGCAACATGTCACACCTGGAAA AAGATGGGCAGGCTACCTTCTTCA 151 60 
IL-6 NM_000600.3 AGCCACTCACCTCTTCAGAACGAA CAGTGCCTCTTTGCTGCTTTCACA 121 60 
TNF-α NM_000594.2 CACCACTTCGAAACCTGGGA CACTTCACTGTGCAGGCCAC 115 60 
IFN-β NM_002176.2 AACTGCAACCTTTCGAAGCC TGTCGCCTACTACCTGTTGTGC 123 60 
RANTES NM_002985.2 TGCCTGTTTCTGCTTGCTCTTGTC TGTGGTAGAATCTGGGCCCTTCAA 92 60 
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2.5j Cytokine / chemokines measurements 
Analysis of cytokines was carried out at the ISL at the National Ireland 
University Maynooth. Fresh blood sample was transported in ice cold 
packs from MRH, Mullingar to ISL, Maynooth and processed on the same 
day. Serum was used for measuring TNFα, IL-6, IL-β, IL-10, IL-8, IL-12p70 
and IFN-γ with a 96-Well MULTI-ARRAY 7-Multiplex Assay (Meso Scale 
Discovery, 9238 Gaither Road, Gaithersburg, Maryland 20877, USA). 
Serum was used for measuring IFN-β and Rantes using Meso Scale 
Discovery (MSD) single-plex 96-well plates. MSD was a sector 2400 
analyser and operated through electrochemiluminescence technology. 
The instrument measured the intensity of emitted light to afford a 
quantitative measure of TNFα, IL-6, IL-β, IL-10, IL-8, IL-12p70, IFN-γ and 
Rantes present in the sample.  
 
2.5j.1 Meso Scale Human Pro-inflammatory 7-Plex Assay 
Serum from participants was used for measuring IL-1β, TNFα, IL-6, IL-8, 
IFNγ, IL-12p70, and IL-10 levels using a Meso Scale 96-Well Human Pro-
inflammatory 7-plex ultra sensitive assay kit (MSD). The Human 7-Plex 
assay detected IL-1β, TNFα, IL-6, IL-8, IFNγ, IL-12p70, and IL-10 in a 
sandwich immunoassay format. The 7-plex assay was supplied as a 96 
well ultra sensitive plate pre-coated with IL-1β, TNFα, IL-6, IL-8, IFNγ, IL-
12p70, and IL-10 capture antibodies on spatially distinct spots on the 
plate. First, the pre-coated plate was incubated with 25 µl/well of Diluent 2 
(R51BB-4) supplied with the kit for 30 min at RT with vigorous shaking at 
1000 rpm.  Next, the samples (cell free supernatants) or appropriate 
dilution of stock calibrator blend (highest calibrator point was obtained by 
diluting the stock by 100 fold in Diluent 2 and from this an 8 point standard 
curve with 4-fold serial dilution was prepared-assay range 2500 to 0 pg/ml) 
was added to separate wells of the MSD plate in duplicates. The plate was 
sealed with an adhesive seal and incubated for 2 h with vigorous shaking 
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(1000 rpm) at RT. Next; the plate was washed three times with wash 
buffer (PBS-T) and was pat dry. The SULFO-TAG Detection Antibody 
Blend (D2008-2) provided as 50 × stock solution was diluted to a final 
working concentration of 1 ×, by mixing 60 µl of stock antibody blend with 
2.94 ml of Diluent 3 (R51BA-4) supplied with the kit.  Further, 25 µl/well of 
the 1 × detection antibody solution was added to each well of the MSD 
plate and the plate was sealed and incubated for 2 h with vigorous shaking 
(1000 rpm) at RT.  Next, the wash step was repeated and 150 µl/well of 2× 
diluted Read Buffer T (R92TC-3) was added in to each well of the MSD 
plate.  The plate was immediately read on the SECTOR Imager and the 
data was analysed using the MSD Discovery Workbench analysis 
software. 
 
2.5j.2 Meso Scale Human RANTES and IFNβ Assay 
Serum from participants was used for measuring RANTES and IFNβ 
levels using a meso scale 96-Well Human RANTES assay kit and Human 
IFNβ assay kit respectively (MSD). The Human RANTES assay plate 
(L451BFA-1) detected RANTES and Human IFNβ assay avidin plate 
(L15AA-1) detected IFNβ in a sandwich immunoassay format. The 96 well 
ultra sensitive plate was pre-coated with human RANTES capture 
antibody on the RANTES plate. Regarding the IFNβ plate, a 50× anti-
hIFNβ biotinylated capture antibody was diluted to 1x working 
concentration in Diluent 100 (R50AA-4), and 20 µl/well of this 1 × capture 
antibody was manually pipetted onto the MSD plate and incubated at RT 
with gentle shaking for 1 h. Subsequently, the RANTES and IFNβ plates 
were incubated with 25 µl/well of Diluent 2 (R51BB-4) supplied with the kit 
for 30 min at RT with vigorous shaking at 1000 rpm. Next, the samples 
(cell free supernatants) or appropriate dilution of stock calibrators (highest 
calibrator point for RANTES was obtained by diluting the stock (C01BF-2) 
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by 100 fold in Diluent 2 and from this, an 8 point standard curve with 4-fold 
serial dilution was prepared-assay range 2500 to 0 pg/ml, and highest 
calibrator point for IFNβ was obtained by diluting the stock (C01AD-2) by 
25 fold in Diluent 1 (R50CK-4) and from this, an 8 point standard curve 
with 4-fold serial dilution was prepared-assay range 25,000 to 1.5 pg/ml) 
were added to separate wells of the respective MSD plates in duplicates. 
The plates were sealed with an adhesive seal and incubated for 2 h with 
vigorous shaking (1000 rpm) at RT. Next; the plates were washed three 
times with wash buffer (PBS-T) and were pat dry. The SULFO-TAG 
Detection Antibody Blend (D21BF-2) for RANTES and (D21AD-2) for IFNβ 
detection, provided as 50 × stock solution were diluted to a final working 
concentration of 1 ×, by mixing 60 µl of stock antibody blend with 2.94 ml 
of Diluent 3 (R51BA-4). Next, 25 µl/well of the 1 × detection antibody 
solution was added to each well of the respective MSD plates and the 
plates were sealed and incubated for 2 h with vigorous shaking (1000 rpm) 
at RT.  Next, the plates were washed three times with wash buffer (PBS-T) 
and were pat dry. Then, 150 µl/well of 2× diluted Read Buffer T (R92TC-3) 
was added to each well of the MSD plates.  The plates were immediately 
read on the SECTOR Imager 2400 and the data was analysed using the 
MSD Discovery Workbench analysis software. 
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2.6 Statistical analysis 
Data are expressed as median (interquartile range) and represented as 
box-and-whiskers plots. The dark midline in the box represents the 
distribution's median value. The top and bottom edges of the box 
respectively represent the 75th and 25th percentile values. The top and 
bottom of the vertical lines, the whisker respectively represent the upper 
and lower maximum value. χ2 test or Fisher exact test (as appropriate) 
were used to compare proportions. The Mann–Whitney test was used in 
case of non-normally distributed parameters to compare median between 
two groups. Kruskal-Wallis test was used for multiple inter-group 
comparisons in case of parameters that did not show normal distribution. 
If a significant difference was found in inter-group comparisons, post hoc 
multiple comparison analysis with the Dunns multiple comparison test was 
performed. Data were transformed to lognormal format and multifactorial 
ANOVA was applied to evaluate the effect of variables (age, sex, BMI, 
WHR and duration of diabetes) on different inflammatory markers. 
Correlations between values were examined by calculating Spearman 
correlation coefficients. All the statistical analysis was done using the 
Prism 6.0 computer program (GraphPad, La Jolla, CA) and p value less 
than 0.05 was considered significant.  
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Chapter 3 
 
Analysis of metabolic parameters in T2D 
subjects 
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A total of 146 subjects participated for this T2D inflammation study. Thirty-
four healthy volunteers without diabetes acted as controls (NGT) and the 
rest (T2D, n=112) were classified into four groups based on glycaemic 
control and complications as mentioned previously: GC: n=27, GCC: 
n=32, PC: n=21 and PCC: n=32.  
 
The role of various risk factors for the development and progression of 
diabetes have been demonstrated by several epidemiologic studies (Klein 
et al., 2002; Cai et al., 2006).  These factors include type and duration of 
diabetes, age, gender, glycaemic control, hypertension, body mass index, 
smoking, serum lipids and presence of microalbuminuria We have 
evaluated all these risk factors in the current study.  
 
The females were 67.6% in NGT and 42.9% in T2D group.  The median 
age was higher in T2D subjects compared to NGT controls (p<0.001). 
 
The duration of diabetes was calculated for all groups and as it reflects the 
course of disease, the groups with complications and poor glycaemic 
control group had longer duration of diabetes compared to good glycaemic 
control group (p<0.001).  
 
The profile for smoking was similar in both NGT and T2D groups: 20.5% 
were smokers in NGT compared to 20.5% in T2D groups, and 30.7% were 
ex-smoker in NGT as compared to 43.5% in T2D (Table 3.1).  
 
There was significant difference in the BMI and Waist-hip-ratio among 
different groups (p<0.01). The T2D subjects had higher BMI and Waist-
hip-ratio compared to NGT controls.  The median systolic BP was seen 
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significantly raised in GC, GCC and PCC  (p<0.05). However, no 
significant difference was seen in diastolic BP among different groups 
(Table 3.1). 
 
The fasting glucose was higher in all T2D subjects compared to NGT 
controls (p<0.05).  All T2D subjects had raised total cholesterol and 
triglycerides, and low HDL compared to NGT controls (p<0.05). LDL was 
low in T2D subjects compared to NGT likely secondary to lipid lowering 
agents.  
 
Previous epidemiological studies have demonstrated increased 
concentrations of CRP in patients with T2D. However, patients with raised 
CRP, who had evidence of infection, were excluded from this study. This 
study was designed to explore the role of TLRs, cytokines/chemokines 
and adipokines in the pathophysiology of T2D. Knowing that these are 
highly sensitive biomarkers and get influenced by infection; the raised 
CRP was kept an exclusion criteria so as to avoid recruitment of subjects 
with infection, which would have otherwise confounded our results. 
Unsurprisingly, therefore, we did not find any significant difference in CRP 
between different groups (Table 3.2).  
 
A detailed drug history was obtained for all subjects and it was observed 
that a higher percentage of subjects in PC (52.4%) and PCC (71.9%) were 
on insulin compared to GC (7.4%) and GCC (28.1%) groups. In all groups 
most T2D subjects were on lipid lowering agents: GC (85.2%), GCC 
(93.8%), PC (61.9%) and PCC (87.5%) and also on angiotensin 
converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) 
in view of HTN or micro/macro albuminuria: GC (74.1%), GCC (87.5%), 
PC (76.2%), and PCC (81.3%) (Table 3.3).  
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All PCC subjects had one or more microvascular complications 
(retinopathy, neuropathy and nephropathy). Additionally, 53.1% (17 
subjects) of these had one or more macrovascular complications. In GCC 
group, 56.3% (18 subjects) had one or more microvascular complications, 
34.4% (11 subjects) had both macro & microvascular complications and 
9.4% (3 subjects) had only macrovascular complications (Table 3.4). 
Among microvascular complications, retinopathy was higher in PCC 
subjects (40.6%) compared to GCC subjects (18.6%).  No significant 
difference was observed in neuropathy in between two subgroups. 15.6% 
PCC subjects had diabetic foot disease compared to 6.3% GCC subjects 
(Table 3.4). 
 
In PCC, 68.8% subjects had nephropathy compared to 56.3% in GCC 
subgroup. Of these, 18.2% and 22.2% subjects had macroalbuminuria 
respectively. The proportion of T2D subjects having CKD was higher in 
PCC subgroup than GCC subgroup (CKD stage 3; 45.5% vs. 27.7%, CKD 
stage 4; 9% vs. 0%) (Table 3.5).  
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Table 3.1 Baseline subject characteristics: demographics 
BMI, Body Mass Index, SBP, Systolic Blood Pressure, DBP, Diastolic Blood Pressure, WHR, Waist-to-hip ratio Data are  
expressed as median [Inter quartile range]. p value corresponds to the differences between groups.  
Characteristics NGT GC GCC PC PCC p value 
Number 34 27 32 21 32  
Sex (M/F) 11/23 12/15 20/12 13/8 19/13 0.068 
Age (years) 53 [47-59] 62 [51-71] 65 [57-73] 56 [50-60] 60 [55-68] <0.001 
Duration of DM 
(months) - 24 [12-72] 96 [30-168] 108 [60-132] 132[84-180] <0.001 
Smoker Y/N 7/24 3/21 6/26 5/16 9/22 0.659 
Ex smoker Y/N 8/26 8/19 14/18 4/17 8/24 0.271 
BMI (kg/m
2
) 26 [24-30] 32 [29-38] 31 [28-35] 35 [31-37] 34 [29-37] <0.001 
Waist (cm) 91 [82-100] 106 [99-115] 108 [99-115] 110 [99-120] 113 [102-122] <0.001 
WHR 0.92 [0.84-0.96] 
0.96 
[0.90-1.04] 
1.03 
[0.95-1.06] 
1.04 
[0.93-1.18] 
1.02 
[0.97-1.08] <0.001 
SBP (mmHg) 129 [120-137] 
145 
[131-156] 
142 
[131-154] 
130 
[120-145] 
147 
[124-158] 0.005 
DBP (mmHg) 80 [77-85] 80 [71-85] 78 [73-84] 78 [73-88] 77 [68-86] 0.808 
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 Table 3.2 Baseline subject characteristics: biochemical parameters 
Characteristics NGT GC GCC PC PCC 
 
Number 34 27 32 21 32 
Fasting glucose (mM) 4.8 [4.7-5.1] 6.5 [5.8-7.2] 7.6 [6.1-8.2] 10.9[8.3-12.9] 10.6 [7.9-14.6] 
HbA1c (%) 5.6 [5.4-5.7] 6.4 [6.0-6.9] 6.9 [6.4-7.4] 10.2 [9.2-11] 9.6 [8.9-10.8] 
CRP 0.10 [0.06-0.25] 0.20 [0.09-0.30] 0.18 [0.06-0.50] 0.15 [0.06-0.60] 0.20 [0.10-0.40] 
Total cholesterol (mM) 5.9 [5.1-6.6] 3.9 [3.5-4.7] 3.7 [3.1-4.3] 4.2 [3.7-4.8] 3.9 [3.5-4.7] 
LDL cholesterol (mM) 3.6 [2.8-4.3] 2.2 [1.9-2.9] 1.8 [1.5-2.4] 2.3 [1.8-2.9] 2.0 [1.5-2.7] 
HDL cholesterol (mM) 1.6 [1.3-1.9] 1.3 [1.0-1.5] 1.1 [0.9-1.3] 1.1 [1.0-1.3] 1.1 [0.9-1.2] 
Triglycerides (mM) 0.9 [0.7-1.2] 1.5 [1.1-2.0] 1.4 [0.8-2.0] 1.5 [0.8-1.9] 1.8 [1.2-2.5] 
            HbA1c, glycosylated haemoglobin, HDL, high-density lipoprotein, LDL, low-density lipoprotein, CRP, C-reactive protein. Data 
are expressed as median [Inter quartile range].  
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Table 3.3 Baseline characteristics: medications and HTN in different subgroups 
Characteristics NGT GC GCC PC PCC 
n 34 27 32 21 32 
Lipid lowering 
Agents - 23 30 13 28 
Aspirin - 20 25 13 29 
Metformin - 22 26 18 19 
Sulphonylurea - 7 14 16 19 
PPAR γ agonists - 0 3 1 1 
GLP 1 analogs - 2 1 2 1 
DPP IV inhibitors - 0 3 2 2 
Insulin - 2 9 11 23 
ACE inhibitors - 16 20 8 19 
ARB - 4 8 8 7 
HTN - 17 6 7 20 
PPAR γ agonists, Peroxisome proliferator-activated receptor gamma agonists, GLP-1 analogs, Glucagon-like 
peptide-1    analogs, DPP IV inhibitors, Inhibitors of dipeptidyl peptidase 4, ACE inhibitor, Angiotensin-
converting-enzyme inhibitor, ARB, angiotensin receptor blockers, HTN, Hypertension.  
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     Table 3.4 Baseline characteristics: micro/macro vascular complications in different subgroups 
   Characteristics               NGT GC GCC PC PCC 
          n  34 27 32 21 32  
    Retinopathy 0 0 6 0 13 
    Neuropathy 0 0 13 0 14 
    Nephropathy 0 0 18 0 22 
        CKD 0 0 13 0 19 
         IHD 0 0 12 0 17 
        PAD 0 0 2 0 2 
Cerebrovascular 
       disease 0 0 4 0 2 
    Diabetic foot 0 0 2 0 5 
 
     CKD, Chronic kidney disease, IHD, Ischemic heart disease, PAD, Peripheral arterial disease  
 !
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Table 3.5. Baseline characteristics - CKD staging and diabetic nephropathy in GCC and PCC 
!
Characteristics GCC PCC  
n 32 32 
Nephropathy 18 22 
MicroAlb 14 18 
MacroAlb 4 4 
CKD - - 
Stage 1 - - 
Stage 2 8 7 
Stage 3 5 10 
Stage 4 - 2 
Stage 5 - - !
CKD, Chronic Kidney Disease, MicroAlb, Microalbuminuria, MacroAlb, Macroalbuminuria  !
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Analysis of cytokines in T2D subjects !!!!!!!!!!!!!!
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Analysis of cytokines mRNA 
expression in T2D subjects 
 
 
4.1 Results 
The cytokines were measured in NGT and T2D subjects in both 
monocytes and neutrophils. Both neutrophils and monocytes expressed all 
5 cytokines, IL-6, TNFα, IL-1β, IFNβ and Rantes at the transcriptional 
level.  The 2-(ΔΔCt) method, commonly known as the "Delta Delta CT was 
used to analyse the relative changes in gene expression obtained using 
real - time quantitative PCR. Results of the real-time PCR data were 
represented as CT values, where CT was defined as the threshold cycle 
number of PCRs at which amplified product was first detected. There is an 
inverse correlation between CT and amount of target: lower amounts of 
target correspond to a higher CT value, and higher amounts of target have 
lower CT values. The average CT was calculated for both the target genes 
and GAPDH (glyceraldehyde-3-phosphate dehydrogenase is a protein-
coding gene) and the ∆CT was determined as (CT values for the target 
gene) minus (the mean of the CT values for GAPDH). The ∆∆CT was 
calculated by the formula ∆∆CT = (∆CT of target - ∆CT of normal). The N-
fold differential expression in the target gene compared to the normal 
sample counterpart was expressed as 2-∆∆CT (Livak KJ and Schmittgen 
TD, 2001). 
 
 
4.1a Cytokines expression in monocytes in T2D subjects with good 
and poor glucose control  
We can see that the PC and PCC subjects exhibited significantly 
increased TNFα mRNA expression in the monocytes when compared to 
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NGT (Fig. 4.1A). The highest level of IL-6 mRNA was found in monocytes 
from GC subjects (Median value: 12.3-fold), followed by PC subjects 
(10.7-fold) when compared to NGT (Table 4.1). In contrast, complication 
groups, GCC (3.9-fold) and PCC subjects (4.2-fold) showed lesser 
overexpression, compared to NGT subjects (Fig. 4.1B). 
 
IL-1β mRNA was suppressed in all T2D groups, lowest in GCC and PCC, 
compared with NGT (Fig. 4.1C).  Interestingly, highest level of IFNβ mRNA 
was seen in monocytes from PC subjects (Median value: 27-fold), followed 
by PCC (12.4-fold), GC (11.1-fold) and GCC (5.4-fold) when compared to 
NGT (Fig. 4.1D). Similarly, highest level of Rantes mRNA was noticed in 
monocytes from PC subjects (16-fold) and PCC subjects (12.4-fold) (Fig. 
4.2A).  
 
The IL-6 (p<0.05), IL-1β (p<0.05), IFNβ (p<0.001) and Rantes (p<0.001) 
expression in monocytes remained significant among different groups, 
with multifactorial ANOVA after adjustment for age, sex, WHR, BMI, 
duration of diabetes, creatinine and medications (insulin, sulfonylurea, 
metformin, GLP-1 analogues, DPP IV inhibitors, aspirin and statins) (Table 
4.4). Additionally a statistically significant correlation was found between 
IL-1β mRNA in monocytes and BMI in T2D subjects (Spearman’s r = 0.41, 
p<0.05). 
 
In summary, the highest level of IL-6 mRNA was observed in GC group, 
whereas highest level of IFNβ mRNA and Rantes mRNA were noticed in  
PC group, when compared to NGT. On the contrary, IL-1β mRNA 
remained suppressed in T2D groups, compared to NGT.  
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4.1b Cytokines expression in neutrophils in T2D subjects with good 
and poor glucose control  
 
The highest level of TNFα mRNA was seen in neutrophils from GC 
subjects (Median value: 6.4-fold) and PC subjects (3.3-fold), compared to 
NGT. In contrast, TNFα mRNA expressions remain suppressed in PCC 
subjects (0.5-fold), compared to NGT (Fig. 4.3A). GC and PC neutrophils 
over expressed IL-6 mRNA by about 58-fold and 9-fold respectively, 
compared to NGT (Table 4.2). In contrast, complication group subjects, 
GCC (1.3-fold) and PCC subjects (1.2-fold) showed comparable 
expression, when compared to NGT control individuals (Fig 4.3B). 
Similarly, IL-1β mRNA was overexpressed in GC (1.8-fold) and 
suppressed in GCC, PC and PCC groups, compared with NGT (Fig. 4.3C).  
 
We can see that GC and PC neutrophils over expressed IFNβ mRNA by 
35.4-fold and 4.8-fold respectively, compared to NGT (Table 4.3D). In 
contrast, neutrophils in the complication group, GCC (0.7-fold) and PCC 
subjects (1.2-fold) showed comparable expression, compared with NGT. 
Similarly, highest level of Rantes mRNA was seen in neutrophils from GC 
subjects (Median value: 28.7-fold), followed by PC subjects (4.1-fold), 
compared to NGT (Fig. 4.2B). In contrast expression was comparable in 
GCC and PCC subjects.  
 
The TNFα (p<0.001), IL-6 (p<0.001), IFNβ (p<0.001) and Rantes 
(p<0.001) expression remained significant among different groups, using 
multifactorial ANOVA after adjustment for age, sex, WHR, BMI, duration of 
diabetes, creatinine and medications (insulin, sulfonylurea, metformin, 
GLP-1 analogues, DPP IV inhibitors, aspirin and statins) (Table 4.4). 
Additionally, we did not find a correlation between cytokines mRNA and 
BMI in neutrophils. 
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Collectively, our data showed that TNFα, IL-6, IFNβ and Rantes mRNA 
expression were highest in GC neutrophils, when compared to NGT 
controls, whereas comparable expression was evident in GCC and PCC 
groups.  
 
In summary, the study showed that TNFα, IL-6, IFNβ & Rantes mRNA 
expression were highest in GC neutrophils, and IL-6 & IFNβ mRNA were 
overexpressed in GC monocytes compared to NGT. In contrast, IL-1β 
mRNA remained suppressed in monocytes in PC, GCC & PCC, compared 
to NGT. These results suggest an enhanced anti-inflammatory mechanism 
in T2D subjects with good glycaemic control with no complications, 
compared to T2D subjects with poor glycaemic control, and subjects with 
complications. 
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Analysis of serum cytokines in T2D subjects 
 
4.2 Results 
4.2a Pro-inflammatory cytokine levels in T2D subjects with good and 
poor glucose control 
In this study, we did not find statistical significant difference in serum IL-6, 
TNF-α and IL-1β among different groups (Fig. 4.4A, B). The median 
values of serum IL-6 and TNF-α were comparable in GC, GCC and PCC 
subjects compared to NGT (Table 4.3). Similarly, comparable levels of 
serum IL-1β were noticed in GC and GCC, suppressed levels in PC and 
PCC, when compared with NGT (Fig. 4.4C). In contrast, serum IFN-β was 
significantly increased in PC and comparable in GC group, compared to 
NGT control (Table 4.4D), decreased in GCC and PCC group (p<0.05). 
However, after adjustment for covariates the differences in serum IFN-β 
levels became statistically insignificant. 
 
4.2b Anti-inflammatory cytokine and chemokine levels in T2D 
subjects with good and poor glucose control 
IL-10 is an anti-inflammatory cytokine, which serves to suppress the 
production of Th1 cytokines, MHC class II antigens, and costimulatory 
molecules on macrophages and to enhance humoral immunity. Herein, 
serum IL-10 was increased in GC and PC subjects, supressed in GCC and 
PCC subjects, compared with NGT, but statistically insignificant (Fig. 
4.5A). Next we assessed the serum levels of the early response 
chemokine Rantes and the inflammatory chemokine IL-8. Rantes was 
increased in the PC and PCC groups, comparable in GC and GCC 
groups, when compared with NGT control group (Table 4.3). Interestingly, 
Serum IL-8 was comparable in GC group, decreased in PC, GCC and 
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PCC, when compared with NGT. However, no statistically significant 
difference in serum IL-8 and Rantes levels were observed among different 
groups (Fig. 4.5C). 
 
 
4.2c Levels of Th1 cytokines, IL-12 and IFN-γ in T2D subjects with 
good and poor glucose control 
Interleukin 12 (IL-12) activates natural killer and T cells with the secondary 
synthesis and release of IFN-γ thus promoting a Th1- or cell-mediated 
immune response (Fig. 4.6).  Decreased levels of IL-12 was detected in 
the GC, markedly decreased in GCC, PC and PCC patient groups 
compared to the NGT control group (Table 4.3). However, no significant 
difference in serum IL-12 was observed among different groups (Fig. 
4.6A). IFNγ was lower in GC, markedly supressed in the GCC, PC and 
PCC subjects compared to NGT subjects. Again, we did not find any 
significant difference in serum IL-10 amongst different groups (Fig. 4.5B).  
 
We applied multifactorial ANOVA using lognormal data after adjustment 
for age, sex, WHR, BMI, duration of diabetes, creatinine and medications 
(insulin, sulfonylurea, metformin, GLP-1 analogues, DPP IV inhibitors, 
aspirin and statins) and applied, but did not notice any change in 
significance (Table 4.5). Additionally, we did not find correlation between 
serum cytokines and BMI in T2D subjects. 
 
4.2d Cytokines mRNA expression in monocytes & neutrophil and 
serum levels of cytokine for the same individuals 
We analysed the cytokines mRNA expression in monocytes and 
neutrophils, and the serum levels for the same individual in T2D cohort 
and NGT subjects.  A scatterplot of this analysis is depicted in Fig. 4.7 (A-
J) 
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IL-6 mRNA was significantly overexpressed in both monocytes and 
neutrophils from GC group, compared to monocytes from NGT (Fig. 4.7A). 
Similarly, IL-6 mRNA was significantly overexpressed in neutrophils from 
GC compared to IL-6 mRNA in neutrophils from NGT. The serum IL-6 
levels remained statistically insignificant for the same individuals (Fig. 
4.7B). The IFNβ mRNA was significantly overexpressed in neutrophils 
from GC group, compared to NGT neutrophils & monocytes (Fig. 4.7E).  
We did not find significant difference in serum IFNβ levels among different 
groups for the same individuals (Fig. 4.7F). 
 
Rantes mRNA was significantly overexpressed in neutrophils from GC 
group, compared to Rantes mRNA levels in both monocytes and 
neutrophils from NGT (Fig. 4.7I).  Similarly, Rantes was significantly 
overexpressed in monocytes from PC compared to monocytes from NGT. 
The serum Rantes levels did not show significant difference among 
different groups for the same individuals (Fig. 4.7J).  
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Table 4.1 Cytokines mRNA expressions in monocytes from type 2 diabetic 
subjects & healthy controls. Cytokines mRNA were measured in subjects with 
normal glucose targets (NGT), good glucose control (GC), good glucose control with 
micro/macrovascular complications (GCC), poor glucose control (PC), poor glucose 
control with micro/macrovascular complications (PCC) in monocytes at the 
transcriptional level using 2-(ΔΔCt) method and results are expressed as median 
[inter quartile range].  Statistical significance was determined by non-parametric 
Kruskal–Wallis one-way analysis of variance and p<0.05 was considered significant. 
p value corresponds to the differences between groups. !
 
 NGT GC GCC PC PCC 
 
p 
 
 
 
n 8 8 8 8 8  
TNFα 1.0 [0.9-1.2] 
1.2 
[1.2-1.2] 
1.2 
[1.1-2.4] 
1.5 
[1.4-1.6] 
2.2 
[1.9-2.3] <0.001 
IL-6 0.9 [0.9-1.0] 
11.1 
[10.4-12.6] 
3.5 
[2.3-5.5] 
9.6 
[7.4-12.2] 
3.8 
[3.6-3.9] <0.001 
IL-1β 0.9 [0.7-1.3] 
0.1 
[0.1-0.1] 
0.04 
[0.03-0.04] 
0.1 
[0.1-0.1] 
.07 
[.05-0.12] <0.001 
IFNβ 0.9 [0.8-1.2] 
10.0 
[9.5-11.2] 
4.9 
[4.8-5.2] 
24.3 
[20.9-25.2] 
11.2 
[10.1-12.5] <0.001 
Rantes 1.2 [0.7-1.6] 
1.8 
[1.3-2.8] 
7.6 
[7.2-8.0] 
19.2 
[14.6-21.5] 
14.9 
[13.5-16.6] <0.001 !!!!!!!!!!!
 107 
Table 4.2 Cytokines mRNA expressions in neutrophils from type 2 diabetic 
subjects &  healthy    controls. Cytokines mRNA were measured in neutrophils 
from subjects with normal glucose targets (NGT), good glucose control (GC), good 
glucose control with micro/macrovascular complications (GCC), poor glucose control 
(PC), poor glucose control with micro/macrovascular complications (PCC) at the 
transcriptional level using 2-(ΔΔCt) method and results are expressed as median 
[inter quartile range].  Statistical significance was determined by non-parametric 
Kruskal–Wallis one-way analysis of variance and p<0.05 was considered significant. 
p value corresponds to the differences between groups. 
 
 NGT GC GCC PC PCC 
 
p  
n 8 8 8 8 8  
TNFα 1.0 [0.8-1.1] 
6.4 
[5.4-8.0] 
1.0 
[0.9-1.0] 
3.3 
[3.3-3.4] 
0.5 
[0.5-0.7] <0.001 
IL-6 0.9 [0.7-1.3] 
52.1 
[44.4-56.0] 
1.2 
[1.0-1.4] 
8.4 
[8.3-8.5] 
1.1 
[0.6-1.8] <0.001 
IL-1β 1.0 [0.5-0.1.6] 
1.8       
[1.6-2.1] 
0.6 
[0.6-0.7] 
0.4 
[0.3-0.5] 
0.5 
[0.4-1.6] <0.001 
IFNβ 1.0 [0.9-1.0] 
35.4 
[35.0-36.1] 
0.7 
[0.4-1.1] 
4.8 
[4.3-5.2] 
1.2 
[0.5-1.6] <0.001 
Rantes 0.9 [0.8-1.1] 
25.8 
[25.5-26.1] 
0.9 
[0.9-1.0] 
3.7 
[3.6-3.8] 
1.3 
[1.1-1.5] <0.001 
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Table 4.3  Fasting levels of cytokines in the serum in subjects with type 2 
diabetes & controls. Serum levels of cytokines were measured in subjects with normal 
glucose targets (NGT), good glucose control (GC), good glucose control with 
micro/macrovascular complications (GCC), poor glucose control (PC), poor glucose control 
with micro/macrovascular complications (PCC) using multiplex cytokine profiling and results 
are expressed as median [IQR]. Statistical significance was determined by Kruskal–Wallis 
test and p<0.05 was considered significant. p value corresponds to the differences between 
groups. 
 
 NGT GC GCC PC PCC 
 
p 
n 34 27 32 21 32  
IL-6 12.3       [0.9-16.3] 
13.2        
[1.0-19.1] 
12.4        
[1.5-19.3] 
3.8          
[1.4-18.0] 
13.4      
[1.9-18.5] 0.36 
TNFα  18.6   [14.5-22.5] 
19.3      
[12.5-23.1] 
21.7      
[12.8-27.2] 
16.8      
[12.8-23.4] 
23.5    
[18.1-26.7] 0.159 
IL-1β  6.0           [0.9-8.4] 
5.9           
[0.8-8.5] 
6.1          
[2.5-7.6] 
4.6          
[1.6-7.7] 
3.9         
[1.0-5.6] 0.368 
IFNβ 357.2        [8.5-685.4] 
339.8   
[126.3-1263] 
85.8      
[19.8-315.0] 
1082   
[736.6-1427] 
156.0  
[33.2-810.1] 0.010 
Rantes 
54703 
[41015-
77823] 
44307 
[34763-
76833] 
48832 
[40781-
77816] 
70993 
[55969-
131310] 
61766 
[45303-
82123] 
0.080 
IL-8 
63.5 
[25.2-89.8] 
57.3 
[26.7-85.3] 
39.3 
[20.6-68.9] 
41.7 
[24.2-89.1] 
49.4 
[26.6-68.3] 
0.574 
IL-10 
6.8 
[5.1-8.6] 
7.1 
[5.0-8.4] 
6.4 
[4.3-8.6] 
7.5 
[4.7-9.0] 
5.6 
[4.2-6.9] 
0.264 
IL-12p70 
9.2 
[3.9-12.9] 
6.7 
[2.2-9.9] 
5.3 
[2.3-8.3] 
5.9 
[1.9-9.1] 
5.9 
[1.5-10.6] 
 
0.13 
IFNγ 
8.7 
[2.3-11.9] 
6.8 
[2.6-10.6] 
5.0 
[2.1-8.0] 
3.6 
[1.8-8.7] 
5.2 
[2.1-7.1] 
0.304 
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Table 4.4. The multifactorial ANOVA analysis of cytokines mRNA in 
monocytes and neutrophils after adjustment for covariates. Statistical 
significance was determined after adjustment for age, sex, WHR, BMI, 
duration of diabetes, creatinine and medications (insulin, sulfonylurea, 
metformin, GLP-1 analogues, DPP IV inhibitors, aspirin and statins). p 
value corresponds to the differences between groups. 
 
Monocytes p Neutrophils p 
TNFα 0.57 TNFα <0.001 
IL-6 0.009 IL-6 <0.001 
IL-1β 0.026 IL-1β 0.079 
IFNβ <0.001 IFNβ <0.001 
Rantes <0.001 Rantes <0.001 
 
Table 4.5. The multifactorial ANOVA analysis of serum cytokines 
after adjustment for covariates. Statistical significance was determined 
after adjustment for age, sex, WHR, BMI, duration of diabetes, creatinine 
and medications (insulin, sulfonylurea, metformin, GLP-1 analogues, DPP 
IV inhibitors, aspirin and statins). p value corresponds to the differences 
between groups. 
Serum 
cytokines p 
Serum 
cytokines p 
IL-6 0.356 IL-8 0.932 
TNFα 0.198 IL-10 0.164 
IL-1β 0.503 IL-12p70 0.833 
IFNβ 0.257 IFNγ 0.317 
Rantes 0.465   
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Figure 4.1 TNFα, IL-6, IL-1β and IFNβ mRNA expressions in 
monocytes in subjects with type 2 diabetes & controls. Top and 
bottom horizontal lines of the boxplots indicate 25th and 75th percentiles 
respectively; lines within the box indicate median values. TNFα (A), IL-6 
(B) and IFNβ (D) were overexpressed in all T2D groups, compared with 
NGT. In contrast, IL-1β  (C) was suppressed in all T2D groups (n = 8 in 
each group). *p<0.05, **p<0.01, ***p<0.001 vs NGT. 
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Figure 4.2 Rantes mRNA expressions in monocytes & neutrophils in 
subjects with type 2 diabetes & controls. A: Rantes mRNA was 
overexpressed in monocytes from PC & PCC, compared with NGT.  B: In 
neutrophils, Rantes was overexpressed in GC and PC group. NGT, 
Normal glycaemic targets, GC, good glucose control, GCC, good glucose 
control with micro/macrovascular complications, PC, poor glucose control, 
poor glucose control with micro/macrovascular complications (n = 8 in 
each group). *p<0.05, **p<0.01, ***p<0.001 vs NGT. 
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Figure 4.3 TNFα, IL-6, IL-1β & IFNβ mRNA expressions in neutrophils 
in subjects with type 2 diabetes & controls. The TNFα (A), IL-6 (B), IL-
1β (C) & IFNβ mRNAs (D) were overexpressed in neutrophils in T2D 
subjects, compared to NGT. The highest level of TNFα, IL-6 & IFNβ were 
seen in GC group (n = 8 in each group). *p<0.05, **p<0.01, ***p<0.001 vs 
NGT  
 113 
 
 
Figure 4.4 Serum levels of pro-inflammatory cytokines in subjects 
with type 2 diabetes & controls. Serum TNF-α (A), IL-6 (B) and IL-1β (C) 
levels were comparable among different groups.  IFN-β (D) levels were 
significantly increased in PC group, compared to NGT. Values are 
expressed as pg/ml (n = 34 vs 27 vs 32 vs 21 vs 32). *p<0.05, **p<0.01, 
***p<0.001 vs NGT. 
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Figure 4.5 Anti-inflammatory 
cytokine and chemokine 
serum levels in subjects 
with type 2 diabetes & 
healthy controls. 
Serum IL-10 (A), Rantes (B) 
and IL-8 (C) were comparable 
in different T2D groups and 
NGT. NGT, Normal glycaemic 
targets (n = 34), GC, good 
glucose control (n = 27), GCC, 
good glucose control with 
micro/macrovascular 
complications (n = 32), PC, 
poor glucose control (n = 21), 
PCC, poor glucose control 
with micro/macrovascular 
complications (n = 32). Values 
are expressed as pg/ml.  
*p<0.05, **p<0.01, ***p<0.001 
vs NGT. 
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!
Figure 4.6 Serum levels of IL-12 and IFN-γ in subjects with type 2 
diabetes & healthy controls. Serum IL-12 (A) and IFN-γ (B) were 
comparable in different T2D groups and NGT.  NGT, Normal glycaemic 
targets (n = 34), GC, good glucose control (n = 27), GCC, good glucose 
control with micro/macrovascular complications (n = 32), PC, poor glucose 
control (n = 21), PCC, poor glucose control with micro/macrovascular 
complications (n = 32). Values are expressed as pg/ml. *p<0.05, **p<0.01, 
***p<0.001 vs NGT. 
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Figure 4.7 page 116 – 118. Scatter diagram plotting cytokines mRNA 
expression in monocytes/neutrophil and the serum levels for the same 
individuals.  (A) IL-6 mRNA was overexpressed in both monocytes and 
neutrophils from GC group, compared to NGT neutrophils. Serum IL-6 (B), 
TNFα mRNA (C) and serum TNFα (D) remained statistically insignificant for 
the same individuals. 
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Figure 4.7 Contd.  IFNβ mRNA was overexpressed in neutrophils from GC 
group, compared to NGT neutrophils & monocytes. Serum IFNβ (B), IL-1β 
mRNA (C) and serum IL-1β (D) remained statistically insignificant for the 
same individuals. 
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Figure 4.7 Contd.  Rantes mRNA (I) was overexpressed in neutrophils from GC 
group, compared to NGT neutrophils & monocytes. Serum Rantes (J) remained 
statistically insignificant for the same individuals. NGT, Normal glycaemic targets, 
GC, good glucose control, GCC, good glucose control with micro/macrovascular 
complications, PC, poor glucose control, PCC, poor glucose control with 
micro/macrovascular complications, M, monocytes, N, neutrophils. Values are 
expressed as pg/ml. *p<0.05, **p<0.01, ***p<0.001 vs NGT. 
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4.3 Discussion 
To the best of our knowledge, this is the first study that has sought to 
evaluate serum cytokine levels and cytokines mRNA expressions among 
diabetic subjects with good glycaemic control with/without complications 
and poor glycaemic with/without complications.  Herein, we investigated 
the cytokines mRNA expression in the monocytes and neutrophils and 
also characterised the cytokines profile in serum of subjects with T2D and 
NGT and evaluated whether perturbations in cytokines occur as a 
consequence of micro- and macrovascular complications.  
 
Previous cross-sectional and prospective studies have described an 
elevation in levels of circulating acute-phase proteins such as CRP, 
cytokines such as IL-1β, IL-6 and TNF-α , and chemokines in subjects with 
T2D  (Donath & Shoelson, 2011). We determined serum levels of the Th1 
cytokines (TNF-α, IL-1β, IL-6, IL-12p70 and IFN-γ) which stimulate cell-
mediated immunity, and promote inflammation and cytotoxicity. We also 
assessed serum levels of the Th2 cytokine, IL-10, which is purported to 
mediate a protective function during diabetes. We also evaluated TNF-α 
mRNA, IL-1β   mRNA, IL-6 mRNA, Rantes mRNA and IFN-γ mRNA 
expressions in both monocytes and neutrophils in T2D and NGT cohort. In 
the present study, strict exclusion criteria were applied to the study to 
include exclusion of subjects with intercurrent illnesses and infections.   
 
 
 
 
 
 120 
Pro-inflammatory cytokine levels in T2D subjects with good and poor 
glucose control  
Given the current hypothesis that T2D is an inflammatory condition 
(Donath & Shoelson, 2011), we initially evaluated levels of serum IL-1β, 
IL-6 and TNF-α. In relation to previous studies showing that elevated TNF-
α, IL-6 and IL-1β are risk factors for T2D (Donath & Shoelson, 2011; 
Spranger et al., 2003; Masters et al., 2010), we did not find any significant 
difference in serum levels of IL-6 and TNF-α in subjects with T2D, 
compared with NGT. However, IL-6 mRNA was significantly 
overexpressed in both monocytes and neutrophil from GC and PC, 
compared with NGT. Similarly, TNF-α mRNA was significantly 
overexpressed in GC neutrophils, compared with NGT. TNF-α mRNA was 
significantly overexpressed in PC and PCC monocytes, but after 
adjustment for covariates, it became statistically insignificant (Table 4.4). 
Our results coincide with previous studies, which showed overexpressed 
TNF-α mRNA and IL-6 TNF-α in T2D subjects (Tsiotra et al., 2007; 
Gonzalez et al., 2012).  
 
A study by Huseynova et al. (2013) found that subjects with T2D had 
increased levels of TNF-α and IL-8 in the stage of decompensation.  In this 
study T2D subjects were classified according to disease duration into 3 
groups: under one year- stage of compensation (n = 28), from six to ten 
years - stage of subcompensation (n = 28), over ten years- stage of 
decompensation (n =28). HbA1c was high in stage of decompensation 
(11.4 ± 0.32%) compared to compensation stage (6.1 ± 0.05). We think 
that elevated TNF-α and IL-8 in the T2D subjects in this study were related 
poor glycaemic status rather than the duration of disease i.e. 
decompensation. We did not find staging based on duration of diabetes. In 
our study, highest levels of TNF-α mRNA were present in GC compared to 
NGT.  
 
 121 
We think that discrepancy among these two studies can be attributed to  
(I) duration of the diseases; the majority of subjects included in our study 
have a longer disease duration  (mean duration 9 years) (II) small sample 
size, (III) different T2D study cohort; in our study subjects were classified 
as per glycemic status and presence/absence of complications. We think 
that duration of disease, glycaemic status and presence or absence of 
complications might explain the apparent discrepant results between these 
two studies.  
 
Interestingly, our monocyte data showed significantly decreased 
expressions of IL-1β mRNA in GCC, PC and PCC subjects, compared 
with healthy controls (p<0.05). In parallel to our study, Mooradian et al. 
(1991) has described undetectable levels of IL-1α and IL-1β in a group of 
137 patients with long-standing hyperglycaemia. The mean duration of 
diabetes in his  group was 14.1 ±6.7 y  and complications were not 
specified. In an another prospective study, cytokines were analysed in 53 
T2D subjects with and without DR, and compared with healthy controls, 
and it was found that serum levels of IL-1β  and IL-6 were undetectable in 
all diabetic subjects (Doganay et al., 2002). It has been shown that 
metformin (Isoda et al., 2006; Bestermann et al., 2011), PPAR-γ agonists 
(Jiang et al., 1998b) and GLP-1 analogues (Chaudhuri et al., 2012) lower 
the IL-1β concentration. In our study, IL-1β mRNA was significantly 
suppressed in neutrophils in PC subjects, compared with healthy controls 
(p<0.05), however after adjustment for various covariates it became 
statistically insignificant (Table 4.5). Furthermore, IFN-β has been shown 
to reduce the maturation of IL-1β by reducing the activation of nucleotide-
binding domain and leucine-rich repeat containing protein 3 (NLRP3) 
(Guarda et al., 2011). The T2D subjects in our study have elevated IFN-β 
and this might have affected IL-1β as well.  
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IFN-β is associated with anti-viral immunity but has also shown to 
immunomodulate the Th1/Th2 cytokine profile by attenuating the secretion 
of IFN-γ  and IL-12, while augmenting IL-4 and IL-10 secretion (Sellner et 
al., 2008). It has been shown that Interferon therapy can trigger induction 
of several autoimmune diseases, including T1D (Nakamura et al., 2011). A 
study on mice has suggested role of IFN-β in the onset of T1D (Pelegrin et 
al., 1998). In our study, serum levels of IFN-β were significantly raised in 
PC compared to NGT control (Table 4.4D), however, it became 
statistically insignificant after adjustment for covariates (Table 4.5D). We 
showed that IFN-β mRNA was significantly overexpressed in both 
monocytes and neutrophils from GC and PC group, compared to NGT. 
However,  in the absence of human studies exploring the role of IFN-β 
inT2D, the significance of this finding is not known, and we think that 
larger studies are required to understand the role of IFN-β in T2D 
pathophysiology.  
 
Collectively, our data showed that mRNA expressions of  proinflammatory 
cytokines IL-6, TNF-α and IFN-β  were increased in neutrophils, and IL-6 
and IFN-β were increased in monocytes in GC group, compared to NGT. 
In contrast, IL-1β mRNA expression was significantly decreased in GCC, 
PC and PCC subjects, compared to NGT. It suggests an upregulated anti-
inflammatory mechanism in T2D subjects with good glycaemic control with 
no complications, compared to T2D subjects with poor glycaemic control, 
and subjects with complications. 
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Anti-inflammatory cytokine and chemokine levels in T2D subjects 
with good and poor glucose control  
Chemokines such as IL-8 and Rantes are cardinal in the pathogenesis of 
all inflammation since they mediate the arrival of inflammatory cells to the 
site of both acute and chronic inflammation (Maier et al., 2008). Regarding 
diabetes, three studies found that in mouse models and in humans, 
obesity was associated with infiltration of macrophages into adipose tissue 
and adipose tissue from obese mice exhibit a significant upregulation of 
chemokines (Herder et al., 2005). Few studies have demonstrated an 
elevated level of Rantes in patients with T2D (Maier et al., 2008; Herder et 
al., 2008). In our study, serum Rantes levels were comparable among 
different groups. However, we showed that Rantes mRNA was 
overexpressed in monocytes from PC subjects (16-fold) (p<0.001), 
followed by PCC subjects (12.4-fold) (p<0.001), compared to NGT. 
Similarly, in neutrophils, Rantes mRNA was overexpressed in GC 
(p<0.001) and PC (p<0.01) subjects, compared with NGT. Though the 
Rantes mRNA was overexpressed in our study, it was not possible to say 
whether it was a consequence of hyperglycaemia or had a causal role in it. 
However, Augsburg Cohort Study suggested that raised Rantes was a 
consequence rather than cause of hyperglycaemia. In this study, DNA 
samples were analysed from 502 individuals with and 1632 individuals 
without incident T2D, CCL5 genotypes and RANTES serum 
concentrations were determined, and associations between genotypes, 
haplotypes, serum levels, and T2D were assessed. It was noticed that 
RANTES/CCL5 gene variants and serum levels were not causally related 
with T2D.  
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The serum IL-8 was comparable among different groups in our study, 
which is in disagreement with previous studies (Fig. 4.5C). Esposito et al. 
(2003) has shown increased plasma levels of IL-8 in newly diagnosed T2D 
subjects (n = 30), compared with healthy subjects. In another similar 
study, Zozuliæska et al. (1999) showed elevated plasma levels of IL-8 in 
T2D subjects (n =20). The medications and diabetes associated 
micro/macrovasular complications status were not described in these 
studies. We think that our study cohort was different from these studies as 
our T2D subjects were on multiple oral agents and/or insulin, and subjects 
had longer duration of diabetes, which might have suppressed the IL-8 
levels. Furthermore, both studies had small sample size, which could have 
affected their results. Elner et al. (1995) has suggested that IL-8 
participates in the pathogenesis of diabetic retinopathy. He reported an 
increase in IL-8 concentrations in the vitreous of patients with diabetic 
retinopathy. This study involved 30 patients with proliferative diabetic 
retinopathy (PDR), 13 patients with proliferative vitreoretinopathy (PVR), 
and 26 control individuals, and IL-8 was measured in the vitreous. We did 
not analyse serum cytokines based on DR stages in this study, which was 
a limitation. We think that studies with larger sample size are required to 
draw a conclusion regarding the role of IL-8 in T2D. 
 
In this study serum IL-10 levels were statistically insignificant among 
different groups. However, Yaghini et al. (2011) showed that the serum 
levels of IL-10 were decreased in T2D subjects (n = 131) compared to 
controls (n = 120). Similarly, the Leiden 85-Plus Study, which included a 
cohort of 553 subjects showed that low IL-10 production capacity was 
associated with high plasma glucose, and high HbA1c, (Exel et al., 2012). 
In this study blood samples were collected under nonfasting conditions, 
which was a limitation. In our study, we did not find a correlation between 
Hba1c & IL-10. The difference regarding IL-10 in our study and these 
studies is possibly due to smaller sample size in our study.  
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In summary, we observed that Rantes mRNA expression was markedly 
overexpressed in neutrophils from GC group, however, variable 
expression was seen in monocytes. Collectively, it indicates an activated 
inflammatory mechanism in subjects with T2D.  
 
Levels of Th1 cytokines, IL-12 and IFN-γ in T2D subjects with good 
and poor glucose control 
In this study, we observed low serum levels of IL-12 and IFN-γ in T2D 
subjects, which was statistically insignificant. Previous studies have shown 
conflicting results. Tsiavou et al. (2004) has demonstrated low serum 
levels of Th1 cytokines, IFN- γ and IL-12 in T2D subjects. In contrast, 
Wegner et al. (2008) demonstrated elevated IL-12 serum levels in T2D 
subjects. His study included 109 subjects and T2D subjects were treated 
with sulfonylurea. In another human study, which included 80 subjects, 
Winkler et al. (1998) demonstrated elevated serum IL-12 in T2D subjects. 
The patients medication were not specified in this study.  Our study differ 
from these studies as our T2D study cohort was different and most of our 
T2D subjects were on multiple OHA ‘s and/or insulin, and this altogether 
might have suppressed serum IL-12 in the our T2D cohort. We think that 
larger studies are required to ascertain the role of cytokines in T2D. 
 
An appropriate balance between proinflammatory (Th1) and anti-
inflammatory (Th2) cytokines is critical to maintain homeostasis thus 
avoiding unwanted chronic inflammatory pathology. While the Th1 
cytokines stimulate cell-mediated immunity, and promote inflammation and 
cytotoxicity, the Th2 cytokines assure regulatory function, thus mediate 
protective function during diabetes. Collectively, our data showed that 
mRNA expressions of  proinflammatory cytokines IL-6, TNFα and IFN-β  
were significantly increased in neutrophils, and IL-6 and IFN-β were 
significantly increased in monocytes in GC group, compared to NGT. 
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Chemokine, Rantes mRNA was also found ovexpressed in GC in 
nutrophils.  In contrast, IL-1β mRNA expression was significantly 
decreased in GCC, PC and PCC subjects, compared to NGT. It suggests 
that T2D subjects with good glycaemic control with no complications have 
upregulated inflammatory mechanisms, whereas T2D subjects with poor 
glycaemic control, and subjects with complications have decreased 
inflammation. 
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Chapter 5 
 
 
Analysis of adipokines in T2D subjects 
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5.1 Results 
The adipokines were measured in NGT and T2D subjects in both 
monocytes and neutrophils. Both neutrophils and monocytes expressed all 
three adipokines, RBP-4, LCN-2 and adiponectin at the transcriptional 
level.  The 2-(ΔΔCt) method was used to analyse the relative changes in 
gene expression obtained using real-time quantitative PCR.  
 
5.1a Adipokines expression in monocytes in T2D subjects with good 
and poor glucose control  
The highest level of RBP4 mRNA was seen in monocytes from GC 
subjects (6.2-fold), followed by increased expression in GCC (2.8-fold) 
when compared to NGT (Fig. 5.1A). In contrast, PC and PCC subjects 
showed comparable RBP4 expression when compared to NGT control 
individuals (Table 5.1). 
 
The highest level of LCN2 mRNA was observed in monocytes from GC 
subjects (2-fold) (Fig. 5.1B). In contrast, significantly decreased LCN2 
expression was evident in PC and PCC subjects compared to NGT. 
Similarly, adiponectin mRNA was overexpressed in monocytes from GC 
subjects (1.4-fold) and significantly decreased levels were seen in PC and 
PCC subjects, compared with NGT (Fig. 5.1C). The RBP4, LCN2 and 
adiponectin mRNA expressions remained significant among different 
groups with multifactorial ANOVA using lognormal data after adjustment 
for age, sex, WHR, BMI, duration of diabetes, creatinine and medications 
(insulin, sulfonylurea, metformin, GLP-1 analogues, DPP IV inhibitors, 
aspirin and statins) (p<0.001) (Table 5.3). 
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In summary, the RBP4, LCN2 and adiponectin were overexpressed in 
monocytes from GC subjects when compared to NGT controls. On the 
contrary, decreased  expression of the LCN2 and adiponectin was seen in 
PC and PCC subjects compared to NGT individuals. 
 
5.1b Adipokines expression in neutrophils in T2D subjects with good 
and poor glucose control  
GC and PC neutrophils over expressed RBP4 mRNA, about 40-fold and 6-
fold respectively, compared to NGT (Fig. 5.2A)  (Table 5.2). Similarly, 
LCN2 mRNA expression was significantly upregulated in GC (25.2-fold) 
and PC (3.6-fold) compared with NGT (Fig. 5.2B).  We can see that 
adiponectin mRNA expression was also significantly enhanced in GC 
(30.7-fold) compared to NGT (Fig. 5.2C). The RBP4, LCN2 and 
adiponectin mRNA expressions remained significant among different 
groups with multifactorial ANOVA using lognormal data after adjustment 
for age, sex, WHR, BMI, duration of diabetes, creatinine and medications 
(insulin, sulfonylurea, metformin, GLP-1 analogues, DPP IV inhibitors, 
aspirin and statins) (p<0.001) (Table 5.3).  Additionally, we did not find 
correlation between adipokines and BMI in both monocytes and 
neutrophils in T2D subjects.  
 
In summary, our data showed that all three adipokines, RBP4, LCN2 and 
adiponectin were significantly overexpressed in GC neutrophils compared 
to NGT controls. Moreover, neutrophils from PC subjects also displayed 
the enhanced expression of LCN2 mRNA compared to NGT. In contrast, 
comparable expression of adipokines was evident in  GCC and PCC 
subjects compared to NGT.  
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Collectively, the study showed that RBP4, LCN2 and adiponectin were 
overexpressed in both monocytes and neutrophils in GC subjects. In 
contrast, variable expression was  evident in PC, GCC and PCC subjects 
compared to NGT controls. 
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Table 5.1  Adipokines mRNA expressions in monocytes from type 2 
diabetic subjects &  healthy controls. Adipokines mRNA were measured in 
subjects with normal glucose targets (NGT), good glucose control (GC), good 
glucose control with micro/macrovascular complications (GCC), poor glucose 
control (PC), poor glucose control with micro/macrovascular complications (PCC) 
in monocytes at the transcriptional level using 2-(ΔΔCt) method and results are 
expressed as median [inter quartile range].  Statistical significance was 
determined by Kruskal–Wallis test and p<0.05 was considered significant. p 
value corresponds to the differences between groups. 
 
 
 NGT GC GCC PC PCC 
 
p  
n 8 8 8 8 8  
RBP4 
1.0 
[0.9-1.0] 
6.2 
[4.3-7.0] 
2.8 
[2.6-3.0] 
1.3 
[1.0-1.5] 
1.0 
[0.8-1.3] 
<0.001 
LCN2 
1.0 
[0.9-1.1] 
2.5 
[2.3-2.6] 
1.0 
[0.9-1.0] 
0.5 
[0.5-0.6] 
0.6 
[0.5-0.7] 
<0.001 
Adiponectin 
1.1 
[0.7-1.5] 
1.6 
[1.4-1.7] 
0.8 
[0.7-0.8] 
0.3 
[0.3-0.4] 
0.3 
[0.2-0.3] 
<0.001 
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Table 5.2  Adipokines mRNA expression in neutrophils from type 2 
diabetic subjects & healthy controls. Statistical significance was determined 
by Kruskal–Wallis test and p<0.05 was considered significant. p value 
corresponds to the differences between groups. 
 
 
 NGT GC GCC PC PCC 
 
p  
 
n 8 8 8 8 8  
RBP4 1.0  [0.8-1.1] 
39.6  
[36.5-41.8] 
1.1  
[0.7-1.9] 
5.4  
[4.8-6.8] 
0.4  
[0.2-0.7] <0.001 
LCN2 1.0  [0.9-1.1] 
25.2  
[18.8-32.9] 
1.5  
[1.3-1.7] 
3.6  
[3.2-4.3] 
0.9  
[0.3-1.6] <0.001 
Adiponectin 1.0  [0.9-1.0] 
30.7  
[29.5-31.6] 
0.7  
[0.5-1.0] 
4.0  
[2.7-6.7] 
0.6  
[0.3-1.5] <0.001 
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Table 5.3. The multifactorial ANOVA analysis of adipokines mRNA in 
monocytes and neutrophils after adjustment of covariates. Statistical 
significance was determined after adjustment for age, sex, WHR, BMI, duration 
of diabetes, creatinine and medications (insulin, sulfonylurea, metformin, GLP-1 
analogues, DPP IV inhibitors, aspirin and statins). p value corresponds to the 
differences between groups. 
 
Monocytes p Neutrophils p 
RBP4 <0.001 RBP4 <0.001 
LCN2 <0.001 LCN2 <0.001 
Adiponectin <0.001 Adiponectin <0.001 
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Figure 5.1 RBP4, LCN-2 & adiponectin mRNA expressions in 
monocytes in subjects with type 2 diabetes & controls. The RBP4 
mRNA (A) was overexpressed in monocytes from GC and GCC, 
compared to NGT. LCN2 (B) and adiponectin (C) mRNAs showed 
decreased expression in PC and PCC monocytes, compared to NGT.  
RBP-4, Retinol binding protein 4, LCN-2, Lipocalin-2 (n = 8 in each group). 
*p<0.05, **p<0.01, ***p<0.001 vs. NGT. 
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Figure 5.2 RBP4, LCN 2 & adiponectin mRNA expressions in 
neutrophils in subjects with type 2 diabetes & controls. The RBP4 (A), 
LCN2 (B) and adiponectin (C) mRNAs were significantly overexpressed in 
GC neutrophils, compared to NGT. LCN2 mRNA was also overexpressed 
in PC compared to NGT. RBP-4, Retinol binding protein 4, LCN-2, 
Lipocalin-2 (n = 8 in each group). *p<0.05, **p<0.01, ***p<0.001 vs. NGT. 
 
 !
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5.2 Discussion 
In the present study, we have investigated three adipokines, i.e., 
adiponectin, LCN2 and RBP4 mRNA expression in monocytes and 
neutrophils in T2D subjects and compared them with the healthy controls.  
 
Only few studies have evaluated the expression of human adiponectin at 
mRNA level in the monocytes.  The adiponectin receptor 1 (AdipoR1) and 
adiponectin receptor 2 (AdipoR2)  receptors are ubiquitously expressed in 
most organs as well as in human peripheral monocytes, and in monocyte-
derived macrophages (Pang & Narendran, 2008). Most of the data 
published so far indicate that circulating adiponectin and the mRNA 
expression of AdipoR1 and AdipoR2 are reduced in IR postulating a state 
of adiponectin resistance in glucose intolerant animals and humans. 
(Weigert et al., 2008). One study has revealed a positive correlation 
between monocytic AdipoR1 mRNA and systemic adiponectin 
concentration in obesity (Weigert et al., 2008). Whereas, another study 
has shown a positive correlation between Lymphocytic AdipoR1 mRNA 
and serum adiponectin level (Alberti et al., 2007). In our study we 
evaluated adiponectin mRNA expression on monocytes and neutrophils 
but did not investgate AdipoR1 and AdipoR2 mRNA separately.  
 
LCN2 is expressed in neutrophils and interestingly, neutrophil gelatinase-
associated lipocalin was originally isolated from the supernatant of 
activated human neutrophils (Kjeldsen et al., 1993). There might be a 
correlation between LCN2 expression on leucocytes and serum LCN2 
concentration, but we did not find any study, which evaluated LCN2 mRNA 
expression on leucocytes. Similarly, RBP4 expression has been studied in 
adipocytes and macrophages  (Brochi et al., 2010) but the studies on 
RBP4 expression in monocytes or neutrophils are lacking. 
 
 Adiponectin has been identified as insulin sensitizing adipocyte-derived 
protein (Esteve et al., 2009), which is paradoxically decreased in obesity 
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(Bruun et al., 2003a).  In a human study, Brun et al. (2003) showed that 
plasma levels of adiponectin were higher in lean subjects compared with 
obese subjects, and adiponectin levels inversely correlated with measures 
of adiposity [BMI (P 0.05)]. He further showed that weight loss resulted in 
increase in plasma adiponectin and an increase in adipose tissue mRNA 
levels. In our study, we did not find correlation between adipokines and 
BMI in both monocytes and neutrophils in T2D subjects. Previous studies 
have shown that the circulation levels of adiponectin are lower in T2D 
(Hotta et al., 2000; Weyer et al., 2001) and in IR  states (Chang et al., 
2009; Yang et al., 2002c). Similarly our data also showed suppressed 
adiponectin in monocytes from PC and PCC, compared to NGT. However, 
adiponectin mRNA was overexpressed in neutrophils from GC compared 
to NGT. Whether increased adiponectin in GC is a protective response to 
overcome IR or a reflection of excellent glycaemic control, median HbA1c 
of 6.4 [6.0-6.9] (median [IQR]), remains questionable. The lifestyle 
modification and weight reduction also enhances plasma adiponectin 
concentration in T2D subjects (Hotta et al., 2000; Balgopal et al., 2005), 
however, the contribution of these measures were not measured in our 
study. The subjects were not asked about weight loss and exercise 
programme they might be involved in, at the time of recruitment and IR 
was also not calculated. However,  absence of micro or macrovascular 
complications and shorter duration of diabetes in GC as compared to other 
T2D groups, argues against IR in the GC group.  
 
It has been shown that adiponectin plasma levels deteriorate early in the 
development of obesity and rapidly achieve trough levels with further 
weight gain and thus, the significance of low adiponectin levels for the 
metabolic and cardiovascular risk is not apparent in patients beyond a 
certain BMI cutoff or in patients with already visible end-organ damage 
(Engeli et al., 2003). Hotta et al., (2000) showed that serum adiponectin 
levels does not correlate with existing retinopathy in diabetic patients. Our 
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data also showed that adiponection expression was significantly reduced 
in PCC in monocytes, compared to NGT. 
 
In our study, highest levels of adiponectin mRNA & IL-6 mRNA were 
noticed in neutrophils in GC group compared to healthy controls and 
decreased levels were seen in PCC in monocytes (p<0.05). However, it 
has been shown that serum adiponectin concentrations are inversely 
associated with the degree of inflammatory response in both 
cardiovascular disease and critical illness (Ouedraogo et al., 2007). 
Adiponectin has  been shown to have  protective metabolic and anti-
inflammatory properties (Engeli et al., 2003). A human study has 
demonstrated an independent inverse correlation between low adiponectin 
(plasma levels and adiponectin gene expression from adipose tissue) and 
high plasma levels of hs-CRP and IL-6 (Engeli et al., 2003). In a study on 
porcine macrophages adiponectin was shown to suppress LPS-stimulated 
release of IL-6 (Wulster-Radcliffe et al., 2004). We think that our results 
are at variance with previous findings because of different methodologies 
i.e, we measured adipokines mRNA expressions in monocytes and 
neutophils, whereas other studies had measured adipokines in serum.and 
adipocytes. Though, it is plausible to speculate that higher levels of 
adiponectin observed in GC is a protective measure for  counteracting IR 
and inflammation,  whereas decreased adiponectn in PCC is a refection of 
downregulation of receptor as a result of sustained activation, resulting in 
complications, the  interpretation is limited by the small sample size in this 
study. 
 
The RBP4 is an adipokine associated with obesity and comorbidities, 
which  correlates inversely with insulin sensitivity and higher levels have 
been seen in subjects with IGT and T2D (Yang et al., 2005; Graham et al., 
2006; Cho et al., 2006). Interestingly, highest levels of RBP4 mRNA were 
seen in GC in both monocytes and neutrophils and a decreasing trend 
was evident in other T2D cohorts. The weight loss and exercise have been 
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shown to decrease RBP4 levels in subjects with IR and T2D (Graham et 
al., 2006; Ku at al., 2010), whereas insulin-sensitizing agent pioglitazone 
has been shown to increase RBP4 gene expression (Yao-Borengasser et 
al., 2007; Sell et al., 2007). However, in our study, only 5 T2D subjects 
were on PPAR-γ agonists out of 112 (Table 3.3). Interestingly, in line with 
our study, few other studies also did not find any correlation between 
circulating RBP4 levels and IR (Ulgen et al., 2010; Promintzer et al., 
2007).  We think that poor glycaemic control and the complications might 
have suppressed the RBP4 expression in  PC, GCC and PCC, but the 
data is limited because of small sample size.  
 
The serum RBP4 levels correlates with the degree of IR (Graham et al., 
2006), but the mechanism by which RBP4 induces IR is not well known 
(Esteve et al., 2009).  IR is associated with increased risk of both micro- 
and macrovascular complications (Kilpatrick et al., 2007). We tried to 
explore the role of RBP4 in diabetes associated chronic micro/macro 
vascular complication. One study has suggested role of RBP4 in chronic 
inflammatory DR; the serum RBP4 level were significantly elevated in 
individuals with prolferative DR compared with those with no DR or simple 
DR and (Li et al., 2010). In contrast,  another study in DN suggested it is 
impaired kidney function that determine RBP4 serum concentration in T2D 
nephropathty patients rather than T2D per se;  the RBP4 concentration 
was found elevated equally in T2D and non diabetic subjects with impaired 
renal function (Andrea et al., 2008). In our T2D subjects, retinopathy was 
seen in 40.6% PCC subjects, compared with 18.6% GCC subjects, 
neuropathy was evident in 41% GCC subjects and 44% PCC subjects, 
and nephropathy was seen in 68.8% PCC compared to 56.3% GCC 
subjects.  However, we demonstrated suppressed RBP4 expression in our 
PCC group. It suggests that sustained activation of receptors, resulting in 
diabetic complication, lead to downregulation of receptor for limitation and 
termination of systemic inflammatory response 
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Our study clearly showed that the LCN2 mRNA levels were highest in GC 
in both neutrophils (p<0.05) and monocytes, and a decreasing trend was 
evident in other T2D cohorts. Few studies have also demonstrated 
increased LCN2 expression in obese animals and human subjects with 
T2D (Wang et al., 2007; Yan et al., 2007).  It has been shown that 
hyperglycaemia increases the expression of LCN2 by inducing IR, and the 
thiazolidinediones, an insulin-sensitizing agent reduces it (Wang et al., 
2007; Yan et al., 2007). Given the anti-inflammatory role of LCN2, 
increased LCN2 in obesity and IR appears to be a protective mechanism 
against inflammation.   
 
Collectively, we found that all three adipokines, adiponectin, LCN2 and 
RBP4 were overexpressed in the T2D subjects and indicate an 
inflammatory/anti-inflammatory and IR/insulin sensitizing milieu in early 
diabetes. We think that higher levels of adipokines observed in early 
diabetes is a reflection of  protective measure to prevent complication, 
whereas supressed expression observed in late diabetes is a reflection of 
downregulation of receptors to curtail the inflammation.  
 
No study that we are aware of has compared adipokine expression among 
diabetic subjects with good glycaemic control with/without complications 
and poor glycaemic with/without complications.  In presence of the limited  
data from this relatively small study  it is difficult to interpret the exact role 
of adipokines in the pathophysiology of T2D, and further studies are 
needed in a similar but larger cohort and with an expanded profile 
including measurement of IR and serum adipokine levels. 
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Chapter 6 
 
 
 
Analysis of TLR expression in T2D 
subjects 
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6.1 Results 
6.1a TLR expression in monocytes in T2D subjects with good and 
poor glucose control  
Toll like receptor gene expression was evaluated in the monocytes and 
neutrophils of subjects with T2D and NGT individuals. All TLRs 1-10 were 
expressed on both monocytes and neutrophils. The 2-(ΔΔCt) method was 
used to analyse the relative changes in gene expression obtained using 
real - time quantitative PCR.  
 
The expression of TLR 1-10 mRNA in monocytes obtained from NGT and 
T2D are depicted in Fig 6.1 (Table 6.1). It was found that TLR1 mRNA was 
overexpressed by 3-fold and 2-fold in the monocytes of GC and GCC 
subjects, respectively, when compared with NGT (p<0.001). In contrast, 
comparable expression was evident in PC and PCC subjects (Fig. 6.1A). 
 
TLR2 mRNA was overexpressed in the monocytes from GC subjects (1.6-
fold), whereas decreased expression was evident in the PC (0.7-fold) and 
PCC subjects (0.5-fold), compared to NGT (Fig. 6.1B). Similarly, TLR3 
mRNA was upregulated by 4.7-fold and 2.3-fold in the monocytes of GC 
and GCC subjects, respectively compared to NGT, whereas comparable 
expression was observed in the PC and PCC subjects (Fig. 6.1C).  
 
Interestingly, T2D subjects in all groups exhibited a comparable TLR4 
mRNA expression in the monocytes when compared to NGT (Fig. 6.1D). 
The highest level of TLR5 mRNA was seen in the monocytes from GC 
subjects (3.3-fold), followed by GCC (1.5-fold) compared to NGT (Fig. 
6.1E). In contrast, comparable expression was noticed in PC and PCC 
subjects. TLR6 mRNA was overexpressed in the monocytes from GC 
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subjects (2.5-fold) compared to NGT, whereas, comparable expression 
was evident in GCC, PC and PCC subjects (Fig. 6.1F).  
 
We can see that TLR7 mRNA expression was upregulated in the 
monocytes from PC (12-fold), GCC (9.3-fold) and PCC (3.9-fold), markedly 
upregulated in GC subjects (24.4-fold), when compared to NGT (Fig. 
6.1G). The monocytes of GC overexpressed TLR8 mRNA by 2.1-fold, 
compared to NGT, whereas comparable expression was noticed in GCC 
(1.5-fold), PC (1.2-fold) and PCC subjects (1.3-fold) (Fig. 6.1H).  
 
TLR9 mRNA was overexpressed by 6.3-fold and 2-fold in the monocytes 
of GC and GCC subjects compared to NGT (Fig. 6.1I). In contrast, PCC 
subjects (0.8-fold) exhibited decreased TLR9 mRNA expression when 
compared to NGT controls. Similarly, the monocytes of GC and GCC 
overexpressed TLR10 mRNA by 5.8-fold and 2.2-fold respectively 
compared to NGT, whereas suppressed expression was observed in the 
PCC subjects (Fig. 6.1J). The TLR mRNA 1, 3, 5, 6, 7, 9 & 10 remained 
statistically significant among different groups after adjustment for age, 
sex, WHR, BMI, duration of diabetes, creatinine and medications (insulin, 
sulfonylurea, metformin, GLP-1 analogues, DPP IV inhibitors, aspirin and 
statins) using lognormal data with multifactorial ANOVA (Table 6.2).  
Additionally, We did not find correlation between TLRs mRNA in 
monocytes and BMI in T2D subjects.  
 
In summary, monocytes from GC group overexpressed all TLRs mRNA 1-
10 and mRNA levels of TLR1, 3, 5, 7, 9 & 10 were significantly highest 
compared to NGT. TLR 1, 5, 7 &-10 were overexpressed in the monocytes 
from GCC subjects compared to NGT (p<0.05).  
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Table 6.1 TLR mRNA expressions in monocytes from subjects with type 2 
diabetes & healthy controls. TLRs mRNA were measured in subjects with normal 
glucose targets (NGT), good glucose control (GC), good glucose control with 
micro/macrovascular complications (GCC), poor glucose control (PC), poor glucose 
control with micro/macrovascular complications (PCC) in monocytes at the 
transcriptional level using 2-(ΔΔCt) method and results are expressed as median 
[inter quartile range].  Statistical significance was determined by Kruskal–Wallis test 
and p<0.05 was considered significant. p value corresponds to differences between 
groups. 
 
 NGT GC GCC PC PCC 
 
p value 
 
n 8 8 8 8 8  
TLR 1 0.9 [0.8-1.3] 
2.7 
[2.5-2.9] 
1.8 
[1.7-1.9] 
1.1 
[1.0-1.1] 
0.9 
[0.8-1.2] <0.001 
TLR 2 0.9 [0.8-1.0] 
1.5 
[1.3-1.6] 
0.9 
[0.9-1.1] 
0.7 
[0.6-0.8] 
0.5 
[0.3-0.9] <0.001 
TLR 3 1.0 [0.9-1.1] 
4.7 
[4.6-4.8] 
2.3 
[2.2-2.3] 
1.0 
[1.0-1.1] 
0.8 
[0.6-0.9] <0.001 
TLR 4 1.0 [0.8-1.2] 
1.3 
[1.1-1.5] 
1.1 
[1.0-1.2] 
0.9 
[0.7-1.0] 
0.8 
[0.6-1.2] 0.011 
TLR 5 1.0 [0.9-1.0] 
3.3 
[3.2-3.3] 
1.4 
[1.2-1.7] 
1.1 
[1.0-1.2] 
1.2 
[0.9-1.4] <0.001 
TLR 6 1.0 [0.8-1.2] 
2.5 
[1.5-3.3] 
0.7 
[0.6-0.9] 
0.5 
[0.3-0.9] 
0.9 
[0.5-1.9] 0.002 
TLR 7 0.9 [0.7-1.4] 
22.0 
[20.9-24.4] 
8.4 
[8.2-8.8] 
10.8 
[9.9-11.2] 
3.5 
[2.9-6.1] <0.001 
TLR 8 0.9 [0.8-1.1] 
1.9 
[1.9-2.0] 
1.4 
[1.3-1.4] 
1.1 
[1.0-1.1] 
1.2 
[0.6-2.0] <0.001 
TLR 9 0.9 [0.9-1.0] 
5.7 
[5.2-5.9] 
1.8 
[1.7-1.9] 
1.0 
[1.0-1.0] 
0.7 
[0.6-0.8] <0.001 
TLR 10 1.0 [0.8-1.1] 
5.8 
[5.4-6.2] 
2.2 
[1.9-2.5] 
1.1 
[1.1-1.2] 
0.5 
[0.3-0.7] <0.001 
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Table 6.2. The multifactorial ANOVA analysis of TLRs mRNA in 
monocytes and neutrophils after adjustment of covariates. Statistical 
significance was determined after adjustment for age, sex, WHR, BMI, 
duration of diabetes, creatinine and medications (insulin, sulfonylurea, 
metformin, GLP-1 analogues, DPP IV inhibitors, aspirin and statins). p 
value corresponds to the differences between groups. 
 
Monocytes p Neutrophils p 
TLR 1 0.008 TLR 1 0.029 
TLR 2 0.574 TLR 2 0.057 
TLR 3 <0.001 TLR 3 <0.001 
TLR 4 0.362 TLR 4 0.048 
TLR 5 0.018 TLR 5 <0.001 
TLR 6 0.037 TLR 6 0.002 
TLR 7 0.012 TLR 7 <0.001 
TLR 8 0.237 TLR 8 0.001 
TLR 9 <0.001 TLR 9 <0.001 
TLR 10 <0.001 TLR 10 <0.001 !
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Figure 6.1 (Pages 146-147) - 
TLR mRNAs expression in monocytes of subjects with type 2 diabetes 
& controls.  All TLRs mRNA 1-10 were overexpressed in GC group, and 
mRNA levels of TLR1, 3, 5, 7, 8, 9 & 10 were highest compared to NGT. 
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Figure 6.1 contd. from page 146 
TLR 1, 5, 7 & 10 were overexpressed in the monocytes from GCC 
subjects compared to NGT. TLR7 mRNA was markedly overexpressed in 
monocytes from GC (22-fold) compared to NGT. TLR, Toll Like Receptor 
(n = 8 in each group). *p<0.05, **p<0.01, ***p<0.001 vs NGT. 
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6.1b TLR expression in neutrophils in T2D subjects with good and 
poor glucose control  
The expression of TLRs 1-10 mRNA in neutrophils obtained from NGT 
and T2D are depicted in Fig 6.2 (Table 6.3). It was found that TLR1 mRNA 
was overexpressed by 2.4-fold in the neutrophils of GC subjects compared 
to NGT (Fig. 6.2A).  In contrast, comparable expression was evidenced in 
other groups.  Similarly, TLR2 mRNA was overexpressed by 1.6-fold and 
1.9-fold in the neutrophils of GC and GCC subjects respectively, 
compared to NGT, whereas comparable expression was evidenced in PC 
and PCC subjects (Fig. 6.2B). 
 
Interestingly, TLR3 mRNA expression was markedly upregulated by about 
28-fold and 4-fold in the neutrophils of GC and PC subjects, respectively 
compared to NGT (Fig. 6.2C). In contrast, suppressed expression was 
observed in the GCC and PCC subjects. We can see that highest level of 
TLR4 mRNA was seen in neutrophils from GC subjects (5.4-fold), followed 
by PCC (3.5-fold) and GCC (3.3-fold), compared to NGT. In contrast, 
TLR4 expression in PC (2.3-fold) group was comparable (Fig. 6.2D).  
 
The TLR5 mRNA, similar to TLR3 mRNA, was markedly overexpressed by 
27.5-fold and 5.9-fold in the neutrophils of GC and PC subjects compared 
to NGT, whereas GCC and PCC subjects overexpressed the TLR5 mRNA 
by 3.6-fold and 2.4-fold, respectively compared to NGT control individual 
(Fig. 6.2E).  
 
TLR6 mRNA expression was upregulated by 9.7-fold in the neutrophils of 
GC subjects compared to NGT. In contrast, comparable expression was 
evidenced in GCC subjects (0.9-fold), and suppressed expression in PCC 
subjects (0.5-fold) (Fig. 6.2F). Interestingly, the neutrophils of GC 
overexpressed TLR7 mRNA by 61.5-fold, followed by increased 
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expression in PC by 4.9-fold compared to NGT. In contrast, GCC and PCC 
exhibited comparable expression compared to NGT (Fig. 6.2G).  
 
The neutrophils of GC and GCC overexpressed TLR8 mRNA by 4.5-fold 
and 2.1-fold respectively, when compared with NGT, whereas PCC (0.7-
fold) exhibited decreased expression compared to NGT (Fig. 6.2H). 
 
The TLR9 mRNA expression was markedly enhanced in the neutrophils of 
GC (25.5-fold) and PC (3.6-fold), comparable in GCC (1.9-fold), when 
compared with NGT. In contrast, PCC subjects (0.5-fold) showed 
decreased expression, compared to NGT (Fig. 6.2I). Similarly, highest 
level of TLR10 mRNA was seen in neutrophils from GC subjects (12.8-
fold) compared to NGT. In contrast GCC (1.3 fold) and PC group (2.3-fold) 
exhibited comparable expression, and PCC group (0.8-fold) showed 
decreased expression, compared to NGT (Fig. 6.2J). All TLRs 1-10 except 
TLR 2 remained statistically significant among different groups after 
adjustment for age, sex, WHR, BMI, duration of diabetes, creatinine and 
medications (insulin, sulfonylurea, metformin, GLP-1 analogues, DPP IV 
inhibitors, aspirin and statins) using lognormal data with multifactorial 
ANOVA (Table 6.2). Additionally, we did not find correlation between TLRs 
mRNA in neutrophils and BMI in T2D subjects. 
In summary, the highest expression of TLRs mRNA 1-10, except TLR 2 
were noticed in the neutrophils from GC subjects compared to NGT. 
Similarly, neutrophils from GCC subjects overexpressed TLRs 4 & 5 
compared to NGT. In contrast, the neutrophils from PCC significantly 
overexpressed only TLR4 compared with NGT.  
 
Collectively, these data show that TLRs are overexpressed in type 2 
diabetes subjects in both monocytes and neutrophils and suggest the role 
of TLRs in the pathophysiology of T2D and associated complications.  
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Table 6.3 TLR mRNA expressions in neutrophils from subjects with type 2 
diabetes & healthy controls.  TLRs mRNA were measured in subjects with normal 
glucose targets (NGT), good glucose control (GC), good glucose control with 
micro/macrovascular complications (GCC), poor glucose control (PC), poor glucose 
control with micro/macrovascular complications (PCC) in neutrophils at the 
transcriptional level using 2-(ΔΔCt) method and results are expressed as median [inter 
quartile range].  Statistical significance was determined by Kruskal–Wallis test and p < 
0.05 was considered significant. p value corresponds to differences between groups. 
 
 NGT GC GCC PC PCC 
 
p value 
 
n 8 8 8 8 8  
TLR 1 1.0  [0.9-1.0] 
2.4  
[2.3-2.5] 
1.6  
[1.0-1.9] 
0.6  
[0.6-0.7] 
1.6  
[0.7-2.6] <0.001 
TLR 2 1.0  [0.7-1.2] 
1.6  
[1.5-1.6] 
1.9  
[1.7-2.5] 
0.7  
[0.6-0.8] 
1.3  
[0.9-1.7] <0.001 
TLR 3 1.0  [0.9-1.0] 
28.6  
[28.1-28.8] 
0.4  
[0.4-0.6] 
3.9  
[3.7-4.5] 
0.2  
[0.1-0.6] <0.001 
TLR 4 1.4  [0.5-1.7] 
7.6  
[5.8-8.8] 
4.7  
[3.2-5.7] 
3.3  
[2.8-4.2] 
4.9  
[4.0-5.9] <0.001 
TLR 5 1.0  [0.9-1.0] 
27.5   
[26.3-28.8] 
3.6  
[2.8-4.8] 
5.9  
[5.2-6.9] 
2.4  
[2.3-2.6] <0.001 
TLR 6 1.0  [0.9-1.1] 
9.7  
[8.0-12.8] 
0.9  
[0.8-1.1] 
1.9  
[1.7-2.6] 
0.5  
[0.4-0.6] <0.001 
TLR 7 1.0  [0.9-1.1] 
61.5  
[60.8-62.3] 
1.8  
[1.4-3.6] 
4.9  
[4.7-5.2] 
2.1  
[1.5-2.6] <0.001 
TLR 8 0.9  [0.8-1.1] 
4.1  
[4.0-4.3] 
1.9  
[1.6-2.8] 
1.0  
[0.9-1.1] 
0.7  
[0.7-0.7] <0.001 
TLR 9 0.9  [0.9-1.1] 
22.9  
[22.5-23.4] 
1.7  
[1.6-1.9] 
3.3  
[3.2-3.4] 
0.5 
 [0.4-0.6] <0.001 
TLR 10 0.9  [0.9-1.1] 
11.5  
[10.9-11.8] 
1.2  
[0.8-1.7] 
2.1  
[1.8-2.4] 
0.7 
 [0.6-0.8] <0.001 
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Figure 6.2 (pages 151-152) 
TLRs mRNA expressions in neutrophils of subjects with type 2 diabetes & 
healthy controls:  !
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Figure 6.2 (cont. from page 151) 
TLRs mRNA 1-10, except TLR 2 were significantly overexpressed in GC, and 
TLRs 2, 4 & 5 were overexpressed in GCC in neutrophils, compared to NGT. 
The neutrophils from PCC significantly overexpressed only TLR4 compared 
with NGT. TLR, Toll Like Receptor (n = 8 in each group). *p<0.05, **p<0.01, 
***p<0.001 vs. NGT. 
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6.2 Discussion 
 !
In the present study, we have demonstrated that in monocytes, all TLRs 
mRNA 1-10 were overexpressed in GC group, and  mRNA levels of TLR1, 
3, 5, 7 9 & 10 were highest, compared to NGT. Similarly, in neutrophils, all 
TLRs mRNA, except TLR 2 were significantly overexpressed in GC group, 
when compared to NGT. Similar to our results, previous studies have 
demonstrated increased expression of TLR2 and TLR4 in the monocytes 
derived from patients with type 2 diabetes (Dasu et al., 2010). Previous 
studies did not explore other TLRs in diabetes, but were mainly focussed 
on TLR2 and TLR4, so data on role of other TLRs in T2D is lacking. Our 
novel study suggest that other TLRs are also overexpressed in T2D and 
warrant further investigation to explore the role of different TLRs in the 
pathophysiology of T2D. 
 
We have demonstrated differential expression of TLRs in monocyte and 
neutrophils. The monocytes from GC subjects markedly overexpressed 
TLR7 mRNA (24.4-fold), whereas neutrophils from GC subjects markedly 
overexpressed TLR3 mRNA (28.6-fold), TLR5 mRNA (27.5-fold), TLR7 
mRNA (61.5-fold), TLR9 mRNA (25.5-fold) and TLR10 mRNA (12.8-fold) 
compared to NGT. The differential expression on monocyte and neutrophil 
was also seen in other groups of diabetes.  It has been demonstrated 
previously that monocytes and neutrophils differ in the surface expression 
of TLR mRNAs and this might have attributed to differential expression. 
The Neutrophils constitutively express all  TLRs except TLR5,  while 
monocytes lack  expression of TLR3, TLR6, TLR7, and TLR10 (Muzio et 
al., 2000). Furthermore, it was shown that constitutive expression of TLR5 
was less in neutrophils compared to monocytes and expression of TLR4 
was greater and that of TLR9 lower in monocyte-derived macrophages 
compared to monocytes (O’Mahony et al., 2008). It has also been shown 
that IFN-γ up-regulates TLR2 and TLR4 expression in neutrophils and 
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monocytes, and inflammatory cytokines down-regulate TLR5 expression in 
monocytes (O’Mahony et al., 2008). 
 
The expression patterns of TLRs in different cell types may be an 
important regulatory mechanism of the innate immune response to various 
pathogens.  The neutrophils are the hallmark of acute inflammation, get 
recruited to the site of injury within minutes and have shorter half life in 
circulation of about 6-8 hours (Christian et al., 2011). In contrast, the blood 
monocytes differentiate into tissue macrophages and survive for long 
period and produces various cytokines like IL-1, IL-12 and TNFα 
(Heitbrock, 2007).  The increased monocytic activity and elevated 
biomarkers  have been shown in previous studies in diabetic subjects 
(Devaraj et al., 2006).  Most of the studies have used monocytes for TLR 
expression in various diseases but the studdies using neutrophils in TLR 
expression in T2D inflammation are lacking. Our study demonstrates that 
neutrophils and monocytes expresses different TLR mRNA in T2D 
subjects and thus suggest the significance of  neutrophils in TLR 
evaluation.   
 
In our study, T2D subjects with poor glucose control, and subjects with 
complications showed a trend towards suppressed TLR mRNA 
expression. In monocytes, GCC moderately overexpressed TLR 1, 5, 7 & 
10, whereas PC overexpressed only TLR 7, comapred to NGT. Similarly, 
in neutrophils, GCC moderately overexpressed TLR 4 & 5, whereas PC 
overexpressed TLR 5, 7 & 9 compared to NGT.  PCC subjects 
overexpressed only TLR 4 in neutrophils (p<0.05), and a statistically 
insignificant decreased expression of TLR 3, 6, 8, 9 & 10 was noticed in 
PCC compared to NGT. It is plausible to speculate that downregulation of 
TLRs might have occurred to curtail their sustained activation and to block 
the concomitant increase in proinflammatory cytokines. Whether 
decreased TLR expression leads to compromised innate immune 
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signalling mechanisms and a concomitant predisposition to infections, 
needs to be investigated. 
 
We have shown that neutrophils as well as monocytes markedly 
overexpressed TLR7 mRNA, compared to NGT. We couldn’t not find any 
association of TLR7 with T2D in the literature. However, recently it has 
been shown that TLR7 promotes autoimmune diabetes in animal model by 
activating and producing proinflammatory cytokines, IF-α (Lee et al., 
2011). The significance of raised TLR7 in T2D, as demonstrated in our 
study,  needs to be investigated.  
 
It has been argued previously that TLR4 expression and signalling 
correlates with IR (Reyna et al., 2008; Dasu et al., 2010). In contrast, in 
our study the highest level of TLR4 was seen in GC subjects in neutrophils 
(p<0.05) compared with NGT. The HbA1c and duration of diabetes was 
significantly less in GC compared to other T2D groups, which argue 
against IR in this group. Knowing that most TLRs were markedly 
overexpressed in both monocytes and neutrophils in GC subjects, we 
think that TLRs overexpression in early diabetes indicates low grade 
inflammation and plays a role in the pathogenesis of disease. 
It has been shown that statins, PPAR-γ agonists (Dasu et al., 2009a), 
metformin (Andrews et al., 2012) and angiotensin receptor blockers (Dasu 
et al., 2009b) decrease TLR2 and TLR4 expression and signaling. In our 
T2D cohort, comparable number of subjects in each group were on lipid 
lowering agents,  GC (85.2%), GCC (93.8%), PC (61.9%) and PCC 
(87.5%) , and ACE inhibitor/ARB, GC (74.1%), GCC (87.5%), PC (76.2%), 
and PCC (81.3%). A higher percentage of subjects in GC (81%) and GCC 
(81%) were on metformin, compared to PC (62%) and PCC (59%), despite 
that highest level of TLR4 mRNA was observed in neutrophil in GC group 
compared to NGT (p<0.05). It has been shown that insulin infusion 
significantly suppressed TLRs 1, 2, 4, 7, and 9 mRNA expressions in 
mononuclear cells (Ghanim et al., 2008). In our study a higher percentage 
 156 
of subjects in PC (52.4%) and PCC (71.9%) were on insulin compared to 
GC (7.4%) and GCC (28.1%) groups. Interestingly, TLR 4 was significantly 
overexpressed in neutrophils in PCC, TLR 7 was overexpressed in 
monocytes from PC, and TLR 5, 7 & 9 were overexpressed in neutrophils 
from PC group compared to NGT (p<0.05). We think that glycaemic 
control and the complications affect the expressions of TLRs to a great 
extent. 
 
In summary, our study demonstrated that TLRs are overexpressed in type 
2 diabetes subjects in both monocytes and neutrophils.  The surface 
expression of TLR was different in monocytes and neutrophils and also in 
different groups of T2D. The increased expression of TLRs is suggestive 
of an inflammatory milieu in T2D, however, to understand the significance 
of raised TLRs in T2D pathophysiology and micro/macrovascular 
complication, further investigations are required. 
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Chapter 7 
 
 
Cytokine profiling of Pre-diabetic 
subjects  
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7.1 Introduction 
Several studies have investigated and reported that proinflammatory 
cytokines are elevated in patients with IGT (Muller et al., 2002; 
Ruotsalainen et al., 2006), and predict the conversion to T2D (Pradhan et 
al., 2001). However, there is lack of data regarding the association 
between IFN-β and pre-diabetes. There is also limited information about 
association between TLRs and pre-diabetes. With this in mind, we  
analysed a cohort of 42 healthy Irish subjects to evaluate relationship 
between IGT and circulating cytokine levels, including IFN-β and TLRs.  
However, due to the limited number of pre-diabetes subjects in this group 
thus limiting statistical significance, we opted to preclude the analysis of 
adipokine and TLR expression levels in pre-diabetes. 
 
Our study comprised 34 NGT and 9 pre-diabetes subjects (8 had IFG and 
1 had both IFG and impaired 2h post prandial glucose).  Pre-diabetic 
participants were healthy volunteers and were not on any medications. 
They were 18 years or older and met the exclusion criteria as described 
before. They were diagnosed as pre-diabetes based on ADA criteria after 
an OGTT test (Table 2.3).  
 
7.2 Analysis of metabolic parameters in pre-diabetic 
subjects 
The median age and smoking status was comparable in the NGT and pre-
diabetes group. In NGT group, 22.5% were smokers, 51.6% non-smoker 
and 25.8% ex-smoker, whereas in pre-diabetes group 25% were smokers, 
50% non-smoker and 25 % ex-smoker (Table 7.1). Pre-diabetes subjects 
had significantly higher BMI compared to NGT controls (p<0.05). However, 
no significant difference was seen in the WHR and blood pressure in 
between the two groups.  
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The fasting glucose and HbA1c were significantly higher in pre-diabetes 
subjects compared to NGT controls (p<0.05).  Interestingly, CRP was 
significantly raised in pre-diabetes subjects compared to NGT (p<0.05). 
However, no significant difference was seen in lipid profile in between 
these two groups (Table 7.2). SBP and DBP were taken after a rest of 5 
min and two readings were taken one minute apart. There was no 
significant difference in BP in between the two groups.  
 
7.3 Results 
Serum levels of cytokines were measured in subjects with NGT and pre-
diabetes. 
 
7.3a Pro-inflammatory cytokine levels in subjects with pre-diabetes 
and NGT 
Our data showed that serum levels of IL-6, TNFα and IFNβ were 
increased in pre-diabetes compared with healthy controls (Table 7.3). 
However, there was statistically insignificant difference between the two 
groups (Fig. 7.1A &B).  
 
7.3b Anti-inflammatory cytokine and chemokine levels in subjects 
with pre-diabetes and NGT 
The serum levels of anti-inflammatory cytokine, IL-10 were raised in pre-
diabetic subjects compared to NGT (Table 7.3) (Fig. 7.2E). However, the 
difference remained statistically insignificant between the two groups. The 
serum levels of chemokines, Rantes and IL-8 were elevated in pre-
diabetes group compared with healthy controls (Fig. 7.2D, F). Here again, 
we did not find any statistically significant difference between the two 
groups. 
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7.3c Levels of Th1 cytokines, IL-12 and IFN-γ in subjects with good 
and poor glucose control 
The serum IL-12 and FN-g levels were comparable in pre-diabetes and 
NGT groups (Table 7.3), and statistically no significant difference was 
observed. 
 
The multifactorial ANOVA was applied on all cytokines using lognormal 
values and data were adjusted for age, sex, BMI and WHR, it did not 
reveal any significant difference between pre-diabetes group and healthy 
controls. Additionally, we did not find correlation between serum cytokines 
and BMI in pre-diabetes subjects. 
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Table 7.1 Baseline characteristics of pre-diabetes and healthy controls 
Characteristics NGT Pre-diabetes p value 
n 34 9   
Sex (M/F) 11/23 2/7 0.249  
Age (years) 52.5 [46.7-59.0] 49 [42.5-58.5] 0.439  
Smokers Y/N 7/16 2/4 1.00 
Ex smoker Y/N 8/16 2/4 1.00 
BMI (kg/m2) 25.8 [24.4-30.0] 35.4 [25.1-44.1] 0.047  
Waist (cm) 91.0 [82.0-100.8] 111.0 [86.0-119.0] 0.062 
WHR 0.9 [0.8-0.9] 0.9 [0.8-1.0] 0.683 
SBP (mmHg) 129.0 [120.0-137.5] 127.5 [113.8-141.8] 0.921  
DBP (mmHg) 80.0 [75.0-85.5] 74.0 [71.2-82.5] 0.172  
 
BMI, Body Mass Index, WHR, Waist-Hip ratio, SBP, Systolic Blood Pressure, 
DBP, Diastolic Blood Pressure, data are expressed as median [IQR] (*p<0.05 vs 
NGT) 
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Table 7.2 Baseline biochemical parameters of pre-diabetes and healthy 
control 
 
Characteristics NGT Pre-diabetes  p value 
n 34 9   
Fasting Glucose (mM) 4.8 [4.7-5.1 5.9 [5.7-6.5] <0.001 
HbA1c (%) 5.5 [5.4-5.7] 6.0 [5.7-6.2] <0.001 
CRP 0.1 [0.1-0.3] 0.6 [0.1-1.1] 0.011 
Total cholesterol 
(mM) 5.9 [5.1-6.6] 5.5 [4.5-5.9] 0.176 
LDL cholesterol (mM) 3.6 [2.8-4.3] 3.5 [2.2-4.1] 0.431 
HDL cholesterol (mM) 1.6 [1.3-1.9] 1.2 [1.2-1.8] 0.206 
Triglycerides (mM) 0.9 [0.7-1.2] 1.4 [0.9-1.8] 0.078 
HbA1c, glycosylated haemoglobin, HDL, high-density lipoprotein; LDL, low-
density lipoprotein, CRP, C-reactive protein. Data are expressed as median 
[IQR] (*p<0.05 vs NGT) 
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Table 7.3 Fasting levels of serum cytokines in subjects with pre-diabetes 
and healthy controls                                                                                                                             
Cytokine (pg/ml) Normal Pre-diabetes p value 
n 34 9   
IL-6 12.3 [0.8-16.3] 17.3 [2.0-20.6] 0.086 
TNFα 18.6 [14.5-22.5] 19.7 [17.1-25.7] 0.348 
IL-1β 6.0 [0.9-8.4] 3.3 [0.9-8.9] 0.948 
IFN-β 357.2                [8.5-685.4] 
532.1          
[202.7-1315] 0.305 
Rantes (ng/ml) 54703               [41015-77823] 
57587                  
[38739-620256] 0.510 
IL-8 63.5 [25.2-89.8] 80.6 [20.0-153.4] 0.487 
IL-10 6.8 [5.1-8.6] 8.4 [5.6-10.8] 0.213 
IL-12p70 9.3 [3.9-12.9] 9.8 [3.1-13.2] 0.956 
IFNγ 8.7 [2.3-11.9] 5.2 [1.9-12.5] 0.838 
IL-6, interleukin 6, TNFα, Tumour Necrosis Factor α, IL-1β, interleukin 1β, IFN-β 
interferon β Data are expressed as median [IQR] (p<0.05 vs. NGT) !!! !
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Figure 7.1  Serum levels of pro-inflammatory cytokines and Th1 cytokines, 
IL-12 and IFN-γ in normal and pre-diabetic subjects. A: IL-6 and TNF-α  
levels comparable in pre-diabetic subjects and healthy controls. B: IFN-β levels 
comparable in pre-diabetic subjects and NGT. C: IL-12 and IFN-γ levels 
comparable in pre-diabetes subjects and NGT. Values are expressed as pg/ml 
(Rantes as ng/ml) (n = 34 vs 9). *p<0.05, **p<0.01, ***p<0.001 vs NGT. 
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 Figure 7.2 Serum levels of anti-
inflammatory cytokine and 
chemokine in normal and pre-
diabetic subjects. 
 Serum levels of 
cytokines/chemokines were 
measured using Multiplex assays 
as described in the research 
design and methods. Values are 
expressed as pg/ml (Rantes as 
ng/ml). Rantes (D), IL-10 (E) and 
IL-8 (F) were comparable in pre-
diabetic subjects and healthy 
controls. NGT, Normal Glucose 
Tolerant (n = 34 vs 9). *p<0.05, 
**p<0.01, ***p<0.001 vs NGT. 
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7.4 Discussion 
 
In this study we have evaluated cytokine profiling in pre-diabetic subjects 
and compared them with healthy controls. We observed elevated serum 
levels of IL-6 and TNFα, and suppressed levels of IL-1β in pre-diabetes 
subjects, but the differences were not statistically significant. A 
prospective, case-control study has shown elevated serum levels of pro-
inflammatory cytokines, IL-6 and TNFα, but not IL-1β, in subjects with pre-
diabetes (Spranger et al., 2003). We did not find any human study that 
has evaluated role of IFN-β in relation to pre-diabetes. IFN-β attenuates 
the secretion of pro-inflammatory cytokines while it augments the anti-
inflammatory cytokines (Sellner et al., 2008). In our study, we did not find 
significant difference in serum levels of IFN-β between the two groups. 
Similarly, Th1 cytokines, IL-12 and IFN-γ levels remained statistically 
insignificant.  
 
A population-based KORA Survey S4 study, which included 1653 
subjects, has shown that elevated levels of Rantes were present in pre-
diabetes subjects (Herder et al., 2005). However, our data did not show 
statistically significant differences in the serum levels of anti-inflammatory 
cytokines/chemokines, Rantes, IL-8, and Th2 cytokine IL-12 between the 
two groups. We think that the small sample size of our pre-diabetes cohort 
affected the results.  
 
Few prospective studies have shown an independent positive association 
of CRP with the risk of developing T2D in pre-diabetes subjects (Pradhan 
et al., 2001; Spranger et al., 2003; Hu et al., 2004; Doi et al., 2005). Our 
study also revealed significantly elevated CRP in pre-diabetes compared 
to healthy controls. 
 
In summary, in this study we did not find significant differences between 
Th1 and Th2 cytokines in the pre-diabetes and NGT cohort. The raised 
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CRP alone, in absence of significant levels of other biomarkers, is not 
enough for us to comment on the inflammatory state in pre-diabetic 
subjects. One of the major limitations in this study is the small number of 
pre-diabetes subjects (n=9). Furthermore, among pre-diabetes subjects, 8 
had IFG and 1 had IGT. The pre-diabetes subjects were heavier than the 
NGT subjects, with a mean BMI 35.4 Kg/m2 and 25.8 Kg/m2 respectively, 
and this difference in BMI could have affected the cytokine profile between 
the two cohorts. However, findings were not altered after adjustment for 
age, sex, BMI and WHR. In this study, we did not analyse cytokines 
mRNA expressions in pre-diabetes cohort, because of the small number of 
pre-diabetes subjects, but it would have been interesting to see mRNA 
expressions in pre-diabetes subjects in a larger study. Overall, in presence 
of these limitations, it is difficult to draw definitive conclusions from this 
pre-diabetes study. However, we can suggest a potential role of these 
cytokines as biomarkers for the detection of early/subclinical disease and 
a larger study should be carried out to explore this possibility.  
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Correlation between cytokines, chemokines, adipokines, 
TLRs, T2D and adiposity 
The main objective of this study was to investigate the role of inflammatory 
biomarkers in the pathophysiology of T2D.  We evaluated cytokines and 
TLRs in T2D subjects with good glycaemic control with/without 
complications and poor glycaemic control with/without complications in 
both monocytes and neutrophils, and compared with the NGT controls. In 
addition, given that a number of studies have indicated an association 
between adipokines and T2D, we also investigated the adipokine 
expression in both monocytes and neutrophils in our T2D subjects and 
compared with the NGT controls. It has been shown in previous studies 
that inflammation in T2D subjects starts years before the development of 
T2D. Hence, we also investigated the serum cytokines in pre-diabetes 
subjects to explore the inflammatory cascade at the onset of diabetes. 
However, this was not the part of research protocol. 
 
 Pre-diabetes represents an elevation of plasma glucose above the normal 
range but below that of clinical diabetes and is associated with a high risk 
for T2D, subclinical inflammation, early atherosclerosis, and CVD (Bardini 
et al., 2010). It has been shown that pre-diabetes was associated with 
retinopathy in 2% to 4% of affected subjects in Pima Indians (Gabir et al., 
2000). A prospective, nested case-control study has shown that elevated 
levels of CRP and IL-6 predict the development of T2D (Pradhan et al., 
2001). In contrast, another prospective, case-control study showed that a 
combined elevation of IL-6 and IL-1β, rather than isolated elevation of IL-6 
alone, independently increased the risk of T2D (Spranger et al., 2003). 
Our study showed that subjects with pre-diabetes have elevated serum 
levels of pro-inflammatory cytokines, IL-6, TNFα, and Th1 cytokine, IL-12, 
when compared with NGT controls, but statistically insignificant. Serum IL-
1β and Th1 cytokine, IFN-γ levels were comparable in pre-diabetes 
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subjects. Our study has revealed a significantly elevated CRP in pre-
diabetes cohort compared to healthy controls. However, the elevated CRP 
alone does not suffice to comment on inflammatory status in the pre-
diabetes in a small cohort.  
 
In this study we showed that in neutrophils, the highest levels of pro-
inflammatory cytokines IL-6 mRNA, TNFα mRNA and IFNβ mRNA 
including chemokine, Rantes were present in GC group, when compared 
to NGT control. Similarly, in monocytes, IL-6 mRNA, and IFN-β were 
overexpressed from GC subjects, when compared to NGT. Collectively, 
these data indicate that an inflammatory milieu exists in T2D, and that 
subjects with good glycaemic control with no complications have 
upregulated inflammatory mechanism.  
 
We demonstrated that IL-1β mRNA expression was significantly 
decreased in monocytes from GCC, PC and PCC subjects, compared to 
NGT. Similarly, in monocytes a variable overexpression of IL-6 mRNA, 
TNFα mRNA, IFN-β mRNA and Rantes mRNA was observed in PC, GCC 
and PCC groups, compared with NGT. The IL-6 mRNA, IFN-β mRNA and 
Rantes mRNA were overexpressed in neutrophils from PC group (less 
than GC), compared with NGT. These data further suggest that an 
inflammatory milieu exists in T2D, and subjects with poor glycaemic 
control, and subjects with complications have compromised Th1 cells.  
 
We also investigated adipokines expression in both monocytes and 
neutrophils in different T2D groups and compared with the NGT controls. 
Our study showed that all three adipokines: adiponectin, RBP4 and LCN2 
were overexpressed in both monocytes and neutrophils in T2D subjects, 
compared to NGT. It has been shown that LCN2 exhibits anti-inflammatory 
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properties; antagonises the detrimental effect of TNFα on adipocytes and 
macrophages, upregulates PPAR-γ, adiponectin and leptin and protects 
adipocytes from TNF-α–induced production of IL-6 and MCP-1 (Zhang et 
al., 2008). This suggests that overexpressed LCN2 in T2D subjects is a 
measure to counteract ongoing inflammation in T2D, which is evidenced 
by raised pro-inflammatory cytokines in these subjects. It has been shown 
that circulating RBP4 levels correlate with the degree of IR, and increased 
levels are present in IGT and T2D subjects (Graham et al., 2006). In line 
with previous studies, our study also showed overexpressed RBP4 in both 
monocytes and neutrophils in T2D subjects. In addition, our study also 
showed overexpressed adiponectin in both monocytes and neutrophils in 
T2D subjects. Adiponectin has been shown to exert an insulin-sensitizing 
effect through binding to its receptors AdipoR1 and AdipoR2, and 
activation of AMPK, PPAR-α, and some other unknown signaling 
pathways (Yadav et al., 2013). It is plausible to speculate that 
overexpressed RBP4 is indicating development of IR in the T2D cohort, 
whereas overexpressed adiponectin is reflecting genesis of insulin 
sensitivity, a measure to counteract the IR.  Collectively, we found that all 
three adipokines, adiponectin, lipocalin and RBP4 were overexpressed in 
the T2D subjects indicating that there is an inflammatory and IR milieu, 
which is linked with the pathophysiology of T2D and associated 
complications. 
 
Furthermore, adiponectin has been shown to suppress the LPS-stimulated 
release of IL-6 and induce IL-10 in human monocytes and macrophages 
(Weigert et al., 2008; Kumada et al., 2004; Wulster-Radcliffe et al., 2004). 
In our study, we have demonstrated that IL-6 mRNA was significantly 
overexpressed in GC and PC group, compared with NGT, and serum IL-
10 levels were comparable. Whether the elevated IL-6 has enhanced the 
adiponectin expression or increased adiponectin has suppressed IL-6 to a 
certain extent, remains questionable. 
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Our study clearly showed that the adipokines adiponectin, RBP4 and 
LCN2 mRNA were markedly overexpressed in both neutrophils and 
monocytes in GC subjects, compared with other groups. In contrast, all 
three adipokines were suppressed in both neutrophils and monocytes in 
PCC subjects, and variable expression was evident in GCC and PC 
subjects. It indicates that GC subjects have enhanced inflammatory and IR 
milieu, whereas, PCC subjects have less inflammatory and IR milieu. It is 
plausible to speculate that downregulation of adipokine receptors occurs 
following sustained activation to terminate the inflammation and IR. It is 
also evident that GC subjects have enhanced anti-inflammatory and 
insulin sensitizing milieu, whereas PCC subjects have down-regulated 
anti-inflammatory and insulin sensitizing milieu. It reflects that T2D 
subjects with complications and poor glycaemic control have impaired 
defensive mechanism to combat the inflammation and IR. Collectively, this 
suggests that in T2D subjects with good glycaemic control with no 
complications, there is a release of excess of adipokines and cytokines.  
 
To further investigate the inflammatory cascade in T2D we explored the 
TLRs in this study. Our data clearly showed in monocytes, highest level of 
all TLRs 1-10 [TLR1, 3, 5, 7, 9 & 10 (p<0.05)] were observed in GC group, 
compared with NGT. Similarly, in neutrophils, highest level of all TLRs, 
except TLR 2 were observed in GC, when compared with NGT controls 
(p<0.05). The overexpressed TLRs in both monocytes and neutrophils 
suggest ongoing inflammation in T2D subjects. In contrast, both 
monocytes and neutrophils from GCC, PC and PCC subjects showed a 
trend towards decreased TLR mRNA expression. Whether the decreased 
TLR expression in poor glycaemic state is an indication of compromised 
innate immune signalling mechanisms or a reflection of protective 
mechanism to curtail further increase in pro-inflammatory cytokines, 
remains questionable.  
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The immune response is determined by the actual TLRs that are 
activated. The TLR3, TLR7, TLR8 and TLR9 upon activation induce type I 
IFNs (IFN-β), whereas stimulation of human monocyte-derived 
macrophages and dendritic cells with the TLR8 ligand together with the 
TLR3 or TLR4 ligand lead to synergistic IL-6, IL-10, IL-12, and TNF-α 
mRNA expression and cytokine production (Makela et al., 2009).  In 
parallel to TLRs, our data demonstrated overexpressed IL-6 mRNA and 
IFN-β mRNA in monocytes and neutrophils from GC and PC, and TNF-α 
mRNA and in neutrophils from GC group, compared with NGT. However, 
our study failed to show elevated serum IL-10 and IL-12 levels in T2D 
subjects despite overexpressed TLRs in these subjects. The expression of 
IL-10 and IL-12 is dependent upon TLR2/4 activation and in our study TLR 
2 and TLR 4 in monocyte, and TLR2 in neutrophil was minimally 
overexpressed, compared to other TLRs.  It has been shown that 
metformin (Andrews et al., 2012), statins, PPAR-γ agonists (Dasu et al., 
2009a) and angiotensin receptor blockers (Dasu et al., 2009b) lower the 
expression of TLR 2 /4 in T2D patients. Most of our T2D subjects were on 
these medications and this likely explains the decreased expression of 
TLR 2 and TLR 4 in our T2D cohort.  
 
Recent studies have shown that adipocytes play an important role in the 
physiological regulation of immune responses in fat deposits via TLR 
signaling cascades. Adipose tissue produces and releases a variety of 
pro-inflammatory and anti-inflammatory factors, including the adipokines 
leptin, adiponectin, resistin, RBP4 and visfatin, as well as cytokines and 
chemokines, such as TNF-α, IL-6, monocyte chemo-attractant protein 1, 
and others (Lago et al., 2007). In an animal model, the obesity led to 
upregulated expression of TLR1–9 and TLR11–13 in adipose tissue (Kima 
et al., 2012). The multifactorial ANOVA using lognormal data of cytokines, 
adipokines and TLRs after adjustment for age, sex, WHR, BMI, duration of 
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diabetes, creatinine and medications (insulin, sulfonylurea, metformin, 
GLP-1 analogues, DPP IV inhibitors, aspirin and statins) did not alter the 
results of most inflammatory markers, except of TNF-α, TLR2 & 8 in 
monocytes, IL-1β mRNA and TLR2 in neutrophils. This suggests that there 
is an inflammatory milieu, independent of obesity, which is linked with 
development of T2D and associated micro/macrovascular complications. 
 
Studies have shown that low-grade chronic inflammation and activated 
innate immune mechanisms are involved in the pathogenesis of T2D 
(Pickup et al., 2004). It has been shown that TNF-α signaling impairs 
insulin signaling through serine phosphorylation of IRS-1, reduces GLUT4 
gene expression, and mediates IR (Hotamisligil et al., 1994). Furthermore 
studies revealed that TLR4 contributes to the development of insulin 
resistance and inflammation through activation of pro-inflammatory 
kinases and ROS, and indirectly, via activation of cytokine signaling 
cascades and systemic release of pro-inflammatory, insulin-desensitizing 
factors (Kim et al., 2010). We have also shown that our subjects with T2D 
displayed subclinical, low-grade systemic inflammation including increases 
in cytokines, chemokines, adipokines and TLRs, although the degree of 
immune activation was far below that is seen in acute infections. We think, 
that this perturbations in the normal homeostatic balance between 
cytokines, chemokines, adipokines and TLRs serve to promote onset and 
progression of late diabetic complications.  
 
Previous studies have shown that inflammation, and more specifically pro-
inflammatory cytokines, play a determinant role in the development of 
microvascular complications and diabetic cardiovascular diseases. Studies 
have suggested a role of pro-inflammatory cytokines IL-1, IL-6, IL-18, 
TNF-α and TGF-β1 in diabetes microvascular complications (Navale & 
Paranjape, 2013). Our study also demonstrated variable overexpression of 
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IL-6 mRNA, TNF-α mRNA including IFNβ mRNA and Rantes mRNA in 
different T2D groups. In relation to role of TLRs in diabetes complication, 
our PCC subjects overexpressed TLR 4 in neutrophils, and GCC subjects 
overexpressed TLR 1, 5, 7 & 10 in monocytes and TLR 4  & 5 in 
neutrophils, when compared with NGT.  It has been shown that TLR4, due 
to its additional roles in immunostimulation, modulation of inflammation, 
angiogenesis, and tissue repair and regeneration plays a vital molecule in 
wound healing (Seki et al., 2005; Vink et al., 2002; Grote et al., 2011; 
Mollen et al, 2006). TLR4 is also shown to be responsible for the 
expression and regulation of Vascular Endothelial Growth Factor (Pei et 
al., 2008). Wounds devoid of TLR4 or its downstream targets like MyD88, 
take longer time to heal and often develop into chronic non-healing ulcers 
(Macedo et al., 2007). Kanhaiya et al. (2013) has clearly shown that any 
deregulation in the TLR4 mediated downstream signaling lead to chronic 
non-healing ulcers in humans. In line with these studies, TLR4 mRNA was 
overexpressed in both neutrophils and monocytes in our study and none 
of the T2D subjects in our study exhibited active foot ulcer. TLR4 has also 
been shown to promote tubulointerstitial inflammation in DN by 
upregulating IL-6 (Lin et al., 2012).  In our T2D cohort, nephropathy was 
seen in 68.8% and 56.3% in PCC and GCC group, respectively. We did 
not correlate diabetes associated micro/macrovascular complications 
separately with different TLRs. The importance of these overexpressed 
TLRs in diabetes associated complication needs to be investigated.  
 
In our study, a trend toward decreased TLR expression was noticed in PC, 
GCC and PCC monocytes and neutrophils.  TLR 2, 3, 9 and 10 were 
relatively suppressed in the PCC monocytes, and TLRs 3, 6, 8, 9 and 10 
were relatively supressed in the PCC neutrophils, compared to NGT. 
Similarly, all three adipokines were relatively suppressed in both 
neutrophils and monocytes in PCC subjects (LCN2 & adiponectin in 
monocytes p<0.05), compared with NGT, and variable expression was 
evident in GCC and PC subjects. We also observed suppressed IL-
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1b  mRNA expressions in monocytes in GCC, PC and PCC groups, 
compared to NGT. To determine that whether decline in immune function 
in PC, GCC and PCC group is due to poor glycaemic control and diabetes 
complications or due to prolonged duration of diabetes, we applied 
multifactorial ANOVA model and adjusted duration of diabetes as a 
covariant, but the difference among inflammatory markers among different 
groups remained significant. This suggests that decline in immunity in T2D 
is related to poor glycaemic control and diabetes complications rather than 
the duration of disease.  Whether decline in immunity is the result of 
disease process itself or whether patients with suppressed inflammatory 
markers are more susceptible to develop diabetes and associated 
microvascular and macrovascular complications, remains to be 
investigated. 
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Conclusion, Limitations and Further Studies 
To the best of our knowledge, this is the first study that has sought to 
evaluate cytokine levels, adipokines and TLRs expressions among type 2 
diabetic subjects with good glycaemic control with/without complications 
and poor glycaemic with/without complications and compared them with 
healthy controls. The key points are summarized as below- 
1. In T2D with good glycaemic control with no complications, the 
inflammatory and anti-inflammatory mechanisms are overactive; and Th1 
cells are overactive. 
2. In advanced diabetes i.e., poorly controlled T2D and diabetes with 
complications, inflammatory and anti-inflammatory mechanisms gets 
impaired, and Th1 and Th2 response gets suppressed.  
3. In T2D subjects with good glycaemic control with no complications, 
RBP4, an adipokine that induces IR, was overexpressed indicating an 
inflammatory and IR milieu. In contrast, adiponectin, an insulin sensitizing 
adipokine, and lipocalin, an anti-inflammatory adipokine were also 
overexpressed indicating a compensatory mechanism to counteract 
inflammation and protecting from IR.  
4. All three adipokines were suppressed in both neutrophils and 
monocytes in PCC subjects, and variable expressed in GCC and PC 
subjects. This indicates that downregulation of adipokine receptors occurs 
in poorly controlled diabetic subjects and in subjects with complications.  
5. TLRs were overexpressed in monocytes and neutrophils from GC, and 
a trend toward decreased TLR expression was noticed in PC, GCC and 
PCC monocytes and neutrophils. It suggests that downregulation of TLR 
receptors occurs in poorly controlled diabetic subjects and in subjects with 
complications. 
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6. The multifactorial ANOVA using lognormal data of cytokines, adipokines 
and TLRs after adjustment for age, sex, WHR, BMI, duration of diabetes, 
creatinine and medications did not alter the results of most inflammatory 
markers, except of TNF-α, TLR2 & 8 in monocytes, IL-1β mRNA and TLR2 
in neutrophils.  
7. No correlation was found between serum cytokines and BMI, 
adipokines mRNA and BMI, and TLRs mRNA and BMI. Among cytokines 
mRNA expression a correlation statistically significant was found between 
IL-1β mRNA in monocytes and BMI in T2D subjects (Spearman’s r = 0.41, 
p<0.05).   Our data suggests that the inflammatory milieu in diabetes was 
linked with diabetes itself, rather than obesity. 
8. Few TLRs have been linked with complications in diabetes. Our PCC 
subjects overexpressed TLR 4 in neutrophils, and GCC subjects 
overexpressed TLR 1, 5, 7 & 10 in monocytes and TLR 2, 4 & 5 in 
neutrophils, when compared with NGT. The relevance of these 
overexpressed TLRs in diabetes associated complication need to be 
investigated.  
9. Our study demonstrated that neutrophils and monocytes express 
different TLR mRNA in T2D subjects. This indicates the significance of 
neutrophils in TLR evaluation, in addition to the more commonly evaluated 
monocytes.   
 
In summary, our study demonstrates that subjects with T2D exhibit 
perturbations in cytokines, chemokines and adipokines, and TLRs, 
supporting their role in T2D progression and complications. Whether this 
perturbation is the result of disease process itself or whether patients with 
perturbed inflammatory markers are more susceptible to develop diabetes 
and associated microvascular and macrovascular complications, remains 
to be investigated. However the consistently and significantly suppressed 
cytokines, chemokines and adipokines, and TLRs, in  with poor glycaemic 
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control and with complications suggests a “burnt out” disease state re 
emphasizing the role of early management to achieve good glycaemic 
control and avoiding complications. These findings along with other 
previous and ongoing studies might pave the way in the future in 
designing certain therapeutic measures that are aimed at suppressing the 
low grade inflammatory state in early diabetes through anti inflammatory 
cytokines and targeted TLR therapy. 
 
A major limitation of the present work is the sample size; we think that 
more control subjects and T2D subjects should be involved.  Another 
limitation is insulin level, which was not measured; hence IR could not be 
calculated in T2D subjects.  Further, during recruitment the T2D subjects 
were not asked about exercise programs that they may be involved in, 
recent weight loss and change of medications. These factors impact 
insulin sensitivity and thus affect inflammatory markers in diabetes. The 
T2D subjects were on anti-diabetic medications, insulin, statins and ARBs, 
which would have affected the inflammatory markers, but it would have 
been unethical to discontinue the medications to continue the research. 
Finally, we think that serum adipokine levels, which were not measured, 
would have given more information about the role of adipocytes in the 
inflammatory cascade in T2D.   
 
Though this small but exhaustive study has thrown up many interesting 
trends regarding the role of inflammation in diabetes and the notion of 
burnt out diabetes, more robust prospective studies with larger sample 
size are needed to arrive at more conclusive results. Therefore, a 
prospective study should be designed with a larger sample size in a 
similar cohort with expanded profile including measurement of IR and 
serum adipokine levels. The subjects with poorly controlled T2D and with 
complications should be treated intensively and inflammatory markers 
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should be measured at baseline and after one year to assess the change 
in inflammatory markers with change in glycaemic state, to support or 
refute the concept of burnt out diabetes. Additionally, a study should be 
carried out on pre-diabetes subjects with expanded profile to explore that 
whether these inflammatory markers can be used as biomarker to predict 
the development of T2D. This will help in our understanding of the role of 
inflammation in pathophysiology of T2D and the occurrence of diabetic 
complications and designing new therapies in the future. 
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